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Abstract
This thesis deals with statistical issues in the analysis of dependent failure time data
under complex observation schemes. These observation schemes may yield right-censored,
interval-censored and current status data and may also involve response-dependent selec-
tion of individuals. The contexts in which these complications arise include family studies,
clinical trials, and population studies.
Chapter 2 is devoted to the development and study of statistical methods for family
studies, motivated by work conducted in the Centre for Prognosis Studies in the Rheumatic
Disease at the University of Toronto. Rheumatologists at this centre are interested in study-
ing the nature of within-family dependence in the occurrence of psoriatic arthritis (PsA) to
gain insight into the genetic basis for this disease. Families are sampled by selecting mem-
bers from a clinical registry of PsA patients maintained at the centre and recruiting their
respective consenting family members; the member of the registry leading to the sampling
of the family is called the proband. Information on the disease onset time for non-probands
may be collected by recall or a review of medical records, but some non-probands simply
provide their disease status at the time of assessment. As a result family members may
provide a combination of observed or right-censored onset times, and current status infor-
mation. Gaussian copula-based models are studied as a means of flexibly characterizing
the within-family association in disease onset times. Likelihood and composite likelihood
procedures are also investigated where the latter, like the estimating function approach,
reduces the need to specify high-order dependencies and computational burden. Valid anal-
ysis of this type of data must address the response-biased sampling scheme which renders
at least one affected family member (proband) with a right-truncated onset time. This
right-truncation scheme, combined with the low incidence of disease among non-probands,
means there is little information about the marginal onset time distribution from the fam-
ily data alone, so we exploit auxiliary data from an independent sample of independent
individuals to enhance the information on the parameters in the marginal age of onset dis-
tribution. For composite likelihood approaches, we consider simultaneous and two-stage
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estimation procedures; the latter greatly simplified the computational burden, especially
when weakly, semi- or non-parametric marginal models are adopted. The proposed models
and methods are examined in simulation studies and are applied to data from the PsA
family study yielding important insight regarding the parent of origin hypothesis.
Cluster-randomized trials are employed when it is appropriate on ethical, practical,
or contextual grounds to assign groups of individuals to receive one of two or more in-
terventions to be compared. This design also offers a way of minimizing contamination
across treatment groups and enhancing compliance. Although considerable attention has
been directed at the development of sample size formulae for cluster-randomized trials with
continuous or discrete outcomes, relatively little work has been done for trials involving
censored event times. In Chapter 3, asymptotic theory for sample size calculations for
correlated failure time data arising in cluster-randomized trials is explored. When the in-
tervention effect is specified through a semi-parametric proportional hazards model fitted
under a working independence assumption, robust variance estimates are routinely used.
At the design stage however, some model specification is required for the marginal distribu-
tions, and copula models are utilized to accommodate the within-cluster dependence. This
method is appealing since the intervention effects are specified in terms of the marginal
proportional hazards formulation while the within-cluster dependence is modeled by a sep-
arate association parameter. The resulting joint model enabled one to evaluate the robust
sandwich variance, based on which the sample size criteria for right censored event times
is developed. This approach has also been extended to deal with interval-censored event
times and within-cluster dependence in the random right censoring times. The validity
of the sample size formula in finite samples was investigated via simulation for a range of
cluster sizes, censoring rates and degree of within-cluster association among event times.
The power and efficiency implications of copula misspecification are studied, along with
the effect of within-cluster dependence in the censoring times. The proposed sample size
formula can be applied in a broad range of practical settings, and an application to a study
of otitis media is given for illustration.
Chapter 4 considers dependent failure time data in a slightly different context where
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the events correspond to transitions in a multistate model. A central goal in oncology is the
reduction of mortality due to cancer. The therapeutic advances in the treatment of many
cancers and the increasing pressure to ensure experimental treatments are evaluated in a
timely and cost-effective manner, have made it challenging to design feasible trials with
adequate power to detect clinically important effects based on the time from randomiza-
tion to death. This has lead to increased use of the composite endpoint of progression-free
survival, defined as the time from randomization to the first of progression or death. While
trials may be designed with progression or progression-free survival as the primary end-
point, regulators are interested in statements about the effect of treatment on survival
following progression. One approach to investigate this is to estimate the treatment ef-
fect on the time from progression to death, but this is not an analysis that benefits from
randomization since the only individuals who contribute to this analysis are those that
experienced progression. Also assessing the treatment effect on marginal features might
lead to dependent censoring for the survival time following progression as other variables
which have both effect on progression and post-progression survival time are omitted from
the model. In Chapter 4 we consider a classical illness-death model which can be used to
characterize the joint distribution of progression and death in this setting. Inverse proba-
bility weighting can then be used to address for the observational nature of this improper
sub-group analysis and dependent censoring. Such inverse weighted equations yield con-
sistent estimates of the causal treatment effect by accounting for the effect of treatment
and any prognostic factors that may be shared between the model for the sojourn time
distribution in the progression state and the transition intensity for progression. Due to the
non-collapsibility of the Cox regression model we focus here on additive regression models.
Chapter 5 discusses prevalent cohort studies and the problem of measurement error in
the reported disease onset time along with other topics for further research.
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Chapter 1
Introduction
1.1 Overview
Interest in health research often lies in characterizing the distribution of multiple events
over a period of time. In many settings the goal is to estimate the cumulative risk of each
type of event and to examine associated covariate effects through specification and fitting
of regression models. Understanding the nature and extent of stochastic dependencies
between different types of events may also be of primary scientific interest, in which case
one must choose among a number of frameworks that can be adopted to explore these
relationships. The various approaches one can adopt for joint modeling differ in precisely
how the dependence is expressed, and the extent to which simple features of the marginal
distributions are retained. This thesis is concerned with three different problems involving
dependent failure time data. A second theme in this work is the importance of dealing
appropriately with the sampling or observation conditions to ensure valid inference. We
discuss the particular research projects in more detail in Section 1.3 and in the subsequent
chapters, but mention them briefly here.
The first problem involves the analysis of data from a family-based study of disease
onset times. Here the primary interest is in understanding the dependence structure within
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families with a view to elucidating the possible genetic basis of disease, as well as testing
hypotheses regarding the dependence structure through use of second-order models. The
biased response-dependent sampling scheme used for family studies is addressed here by
treating the probands disease onset time as right-truncated. The model and approach to
inference adopted here offers a useful framework for exploring these questions and also offers
a good basis for future analyses of genetic effects. The second problem involves the design
of cluster-randomized trials where the primary goal is to assess the effect of randomized
treatment on the time to an event of interest. The fact that there is a within-cluster
dependence is a nuisance in this setting, as it is not of scientific interest. Understanding
the extent of this association is important for designing such studies, however, since the
magnitude of the within-cluster association determines the variability of the estimators
obtained under a working independence hypothesis. While issues of response-dependent
observation are not central in this work we do explore the impact of dependent censoring
times within clusters. In both the first and second problems, copula models offer a useful
basis for analysis. The third problem addressed arises in cancer clinical trials where interest
lies in understanding the effect of treatment on progression, progression-free survival, and
overall survival. This is an area that has received a lot of attention in recent years and many
researchers are interested in understanding relationships between estimates of treatment
effect for the various endpoints. To this end we adopt a three-state illness death model as it
offers the most natural framework for studying this disease process. We focus on addressing
questions of causal analysis of the randomized treatment on the post-progression survival
time defined as the sojourn time in the “progression” state.
In the following section an overview is provided of the various approaches one can adopt
for the analysis of multiple lifetime events.
2
1.2 Statistical Methods for Multivariate Failure Times
Multivariate failure times arise routinely in clinic trials and observational studies (Lawless,
2003). In such contexts, interest often lies in covariate effects on marginal features of the
responses, but understanding of the covariance structure, or more broadly the stochastic
relationship between events, is also often important. There are several frameworks for
the statistical analysis of multivariate failure time data, including intensity-based models,
partially conditional models, frailty models, copula models and robust marginal methods;
we review these, following an introduction to some notation.
Suppose that there are K types of events, and let Tik denote the time of the type k event
for individual i, k = 1, . . . , K, i = 1, . . . ,m. Let {Nik(t), 0 < t} denote the corresponding
right-continuous counting process, where Nik(t) = I(Tik ≤ t) indicates that the type k
event occurred at or before time t, dNik(t) = 1 if type k event occurs at time t, and
dNik(t) = 0 otherwise, i = 1, . . . ,m. If Cik denotes the censoring time for the type k event
for individual i, the observed time is Xik = min(Tik, Cik), and we let δik = I(Xik = Tik);
often Cik = Ci, k = 1, . . . , K. If Zik(t) is a vector of exogenous or endogenous covariates
for the type k event for individual i, {Zik(t), 0 < t} denotes the covariate process.
1.2.1 Intensity-Based Models for Multivariate Failure Times
Let Ni(s) = (Ni1(s), . . . , NiK(s))
′ and Zi(s) = (Z ′i1(s), . . . , Z
′
iK(s))
′. The history Hi(t) =
{Ni(s), 0 ≤ s < t, Zi(s), 0 ≤ s ≤ t} at time t contains the information on the number,
times, and types of events over [0, t), along with the covariate data over [0, t].
For individual i, the intensity function for a type k event is
lim
∆t→0
P (∆Nik(t) = 1|Hi(t))
∆t
= Yik(t)λik(t|Hi(t))
where ∆Nik(t) = Nik((t+ ∆t)
−)−Nik(t−) is the number of type k events over the interval
[t, t+ ∆t), and Yik(t) = I(Nik(t
−) = 0).
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In this framework, the association between processes is incorporated through the in-
clusion of a dependence on the history for process l in the intensity for type k events,
(k 6= l). For continuous time processes where at most one event can occur at any time,
these intensity functions fully define the multivariate counting processes (Andersen et al.,
1993). While this formulation completely specifies a multivariate model, intensity-based
methods involve extensive conditioning on the process history (which includes endogenous
variables), and hence in the context of clinical trials, they are not ideal for examining
treatment effects (Kalbfleisch and Prentice, 2002).
1.2.2 Partially Conditional Models
Markov multi-state models offer an alternative approach for the analysis of multivariate
failure times. In this framework the vector-valued counting process can be represented by a
state occupied in a multistate model and the occurrence of an event can be represented as
a transition from one state to another. In general, multi-state models are defined by their
transition intensities, and hence estimation and inference regarding life history process
are based on transition intensities and transition probabilities. Let {Vi(s), 0 ≤ s} be
a multi-state stochastic process with 2K states numbered 1, . . . , 2K , and defined by the
unique values of Ni(s), and let {Zi(s), 0 ≤ s} denote the covariate process. Suppose
Y vij(t) = I(Vi(t
−) = j) indicates that individual i is at risk of transition out of state j
at time t, and Hi(t) = {Vi(s), 0 ≤ s < t;Zi(s), 0 ≤ s ≤ t} denotes the history of the
multi-state and covariate processes for individual i. In modulated Markov models,
λijk(t|Hi(t)) = Y vij(t)qjk(t) exp(Z
′
ijk(t)βjk)
where λijk(t|Hi(t)) is an intensity function and qjk(t) is a baseline transition rate.
With censored data, let Ci denote a common censoring time for individual i, Yi(t) =
I(t ≤ Ci) and Y¯ vij(t) = Yi(t)Y vij(t). If Qjk(t) =
∫ t
0
qjk(u)du is the cumulative baseline
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transition rate, we obtain a profile likelihood estimator
dQ̂jk(u; βjk) =
∑m
i=1 Y¯
v
ij(u)dN
v
ijk(u)∑m
i=1 Y¯
v
ij(u) exp(Z
′
ijk(u)βjk)
,
where dN vijk(t) = 1 if a j → k transition occurs at time t, i.e. dN vijk(t) = I(Vi(t−) =
j, Vi(t) = k). Upon obtaining an estimate β̂jk we substitute into the expression above to
get dQ̂jk(u; β̂jk).
In the context of a one-sample problem, we obtain simply
dQ̂jk(u) =
∑m
i=1 Y¯
v
ij(u)dN
v
ijk(u)∑m
i=1 Y¯
v
ij(u)
, (1.2.1)
and Q̂jk(t) =
∫ t
0
dQ̂jk(u). The Aalen-Johansen estimate (Aalen, 1978) of the transition
probability matrix P(s, t), with entries Pjk(s, t) = P (Vi(t) = k|Vi(s) = j), is then
P̂(s, t) =
∏
(s,t)
{I + dQ̂(u)} (1.2.2)
where dQ(t) is a matrix with entries dQjk(t) in (j, k), j 6= k, and the diagonal (j, j) is
−∑k 6=j dQjk(t).
Aalen et al. (2001) and Datta and Satten (2001) pointed out that the Aalen-Johansen
estimator of the state occupancy probabilities in the first row of P̂(0, t) are consistent,
even for non-Markov multi-state processes provided censoring is independent. Entries of
this matrix can therefore be used to estimate the marginal survival distributions.
1.2.3 Frailty Models for Multivariate Failure Times
In frailty models, latent random effects are introduced to characterize how the risk a par-
ticular individual has differs from the average member of the population with the same
covariate profile. Typically the different component failure times are assumed to be con-
ditionally independent given the frailty, but mixing over the distribution of this frailty
induces a dependence and makes these models useful for dealing with correlated data.
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Consider a conditional hazard function for a type k event (Cook and Lawless, 2007),
lim
∆t→0
P (t ≤ Tik < t+ ∆t|Tik ≥ t, uik, Zik(t))
∆t
= uikλik(t|Zik(t)) = uikλ0k(t;αk) exp(Z ′ik(t)βk)
where uik is a frailty independent of an external covariate Zik(t), with mean 1 and variance
φk, λ0k(t;αk) is an unspecified positive function, and βk is the vector of covariate effects
for the type k event.
Multivariate frailty distributions may be specified and so we let ui = (ui1, . . . , uiK)
′
where cov(uik, uil) = φkl accommodates associations between failure times within individu-
als. For convenience, however, it is most common to specify simple models with a common
frailty and here we consider fixed covariates. In this case we let uik = ui with E(ui) = 1
and var(ui) = φ, Zi = (Z
′
i1, . . . , Z
′
iK)
′
, and suppose ui ⊥ Zi. If α = (α′1, . . . , α′K) and
β = (β
′
1, . . . , β
′
K)
′
, then under the conditional independence assumption (Tij ⊥ Tik|Zi, ui),
we get
P (Ti1 > t1, . . . , TiK > tK |Zi;α, β, φ) = Eui
[
K∏
k=1
Fk(tk|ui, Zik;αk, βk)
]
= Eui
[
K∏
k=1
exp
(
−uiΛ0k(tk;α) exp(Z ′ikβk)
)]
where Λ0k(s;α) =
∫ s
0
λ0k(t;α)dt is cumulative baseline hazard function for type k event.
A number of distributions for ui can be specified but the most common is the gamma
distribution which gives
F(t1, . . . , tK |Zi;α, β, φ) =
∫ ∞
0
exp
(
−ui
K∑
k=1
Λ0k(tk;αk) exp(Z
′
ikβk)
)
uφ
−1−1
i e
ui/φ
Γ(φ−1)φφ−1
dui
=
1[
1 + φ
∑K
k=1 Λ0k(tk;αk) exp(Z
′
ikβk)
]φ−1
The joint density for (Ti1, . . . , TiK |Zi) is obtained by differentiation of the joint survivor
function.
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In frailty models, regression parameters must be interpreted conditional on the frailty,
which may not be the desired way of expressing covariate effects. Moreover, the distribu-
tional assumptions about the frailty are difficult to check, and the association structure
is largely treated as a nuisance in frailty models. Hence when association is of interest,
frailty models do not offer an ideal approach to analysis.
1.2.4 Copula Models for Multivariate Failure Times
Copula functions (Joe, 1997) offer a convenient and powerful tool to model the association
between failure times. The dependence structure induced by copula models does not
depend on the marginal models but rather is characterized by the copula model alone,
and as a result the marginal models may be constructed in any desirable way. Using the
copula model, regression parameters in models are marginally meaningful and has the same
interpretation regardless of the choice of the copula function.
A copula function in K dimensions is a multivariate distribution on [0, 1]K , whose
margins are all uniform over [0, 1]. For a K-dimensional uniform random vector U , a
copula indexed by parameter φ is,
C(u1, . . . , uK ;φ) = P (U1 ≤ u1, . . . , UK ≤ uK ;φ) .
Multivariate survival models are obtained based on such a copula as follows. The
marginal probability integral transformation of each random variable is first applied to
create a K dimensional vector of uniform random variables with Uk = Fk(Tk|Zk; θk). These
in turn are then viewed as the components of a multivariate uniform random variable
with their joint distribution governed by a given copula. Under the assumption that
P (Tk ≤ t|Z;ψ) = P (Tk ≤ t|Zk ; θk) for each k = 1, . . . , K, the joint survival function
F(t1, . . . , tK |Z) can be specified by linking all marginal survivor functions Fk(tk; θk) via
the copula as
F(t1, . . . , tK |Z;ψ) = P (T1 > t1, . . . , TK > tK |Z;ψ) = C(F1(t1|Z1; θ1), . . . ,FK(tK |ZK ; θK);φ)
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where ψ = (θ
′
1, . . . , θ
′
K , φ)
′
.
Kendall’s τ is defined as the probability of concordance among two pairs of failure
times, say (Tij, Tik) and (Ti′j, Ti′k), minus the probability of discordances, then
τ = P ((Tij − Ti′j)(Tik − Ti′k) > 0)− P ((Tij − Ti′j)(Tik − Ti′k) < 0) .
Kendall’s τ is a common association measure in this setting since it is functionally
independent of the marginal parameters. The Clayton copula is a widely used copula in
survival analysis and yields, for example, a joint survival distribution of the form
F(t1, . . . , tK |Zi;ψ) =
(
F1(t1|Z1; θ1)−φ + · · ·+ FK(tK |ZK ; θK)−φ −K + 1
)−1/φ
.
The degree of association between two failure times expressed in terms of Kendall’s τ , for
the Clayton copula, is given by τ = φ/(φ+2), where τ = 0 and τ = 1 correspond to the
cases of independence and perfect association respectively. Other copula functions within
the Archimedean family are often used and include the Frank and Gumbel-Houguaard
copulas (Nelsen, 2006).
Elliptical copulas are also often appealing (Fang et al., 1990). The Gaussian copula is a
type of elliptical copulas which has become very popular in many fields because of its easy
implementation and its convenience when obtaining conditional distributions. It also has
the attractive feature that the different pairwise associations can be specified through a
general correlation matrix. The Gaussian copula is constructed from a multivariate normal
distribution by using the probability integral transform
C(u1, . . . , uK) = ΦΣ(Φ−1(u1), . . . ,Φ−1(uK))
where Φ(·) is the cumulative distribution function of a standard normal and ΦΣ(·) is the
joint cumulative distribution function of a multivariate normal distribution with mean zero
and correlation matrix Σ. The Kendall’s τ for the Gaussian copula is τjk = 2arcsin(σjk)/pi,
where σjk is the correlation coefficient of Tij and Tik.
8
1.2.5 Robust Methods for Multivariate Failure Times
Wei et al. (1989) proposed semiparametric methods for multivariate failure times based on
marginal proportional hazards analyses under the working independence assumption. The
so-called WLW approach involves fitting marginal proportional hazards models for each
failure time as if they are independent, and then uses a robust covariance estimator to
account for possible correlations between the failure times.
Suppose Xik = min(Tik, Ci) and δik = I(Xik = Tik). Let Yik(t) = I(t ≤ Tik) be “at
risk” indicator for type k event for subject i, Y¯ik(t) = Yi(t)Yik(t) indicate that subject i is
under observation and at risk for the type k event, and dN¯ik(t) = Y¯ik(t)dNik(t) indicates
the type k event occurred and was observed at time t. Then under the Cox model with
fixed covariates, by assuming independent censoring and a common treatment effect for
each marginal model, the partial likelihood is
L(β) =
K∏
k=1

m∏
i=1
[
exp
(
Z
′
ikβ
)∑m
j=1 Y¯jk(Xik) exp
(
Z
′
jkβ
)]δik
 .
The maximum partial likelihood estimate β̂ solves the estimating equation
U(β) =
K∑
k=1
m∑
i=1
∫ ∞
0
(
Zik − S
(1)
k (β, s)
S
(0)
k (β, s)
)
dN¯ik(s) =
m∑
i=1
Ui(β)
where S
(r)
k (β, s) =
∑m
j=1 Y¯jk(s)Z
⊗r
jk exp(Z
′
jkβ), r = 0, 1, and a
⊗0 = 1, a⊗1 = a, a⊗2 = aa
′
for a vector a. This model can be extended to accommodate different regression coefficients
for each event type by use of a stratified partial likelihood (Wei et al., 1989).
Since no joint distribution of the K type events is assumed, the WLW approach involves
the computing of a robust variance estimator to account for the dependencies. Wei et al.
(1989) derived the asymptotic properties of the maximum partial likelihood estimator
√
n(β̂ − β) −→MVN(0,Q(β))
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where I(β) = E[−∂Ui(β)/∂β′], B(β) = E[Ui(β)U ′i(β)], and Q(β) = I−1(β)B(β)I−1(β)
has the usual sandwich form of robust covariance matrices with component matrices that
can be consistently estimated from the data (Wei et al., 1989); existing software such as
SAS and R can be used to obtain these estimates.
The WLW approach is similar in spirit to the use of generalized estimating equations
proposed by Liang and Zeger (1986) for dealing with longitudinal data, in which marginal
regression models are the primary focus, and the association across repeated measurements
was treated as a nuisance (GEE1). The generalized estimating equation approach does not
require one to completely specify the joint distribution of the correlated failure times, but
rather relies only on the specification of the marginal models; robust variance estimation is
also used in this approach to account for correlations. Prentice (1988) proposed a second
set of estimating equations (GEE2) which allow one to carry out simultaneous inference
about both marginal and association parameters when interest lies in the dependence
structure among the responses. GEE2 improves the efficiency of estimators by exploiting
higher order information about parameters, but the consistency of estimators from GEE2
depends on the correct specification of both the marginal and association models, while
the consistency of GEE1 estimator only depends on the correct specification of marginal
mean model; GEE1 is therefore more robust but less efficient than GEE2.
1.3 Introduction to the Topics of Research
1.3.1 Dependence Modeling for Disease Onset Times within Fam-
ilies
The focus of Chapter 2 is on characterizing the nature and extent of the within-family
association in some feature of the disease process, which is commonly used for the infer-
ence regarding the hereditary nature of disease, especially when the genetic data are not
available. This research topic is motivated by a psoriatic arthritis family study, which is
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conducted in the Centre for Prognosis Studies in Rheumatic Disease at the University of
Toronto.
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis which
can lead to serious disability. It is often associated with joint pain, inflammation and de-
struction (Chandran et al., 2010). The Centre for Prognosis Studies in Rheumatic Disease
at the University of Toronto maintains a clinic registry of patients with psoriatic arthritis.
This cohort has been recruiting and following patients since its inception in 1976. Upon
entry to the clinic, patients undergo a detailed examination and provide serum samples.
Follow-up clinical and radiological assessments are scheduled annually and biannually to
track the changes in joint damage and functional ability, and serum samples are taken
at each clinic visit to measure the changes of markers. To date 1191 patients have been
recruited and their median follow-up is 4.838 years with a median of 6 clinical assessments.
A family study was conducted based on this registry for which the primary goal was
to discover and examine the effect of genetic factors and understand the nature of the
familial dependence in the occurrence of psoriatic arthritis. Hereditary factors are thought
to be important in psoriatic arthritis, as some studies have suggested that close blood
relatives of psoriatic arthritis patients have higher risk of developing this disease compared
to the general population. Understanding the within family association can help researchers
to discriminate genetic and environmental factors and further understand the hereditary
nature of disease process. Another interest of this family study lies in assessing ‘parent of
origin’ effect (Burden et al., 1998), which refers to father-child association in the occurrence
of disease is different than the mother-child association.
A total of 150 families were recruited for the family study by identification of affected
individuals from the clinic registry; these individuals are called the proband. The sizes
of the recruited families range from 2 to 7 individuals including the probands. Since the
probands are in the clinic registry, detailed information on their disease history is available
including demographic and genetic data, as well as the age at the onset of psoriatic arthritis.
For other family members, referred to as non-probands, the disease history is collected by
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retrospective review of medical records or patient recall. The resulting data may include
demographic and other covariate information, information on the relation to the proband,
age at onset of psoriatic arthritis (if affected), and the age at the time of contact. Since
families are selected based on the proband’s disease status, such studies feature a biased
sampling scheme. Furthermore since the disease-related information for the non-probands
is collected by retrospective review of medical records, data may be incomplete on the
onset time of affected individuals and all that may ultimately be known is their status at
the assessment time; other non-probands may be diagnosed for the first time upon contact.
Such individuals furnish current status data, and therefore the family data obtained are
a mix of right-censored and current status data. Figure 1.1 illustrates the right-truncated
onset time of probands and the mixed-type family data provided by the relatives. For this
family, since the proband (labelled 0) was born at calendar time B0 and developed the
disease at age T0 before being recruited to the clinic, their family could be selected for
inclusion into the family study. One relative of this proband was born at calendar time B1
and was found to be disease-free at the time of contact. The second relative was born at B2
and was found to have the condition at the contact time and their disease onset time was
available. The third relative was born at B3 also developed the disease prior to screening
but their onset time information is unavailable and all we know is their disease status at
the time of contact. This family therefore provides a combination of right-censored and
current status data. Another complication for the family study is that limited information
on the marginal distribution of onset time is available from the family data itself, due to
the biased sampling scheme where the probands onset time is right-truncated and due to
the low incidence of disease in the non-probands. This leads to limited information on
both the marginal onset time distribution and the association structure within families.
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Figure 1.1: Lexis diagram illustrating the mixed type family data obtained under the
biased sample scheme.
In Chapter 2 we develop copula-based models for the within-family association in the
onset time of disease which accommodate a complex dependence structure. Second-order
regression models in which dependencies are characterized by Kendall’s τ are developed to
study the within-family association in disease onset times; covariate effects can be mod-
eled on the marginal distributions as well as the within-family associations. Likelihood and
composite likelihoods are adopted for estimation and statistical inference. The proposed
methods accommodate a combination of right-censored and current status observation of
disease onset times among the non-probands. We also consider use of auxiliary data from
independent individuals by augmentating the composite likelihoods to increase precision
of marginal parameter estimates and consequently increase efficiency in dependence pa-
rameter estimation. Simultaneous and two-stage estimation procedures are considered for
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the augmented composite likelihoods, and the large sample theory for estimators under
two-stage estimation procedure is also developed. Simulation studies investigate the em-
pirical bias and relative efficiencies of estimators under different estimation procedures. An
application to a motivating family study in psoriatic arthritis illustrates the method and
provides evidence of excessive paternal transmission of risk.
1.3.2 Cluster-randomized Trials with Censored Failure Times
In Chapter 3 attention is directed towards the design of cluster-randomized trials with
censored event times. In cluster-randomized trials intervention effects are often formulated
by specifying marginal models, fitting them under a working independence assumption,
and using robust variance estimates to address the association in the responses within
clusters. We develop sample size criteria within this framework, with analyses based on
semiparametric Cox regression models fitted with event times subject to right-censoring.
At the design stage, copula models are specified to enable derivation of the asymptotic
variance of estimators from a marginal Cox regression model, and to compute the number
of clusters necessary to satisfy power requirements. Simulation studies demonstrate the
validity of the sample size formula in finite samples for a range of cluster sizes, censoring
rates and degrees of within-cluster association among event times. The power and relative
efficiency implications of copula misspecification is studied, as well as the effect of within-
cluster dependence in the censoring times. Sample size criteria and other design issues
are also addressed for the setting where the event status is only ascertained at periodic
assessments and times are interval-censored.
An illustrative example involving treatment for otitis media (Le and Lindgren, 1996;
Manatunga and Chen, 2000) is considered for illustration. Otitis media is inflammation
of the inner ear which make patients at risk of permanent damage and loss of hearing.
A common intervention involves the surgical insertion of a ventilating tube and interest
may lie in assessing an experimental post-surgery medical therapy designed to prolong the
function of the ventilating tubes. In a randomized trial (Le and Lindgren, 1996), children
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from six months to eight years of age with otitis media requiring surgical insertion of tubes
in the auditory canal are randomized to receive either two weeks of medical therapy with
prednisone and sulfamethoprim or no medical therapy (standard care). In this trial, the
child is then the unit of randomization and the time to failure of the tubes in the left and
right ears would naturally be correlated. Therefore, the proposed sample formulae could be
used for this trial to determine the required number of children to ensure the pre-specified
power.
1.3.3 Causal Analysis of Post-progression Survival in Cancer
Despite the clear need to demonstrate the effect of experimental cancer treatments on
overall survival many trials are designed with the primary analysis based on the compos-
ite endpoint of progression-free survival. The factors influencing the relationship between
treatment effects on progression-free survival and overall survival are complex and mul-
tifaceted but include the progression-free mortality rate and associated treatment effect,
the factors leading to the introduction of rescue interventions upon progression, among
others. In Chapter 4, we consider the three state illness-death model as a framework for
exploring the effect of these factors and issues of causal inference. Recent interest in the
post-progression survival prompts us to focus the effect of randomized treatment on the
sojourn time in the progression state. We focus on examining the effect of treatment on
the sojourn time distribution for state 1. We carry out this study based on an additive
model which is collapsible, determine limiting values of the integrated regression coeffi-
cients under naive analyses, define the causal quantities of interest, and develop weighted
estimating equations which render consistent estimates for the causal functions we derive.
Simulation studies have been carried out to assess the validity of the proposed weighted
estimating equations. We also extend the proposed method to a more general scenario
where a rescue intervention has been introduced upon progression.
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Chapter 2
Augmented Composite Likelihood for
Copula Modeling in Family Studies
using Biased Sampling Schemes
2.1 Introduction
Family studies are routinely designed as a cost-effective approach to investigating the
genetic basis of disease (Laird and Lange, 2006). Such studies typically employ biased
sampling schemes in which individuals in a disease registry are recruited along with con-
senting family members (Fisher, 1934; Cannings and Thompson, 1977; Burton et al., 2000;
Burton, 2003). The individual in the disease registry, called the proband, often provides
more detailed information on the disease history than their respective family members who
we refer to as non-probands. In many settings, for example, it is only known whether the
non-probands have the condition or not at the time of recruitment. Inferences regarding
the hereditary nature of disease are primarily based on the nature and extent of the within-
family association in some feature of the disease process. The importance of constructing
likelihoods which recognize the biased sampling scheme is now well-known (Thompson,
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1993; Glidden and Liang, 2002; Kraft and Thomas, 2000; Lange, 2002; Epstein et al.,
2002).
While much work has been based on binary disease status of individuals (Ziegler et al.,
2000; Matthews et al., 2007), this response is problematic if there is considerable variation
in the age of onset and the age of individuals at the time of assessment. Specification
of multivariate models for the time of disease onset enable one to appropriately address
the fact that disease status is time-dependent. Frailty models are used extensively in this
context (Babiker and Cuzick, 1994; Yashin and Iachine, 1995; Li and Thompson, 1997; Li
et al., 1998; Zhang and Merikangas, 2000; Hsu et al., 2004; Choi et al., 2008; Choi, 2012)
but they do not yield appealing measures of within-family association. Copula functions
(Joe, 1997; Nelsen, 2006) offer a much more appealing framework for joint modeling of
disease onset times within families since they yield measures of association which are
functionally independent of parameters in the marginal distributions. Glidden and Self
(1999) formulated the conditional hazard function with a gamma distributed frailty term so
that the marginalized hazard functions satisfy the Cox model and the resulting joint model
is a Clayton-Oakes model. An approximate EM algorithm can be applied for parameter
estimation. Similarly, Hsu and Gorfine (2006) used a frailty-based approach to analyse
the family data from case-control family studies. Martinussen and Pipper (2005) also
considered the positive stable shared frailty Cox model for which the resulting marginal
hazard is still of the Cox-form.
We develop marginal models for the disease onset time distribution and use Gaussian
copula to model the role of kinship in the strength of within-family associations (Liang
et al., 1991). Covariate effects can be studied in marginal and second-order regression
models in the spirit of Prentice and Zhao (1991). Likelihood and composite likelihood
(Lindsay, 1988; Cox and Reid, 2004) are examined; each recognize the biased sampling
scheme but the latter can offer important simplifications and reduce computational burden
when large families are present. We also explore utility of auxiliary data to address the
poor precision in the onset time distribution resulting from the biased sampling scheme
and study the relative efficiency of simultaneous and two-stage estimation.
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The remainder of this chapter is organized as follows. In Section 2.2 we define notation,
formulate the joint model, and discuss the sampling scheme. Likelihood and composite like-
lihood methods for response-biased data are discussed in Section 2.3 where asymptotic and
empirical studies investigate the relative efficiency of the proposed methods. Extensions
are discussed in Section 2.4 where we handle a combination of right-censored and cur-
rent status observation schemes for non-probands (Sun, 2006). Approaches for making
use of auxiliary data from studies directed at the marginal age of onset distribution are
also discussed here and examined empirically. Two-stage estimation procedure has been
considered for this augmented composite likelihood, and the asymptotic property of this
two-stage estimator has also been established. An application to the motivating family
study on the genetic basis for psoriatic arthritis is given in Section 2.5 where important
insights are made on excessive paternal transmission of risk. Concluding remarks are given
in Section 2.6.
2.2 Second-Order Dependence Models for Disease On-
set Times in Family Studies
Let Tij denote the time of disease onset for individual j in cluster i, and Zij = (Zij1, . . . , Zijp)
′
denote a p× 1 covariate vector, j = 1, . . . ,mi. The marginal cumulative distribution func-
tion and survival functions are F (t|Zij; θ) = P (Tij ≤ t|Zij) and F(t|Zij; θ) = 1−F (t|Zij; θ)
respectively.
The full vector of event times and covariates in cluster i are denoted by Ti = (Ti1, . . . , Timi)
′
and Zi = (Z
′
i1, . . . , Z
′
imi
)′ respectively and we assume Ti ⊥ Ti′ |(Zi, Zi′). Furthermore, we
assume that P (Tij ≤ t|Zi) = P (Tij ≤ t|Zij) for each j. A joint model for the event times in
cluster i can be constructed by specifying an mi dimensional copula function (Joe, 1997),
a multivariate cumulative distribution function with uniform [0, 1] marginal distributions.
That is if Uij ∼ unif(0, 1) and Ui = (Ui1, . . . , Uimi)′, the joint cumulative distribution func-
tion C(ui1, . . . , uimi ; γ) = P (Ui1 ≤ ui1, . . . , Uimi ≤ uimi ; γ) defines a copula indexed by a
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q × 1 parameter vector γ. A joint c.d.f. for Ti|Zi is obtained by taking the probability
integral transform of Tij, setting Uij = F(Tij|Zij; θ), and defining F(ti|Zi;ψ) as
P (Ti1 > ti1, . . . , Timi > timi |Zi;ψ) = C(F(ti1|Zi1; θ), . . . ,F(timi |Zimi ; θ); γ) , (2.2.1)
where ψ = (θ′, γ′)′. The Clayton copula has the form
C(ui1, . . . , uimi ; γ) =
(
u−γi1 + · · ·+ u−γimi −mi + 1
)−1/γ
, γ ∈ [−1,∞) \ {0} , (2.2.2)
where γ is a scalar and Kendall’s τ (Nelsen, 2006; Joe, 1997) is given by τ = γ/(γ + 2),
having a range over [−1, 0) ∪ (0, 1]. This is a member of the Archimedean family (Genest
and Mackay, 1986) which has connections with frailty models (Oakes, 1989) and is invariant
to left-truncation (Manatunga and Oakes, 1996; Oakes, 2005) and as a result it has seen
considerable application in health research.
In many settings however, a single parameter is not adequate for characterizing all
pairwise associations. Nested Archimedean copulas and hierarchical Archimedean copulas
yield flexible dependence models (Fischer et al., 2009), but we here focus on the Gaussian
copula (Fang et al., 1990), a member of elliptical family which accommodates different
pairwise associations through specification of a general correlation matrix. Specifically, for
the Gaussian copula
C(ui1, . . . , uimi ; γ) = Φmi(Φ−1(ui1), . . . ,Φ−1(uimi); γ) , (2.2.3)
where Φ−1(·) is the inverse cumulative distribution function of a standard normal random
variable and Φmi(· ; γ) is the joint cumulative distribution function of a mi×1 multivariate
normal random variable with mean zero and mi×mi correlation matrix Σi(γ) = Σi indexed
by a vector γ with off-diagonal entries σijk. The resulting joint survivor function for Ti|Zi
is then
P (Ti1 > ti1, . . . , Timi > timi |Zi;ψ) =
∫ ri1
−∞
· · ·
∫ rimi
−∞
exp
(−s′i Σ−1i si/2)√
(2pi)mi |Σi|
dsi1 . . . dsimi
(2.2.4)
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where Si ∼ MVNmi(0,Σi), si is a realization, and rij = Φ−1(F(tij|Zij; θ)), j = 1, . . . ,mi.
The association between Tij and Tik conditional on (Zij, Zik) is measured by Kendall’s τ ,
given here by τijk = 2 arcsin(σijk)/pi, 1 ≤ j < k ≤ mi, i = 1, . . . , n.
Flexible modeling of the within-cluster association can be achieved by specifying a
second-order regression model of the form g(τijk) = V
′
ijkγ, where g(·) is a 1-1 differen-
tiable link function mapping Kendall’s τ onto the real line, Vijk is an q × 1 covariate
vector characterizing individuals j and k in cluster i and their relation, and γ is the cor-
responding q× 1 vector of coefficients. There is considerable flexibility in this formulation
in that Vijk may represent cluster-level or individual-level features, or information on the
structural relation between individuals j and k in cluster i. The Fisher transformation
g(τ) = log ((1 + τ)/(1− τ)) is a natural choice for the link function, in which case the
second-order model can be rewritten as
g(τijk) = log ((1 + τijk)/(1− τijk)) = V ′ijkγ . (2.2.5)
2.3 Likelihood and Composite Likelihood Construc-
tion under Biased Sampling
2.3.1 Maximum Likelihood Estimation and Inference
We consider the analysis of family data in which families are sampled due to the disease
status of a particular family member designated as the proband (assume there is only one
proband for each family); without loss of generality we assign this individual label 0 and
increase the dimension of the response and covariate vectors to include this individual. Let
Ti0 denote the disease onset time for the proband in family i, and Ci0 the corresponding
clinic entry time; that is the proband is sampled because Ti0 < Ci0. The mi family
members of proband i have event times Ti1, . . . , Timi which we assume here are observed
subject to right censoring at their recruitment times Ci1, . . . , Cimi respectively. We let
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Xij = min(Tij, Cij) and Yij = I(Tij < Cij), j = 0, . . . ,mi, where Yi0 = 1. If Zi =
(Z ′i1, . . . , Z
′
imi
)′ as before, we let Z¯i = (Z ′i0, Z
′
i)
′ denote the full vector of covariates for
family i, and similarly let Xi = (Xi1, . . . , Ximi)
′, X¯i = (Xi0, X ′i)
′, Ci = (Ci1, . . . , Cimi)
′,
C¯i = (Ci0, C
′
i)
′, Yi = (Yi1, . . . , Yimi)
′ and Y¯i = (Yi0, Y ′i )
′.
Under the assumption of independent and non-informative censoring, the likelihood
contribution from family i is
Li(ψ) ∝ P (X¯i, Y¯i|C¯i, Z¯i, Ti0 < Ci0;ψ) (2.3.1)
which can be expressed in terms of (2.2.1); the condition Ti0 < Ci0 reflects the unique
role of the proband in selecting the family. As a specific example of how one computes
(2.3.1) from (2.2.1), consider a family with only two family members including the proband
(i.e. mi = 1), in which the non-proband is disease-free at the recruitment time Ci1. The
contribution to the likelihood from this family under the Gaussian copula (2.2.3) can be
written as
P (X¯i, Y¯i|C¯i, Z¯i, Ti0 < Ci0;ψ) = P (Ti0, Ti1 > Ci1|C¯i, Z¯i, Ti0 < Ci0;ψ)
= P (Ti0, Ti1 > Ci1|C¯i, Z¯i;ψ)/F (Ci0|Zi0; θ)
= F−1(Ci0|Zi0; θ)
{
− ∂
∂ti0
F(ti0, Ci1|C¯i, Z¯i;ψ)
}
= F−1(Ci0|Zi0; θ)
{
− ∂
∂ti0
∫ qi0
−∞
∫ qi1
−∞
φ2(si0, si1;ψ)dsi0dsi1
}
= F−1(Ci0|Zi0; θ)
{∫ qi1
−∞
φ2(qi0, si1;ψ)dsi1 ·
(
φ−1(qi0)f(ti0|Zi0; θ)
)}
= F−1(Ci0|Zi0; θ)f(ti0|Zi0; θ)Φ
qi1 − σi01qi0√
1− σ2i01
;ψ
 ,
where qij = Φ
−1(F(tij|Zij; θ)) and φ2(si0, si1;ψ) is the density function for bivariate normal
distribution with mean zero and correlation Σi indexed by a vector γ with off-diagonal
entries σijk; ψ = (θ
′, γ′)′.
The contribution to the score vector and information matrix from family i are
Si(ψ) =
∂ logLi(ψ)
∂ψ
=
∂ logP (X¯i, Y¯i|C¯i, Z¯i;ψ)
∂ψ
− ∂ logF (Ci0|Zi0; θ)
∂ψ
, (2.3.2)
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and
Ii(ψ) = − ∂
2 logLi(ψ)
∂ψ∂ψ′
= −
[
∂2 logP (X¯i, Y¯i|C¯i, Z¯i;ψ)
∂ψ∂ψ′
− ∂
2 logF (Ci0|Zi0; θ)
∂ψ∂ψ′
]
, (2.3.3)
respectively. The maximum likelihood estimate ψ̂ solves
∑n
i=1 Si(ψ) = 0 and
√
n(ψ̂−ψ) is
asymptotically normally distributed with mean zero and variance I−1(ψ), where I(ψ) =
E[Ii(ψ)]. The term ∂
2 logF (Ci0|Zi0; θ)/∂ψ∂ψ′ subtracted in (2.3.3) represents the loss of
“information” about the marginal parameters due to the response-biased sampling scheme.
2.3.2 Composite Likelihood under Biased Sampling
When family size mi is large it can be challenging to compute and maximize the full
likelihood. We consider the use of composite likelihood (Lindsay, 1988; Cox and Reid,
2004) comprised of contributions based on lower dimensional subsets of individuals in each
family. Working with lower dimensional distributions leads to considerable simplifications
in the analytical expressions and computation. Let Sir denote the set of (r + 1)−tuples
of individuals in cluster i including the proband where the cardinality of this set is mir =
mi !/[r! (mi − r) ! ], r = 1, . . . ,mi. For example, Si1 = {(0, j), j = 1, 2, . . . ,mi}, Si2 =
{(0, j, k), 1 ≤ j < k ≤ mi} and Simi = {(0, 1, 2, . . . ,mi)}. An element of Sir is identified
by the triple (i, r, s), s = 1, . . . ,mir. Then if D¯i = (Di0, Di1, . . . , Dimi)
′ is an (mi + 1)× 1
vector, let D¯
(r,s)
i denote the subvector containing elements of D¯i which is element (i, r, s)
of Sir. We then define a composite likelihood by
CLi(ψ) ∝
miU∏
r=miL
mir∏
s=1
P (X¯
(r,s)
i , Y¯
(r,s)
i |C¯(r,s)i , Z¯(r,s)i , Ti0 < Ci0;ψ) , (2.3.4)
where miL and miU (1 ≤ miL ≤ miU ≤ mi) determine the dimensions of the joint dis-
tributions contributing to (2.3.4). The issues in selecting composite likelihoods have been
discussed in (Lindsay et al., 2011). The composite likelihood contributions under specified
copula functions can be derived in the similar way as we described in Section 2.3.1.
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If r = miL = miU = 2, then a composite likelihood is obtained based on all triplets of
family members including the proband, as in
CL1i(ψ) ∝
∏
1≤j<k≤mi
P (W¯ijk|C¯ijk, Z¯ijk, Ti0 < Ci0;ψ) . (2.3.5)
whereWij = (Xij, Yij)
′, W¯ijk = (W ′i0,W
′
ij,W
′
ik)
′, C¯ijk = (Ci0, Cij, Cik)′ and Z¯ijk = (Z ′i0, Z
′
ij, Z
′
ik)
′.
This composite likelihood requires working with trivariate distributions. If r = miL =
miU = 1, an even simpler “pairwise” conditional likelihood is obtained,
CL2i(ψ) ∝
mi∏
j=1
P (W¯ij|C¯ij, Z¯ij, Ti0 < Ci0;ψ) , (2.3.6)
which only requires use of bivariate distributions, where W¯ij = (W
′
i0,W
′
ij)
′, C¯ij = (Ci0, Cij)′
and Z¯ij = (Z
′
i0, Z
′
ij)
′. The score functions arising from (2.3.5) and (2.3.6) are U(ψ) =∑n
i=1 Ui(ψ) =
∑n
i=1 ∂ logCLi(ψ)/∂ψ.
If ψ˜ denotes the maximum composite likelihood estimator from (2.3.5) or (2.3.6), then
under standard regularity conditions,
√
n(ψ˜− ψ) converges in distribution to multivariate
normal with mean vector zero, and covariance matrix
asvar(
√
n(ψ˜ − ψ)) = A−1(ψ)B(ψ) [A−1(ψ)]′ , (2.3.7)
where A(ψ) = −E{∂2 logCLi(ψ)/∂ψ∂ψ′} and B(ψ) = E{Ui(ψ)U ′i(ψ)}. This can be con-
sistently estimated by
âsvar(
√
n(ψ˜ − ψ)) = A−1(ψ˜)B(ψ˜)
[
A−1(ψ˜)
]′
, (2.3.8)
where
A(ψ) = −n−1
n∑
i=1
∂2 logCLi(ψ)/∂ψ∂ψ
′ , and B(ψ) = n−1
n∑
i=1
Ui(ψ)U
′
i(ψ) .
For example, if the second composite likelihood (2.3.6) is adopted, then
Ui(ψ) = ∂ logCL2i(ψ)/∂ψ =
mi∑
j=1
Uij(ψ) ,
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where
Uij(ψ) =
∂
∂ψ
logP (Wi0,Wij|C¯ij, Z¯ij, Ti0 < Ci0;ψ) ,
and the A(ψ) and B(ψ) are in the forms of
A(ψ) = −
mi∑
j=1
E
{
∂2 logP (Wi0,Wij |C¯ij , Z¯ij , Ti0 < Ci0;ψ)
∂ψ∂ψ′
}
,
B(ψ) =
mi∑
j,k=1
E
{
Uij(ψ)U
′
ik(ψ)
}
,
which can be estimated by
A(ψ) = −n−1
n∑
i=1
mi∑
j=1
{
∂2 logP (Wi0,Wij |C¯ij , Z¯ij , Ti0 < Ci0;ψ)
∂ψ∂ψ′
}
, (2.3.9)
B(ψ) = n−1
n∑
i=1
mi∑
j,k=1
{
Uij(ψ)U
′
ik(ψ)
}
. (2.3.10)
2.3.3 Asymptotic Relative Efficiency of the Composite Likeli-
hoods
The analytical and computational advantages of composite likelihood come at the cost
of a loss in efficiency. Here we examine the asymptotic relative efficiency of composite
likelihood as a function of the strength of the within-family association.
Consider n = 100 ascertained families, comprised of two generations and made up of two
parents and two children; mi = 3. The proband is randomly selected from the four family
members, and is indexed by j = 0. The same marginal distribution is assumed for the
event times of all family members with Weibull survivor function F(tij; θ) = exp(−(λtij)κ),
j = 0, 1, 2, 3; θ = (λ, κ)′. We let κ = 1.2 and choose λ to give a median age of 45 years
for disease onset. The clinic entry time Ci0 for the proband is normally distributed with
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mean µ = 50 and variance σ2 = 20, and families are recruited into the study only if the
proband satisfies the selection condition Ti0 < Ci0. For individual j in selected family i,
Cij is the random age of contact, assumed to follow N(µ = 60, σ
2 = 10) for individuals
in the first generation and N(µ = 40, σ2 = 10) for individuals in the second generation,
j = 1, 2, 3; the age at contact for individuals in both generations are truncated at 90
years. We consider an exchangeable association structure for simplicity here based on
the Clayton copula with Kendall’s τ varying from 0.05 to 0.6, reflecting small to strong
within-family association. The second-order regression model (2.2.5) is then simplified to
log
(
(1 + τijk)/(1− τijk)
)
= γ0, 0 ≤ j < k ≤ 3.
The asymptotic relative efficiency of the composite likelihood approach is defined as the
ratio of the asymptotic variance of the estimators from the full and composite likelihood
methods. The asymptotic variance can be evaluated by I−1(ψ) based on (2.3.3) for the full
likelihood method and by the robust sandwich variance based on (2.3.7) for the composite
likelihood methods, where the required expectations are taken by Monte Carlo methods.
Figure 2.1 shows the trends of asymptotic variance of estimators and their relative effi-
ciencies under two composite likelihoods compared with the full likelihood method as a
function of the within-family association. It is apparent that the first composite likelihood
approach is nearly as efficient as the full likelihood for all parameters, although there is
some efficiency loss, especially for γ0, when there is mild within-family association. This
makes sense as the first composite likelihood exploits the trivariate distribution and fam-
ilies are of size four. Figure 2.1 also demonstrates that there is significant efficiency loss
incurred when adopting the second composite likelihood. So detailed dependence modeling
should be based on the first composite likelihood. Interestingly, when the within-family
association increases, the efficiency loss of the second composite likelihood become smaller,
especially for the second-order regression coefficient. This is valid as when family members
become more and more like each other (association close to 1), the information provide by
two family members will be similar to the information provided by all family members.
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Figure 2.1: Asymptotic variance (top row) and relative efficiency (bottom row) of the first
(CL1) and the second (CL2) composite likelihood methods compared to the full likelihood
method (Full) for all parameters as a function of the strength of the within-family associa-
tion (Kendall’s τ) for family data with response-biased sampling in the presence of random
right censoring; Clayton copula, n = 100.
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2.3.4 Finite Sample Study of Composite Likelihood Methods
Here we report on simulation studies designed to assess the validity of the likelihood and
two composite likelihoods along with the empirical relative efficiency. The parameter
settings are as in Section 2.3.3 and for the Clayton copula we let Kendall’s τ = 0.40.
To accommodate a more general within-family dependence structure, we also consider a
Gaussian copula of the form (2.2.3) involving three types of association: between-parents,
between-siblings and parent-child, with Kendall’s τ denoted by τpp, τss and τps respectively.
We set τpp = 0.1, τss = 0.4 and τps = 0.2, with the relative sizes of these measures
compatible with the setting where genetic factors may contribute to the aetiology of this
disease. A second-order regression model (2.2.5) can be used to parameterize associations,
log((1 + τijk)/(1− τijk)) = V ′ijkγ = γ0 + γ1Vijk1 + γ2Vijk2 , 0 ≤ j < k ≤ 3 , (2.3.11)
where Vijk1 = I((j, k) pair are siblings), Vijk2 = I((j, k) pair is parent− child), and Vijk =
(1, Vijk1, Vijk2)
′, 0 ≤ j < k ≤ 3.
One thousand datasets of n = 1000 families were then generated and analysed with
likelihood (2.3.1) and the two composite likelihood methods (2.3.5) and (2.3.6). The es-
timates ψ̂ and ψ˜ from the full likelihood and composite likelihoods, respectively, can be
obtained by maximizing the corresponding objective functions using the ‘nlm’ function in
R (R Core Team, 2014), and the variance of estimators from full likelihood approach can
be consistently estimated by V̂ar(ψ̂) = n−1 Î−1(ψ̂), where
Î(ψ̂) = − 1
n
n∑
i=1
[
∂2 logP (X¯i, Y¯i|C¯i, Z¯i;ψ)
∂ψ∂ψ′
− ∂
2 logF (Ci0|Zi0; θ)
∂ψ∂ψ′
] ∣∣∣∣∣
ψ=ψ̂
,
and the variance of estimators under the composite likelihoods approach can be estimated
by V̂ar(ψ˜) = n−1A−1(ψ˜)B(ψ˜)
[
A−1(ψ˜)
]′
, where A(ψ) and B(ψ) are expressed in formulae
(2.3.9) and (2.3.10), respectively.
The empirical properties of marginal parameter estimates and estimated second-order
regression coefficients γ are summarized in Table 2.1 for both dependence structures. For
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all three methods, the biases are negligible, the empirical standard errors (ESE) agree
with the average standard errors (ASE), and the empirical coverage probabilities (ECP)
of nominal 95% confidence intervals are all within an acceptable range. The ASEs are the
smallest for all parameters under the likelihood analysis , followed by those of the first
composite likelihood and then those of the second composite likelihood, in alignment with
expectations based on Section 2.3.3.
Table 2.1: Empirical properties of estimators based on the full likelihood, the first com-
posite likelihood (CL1) and the second composite likelihood (CL2) for family data with
response-biased sampling in the context of right censoring; for the Clayton copula Kendall’s
τ = 0.4 and for the Gaussian copula τpp = 0.1, τss = 0.4, τps = 0.2; n = 1000, nsim = 1000.
Composite Likelihood
Full Likelihood CL1 CL2
PARAMETER† BIAS ESE ASE ECP BIAS ESE ASE ECP BIAS ESE ASE ECP
Clayton Copula
log λ -0.004 0.073 0.074 0.956 -0.004 0.075 0.075 0.950 -0.004 0.099 0.099 0.936
log κ 0.001 0.019 0.019 0.952 0.001 0.019 0.020 0.952 0.001 0.022 0.023 0.953
γ0 0.003 0.085 0.086 0.965 0.003 0.089 0.090 0.957 0.001 0.133 0.133 0.947
τ 0.001 0.035 0.036 0.963 0.000 0.037 0.037 0.957 -0.001 0.055 0.055 0.947
Gaussian Copula
log λ -0.000 0.041 0.041 0.947 -0.001 0.041 0.041 0.940 -0.001 0.047 0.047 0.942
log κ 0.001 0.018 0.019 0.956 0.001 0.018 0.019 0.956 0.001 0.020 0.020 0.956
γ0 -0.001 0.052 0.052 0.951 -0.002 0.054 0.054 0.952 -0.003 0.075 0.075 0.957
γ1 0.002 0.061 0.061 0.934 0.005 0.065 0.063 0.942 0.007 0.091 0.088 0.944
γ2 0.001 0.040 0.042 0.959 0.002 0.043 0.044 0.951 0.003 0.064 0.066 0.947
τpp -0.001 0.026 0.026 0.949 -0.001 0.027 0.027 0.954 -0.002 0.037 0.037 0.956
τss 0.000 0.020 0.020 0.953 0.001 0.021 0.021 0.956 0.001 0.027 0.027 0.948
τps -0.000 0.019 0.019 0.939 -0.000 0.019 0.019 0.943 -0.000 0.024 0.024 0.957
† True parameter values are log λ = −4.112, log κ = 0.182, for Clayton copula γ0 = 0.847; for Gaussian
copula γ = (0.201, 0.647, 0.205)′.
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2.4 Extensions to Deal with Observation and Sam-
pling Complications
2.4.1 Accommodation of Right-censored and Current Status Ob-
servation
Information on disease onset time for non-probands is often collected retrospectively by
a review of medical records or patient recall. For some non-probands determined to have
the disease at the time of recruitment, however, no such information is available; this
may arise when they are diagnosed for the first time upon recruitment, or if there are no
medical records available. Such individuals furnish current status data with respect to their
disease status (Sun, 2006), since all that is known is whether they have the condition at
the time of recruitment and clinical examination. We let Rij indicate that individual j in
cluster i is under a right-censored observation scheme (due to the availability of a medical
history) where Rij = 0 if the individual is under a current status observation scheme; let
Ri = (Ri1, . . . , Rimi)
′ and R¯i = (Ri0, R′i)
′; since the probands in a clinical registry where
detailed information is available; Ri0 = 1, i = 1, . . . , n. We let Ri = {j : Rij = 1}
and R¯i = {j : Rij = 0} to index the sets of family members whose medical history is
available or not for the ith family, respectively. For notational convenience let Xij = Cij
if j ∈ R¯i, so Xij denotes the time of the assessment for such individuals under a current
status observation scheme; as before we let Yij = I(Tij < Cij). This notation enables us to
write the likelihood as
Li(ψ) ∝ P (X¯i, Y¯i|R¯i, C¯i, Z¯i, Ti0 < Ci0;ψ) , (2.4.1)
and the analogous composite likelihoods as
CL1i(ψ) ∝
∏
1≤j<k≤mi
P (W¯ijk|R¯ijk, C¯ijk, Z¯ijk, Ti0 < Ci0;ψ) , (2.4.2)
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where R¯ijk = (Ri0, Rij, Rik)
′, and
CL2i(ψ) ∝
mi∏
j=1
P (W¯ij|R¯ij, C¯ij, Z¯ij, Ti0 < Ci0;ψ) , (2.4.3)
where R¯ij = (Ri0, Rij)
′. The composite likelihood contributions for this mixed-type family
data under the specified copula functions can be derived in the similar way as we described
in Section 2.3.1. For example, consider a family with three family members including the
proband (i.e. mi = 2), with the first member under a right censoring observation scheme
(i.e. Ri1 = 1) and the second member under a current status observation scheme (i.e.
Ri2 = 0). If Yi1 = 0 and Yi2 = 1, then the contribution to the second composite likelihood
(2.4.3) from this family can be written as
CL2i(ψ) =
2∏
j=1
P (W¯ij|R¯ij, C¯ij, Z¯ij, Ti0 < Ci0 ;ψ)
= P (Ti0, Ti1 > Ci1|Ri0 = Ri1 = 1, C¯i1, Z¯i1, Ti0 < Ci0;ψ)
× P (Ti0, Ti2 ≤ Ci2|Ri0 = 1, Ri2 = 0, C¯i2, Z¯i2, Ti0 < Ci0;ψ) ,
where
P (Ti0, Ti1 > Ci1|Ri0 = Ri1 = 1, C¯i1, Z¯i1, Ti0 < Ci0;ψ)
= F−1(Ci0|Zi0; θ) ·
{
− ∂
∂ti0
F(ti0, Ci1|C¯i1, Z¯i1;ψ)
}
,
and
P (Ti0, Ti2 ≤ Ci2|Ri0 = 1, Ri2 = 0, C¯i2, Z¯i2, Ti0 < Ci0;ψ)
= F−1(Ci0|Zi0; θ) ·
[
− ∂
∂ti0
{F(ti0|Zi0; θ)−F(ti0, Ci2|C¯i2, Z¯i2;ψ)}] ,
and the explicit expression of F(ti0, tij|C¯ij, Z¯ij;ψ) depends on the copula functions and
association structure. The asymptotic properties of estimators based on the full likelihood
and the composite likelihoods are similar as we developed in Section 2.3.
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Here we conduct a simulation study to assess the performance of the methods with
right-censored and current status family data. Again we consider two-generation families
comprised of two parents and two children. A Weibull distribution is adopted for the
onset times for all family members; F(tij; θ) = exp(−(λtij)κ), j = 0, 1, 2, 3; θ = (λ, κ)′.
The clinic entry time distribution and examination time distribution for the non-probands
are the same as in Section 2.3.3. We further generate a random binary indicator Rij
for non-probands, j = 1, 2, 3, which indicate their respective observation scheme with
probability P (Rij = 1) = P (Rij = 0) = 0.5; if Rij = 1, then a medical history is available
for this member and we observe Xij = min(Tij, Cij) and Yij = I(Tij < Cij); otherwise,
only current status data are available and we observe Yij = I(Tij < Cij) and Cij. For
within-family association structure, a Clayton copula and a Gaussian copula are considered.
For the latter, three types of associations (between-parents, between-siblings and parent-
child) are considered. The parameter settings for association structure are as in Section
2.3.4. As we discussed, although the full likelihood is more efficient than the composite
likelihood, computing and maximizing the full likelihood is very complex when the family
size is large, the within-family association structure is complex or the family data is in
mixed-type. Furthermore, the first composite likelihood is almost as efficient as the full
likelihood in most cases, which is also supported by our asymptotic relative efficiency
study. We therefore only apply the extended composite likelihoods (2.4.2) and (2.4.3) to
the mixed-type family data with ascertainment bias. Table 2.2 summarizes the empirical
properties of estimates based on the extended composite likelihood for mixed-type family
data with response-biased sampling under the exchangeable and more general within-family
structures, respectively. We find that the bias are all negligible, the empirical standard
errors (ESE) agree with the average robust standard errors (ASE), and the empirical
coverage probabilities (ECP) of nominal 95% confidence intervals are within the acceptable
range for all parameters. The ASE under the first composite likelihood are smaller than
those of the second composite likelihood approach. These findings support the validity of
the extension of our proposed composite likelihood approaches to the mixed-type family
data subject to the response-biased sampling.
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Table 2.2: Empirical properties of estimators based on composite likelihoods CL1 and CL2
for a 50:50 mix of right-censored and current status family data under response-biased
sampling; for the Clayton copula Kendall’s τ = 0.4 and for the Gaussian copula τpp = 0.1,
τss = 0.4, τps = 0.2; n = 1000, nsim = 1000.
Composite Likelihood CL1 Composite Likelihood CL2
PARAMETER† BIAS ESE ASE ECP BIAS ESE ASE ECP
Clayton Copula
log λ -0.001 0.084 0.081 0.947 -0.005 0.112 0.109 0.942
log κ -0.000 0.023 0.023 0.953 -0.000 0.027 0.027 0.955
γ0 -0.001 0.102 0.100 0.944 0.002 0.149 0.148 0.958
τ -0.001 0.042 0.042 0.945 -0.001 0.062 0.062 0.948
Gaussian Copula
log λ -0.001 0.043 0.043 0.954 -0.001 0.049 0.049 0.951
log κ 0.000 0.022 0.022 0.950 0.000 0.024 0.024 0.952
γ0 0.001 0.064 0.063 0.937 -0.001 0.083 0.083 0.950
γ1 -0.000 0.073 0.073 0.951 0.003 0.096 0.097 0.950
γ2 -0.001 0.052 0.052 0.948 0.001 0.071 0.073 0.955
τpp 0.000 0.032 0.031 0.938 -0.000 0.041 0.041 0.950
τss -0.000 0.023 0.024 0.959 0.001 0.029 0.030 0.949
τps -0.000 0.022 0.021 0.937 0.000 0.028 0.027 0.942
† True parameter values are log λ = −4.112, log κ = 0.182, for Clayton copula γ0 = 0.847; for Gaussian
copula γ = (0.201, 0.647, 0.205)′.
33
2.4.2 Use of Auxiliary Data on the Marginal Incidence and Two-
Stage Estimation
While it is compelling to formulate models for the onset time distribution to address
the current status nature of the data, there is limited information on the marginal onset
time distribution from the family study itself since the onset times of probands are right-
truncated and the incidence is typically low among non-probands. Auxiliary data are often
available however, which has the potential to enhance efficiency of estimation considerably
depending on the nature of the auxiliary data. Readily available auxiliary data is, for
example, the right-truncated disease onset time among individuals not selected for inclusion
in the family study; assuming participants are randomly selected and this data can be
easily incorporated as we show shortly. There may also be information available from
other clinical registries of similar psoriatic arthritis patients. Alternatively one may exploit
current status data from a cross-sectional survey (Gelfand et al., 2005) as we do in the
application.
Let F denote the set of probands in the family data and A the set of individuals in the
auxiliary sample; we consider auxiliary data of various types. In the presence of auxiliary
data, the augmented composite likelihoods corresponding to (2.4.2) and (2.4.3) become
ACL1(ψ) =
∏
i∈F
∏
1≤j<k≤mi
P (W¯ijk|R¯ijk, C¯ijk, Z¯ijk, Ti0 < Ci0;ψ)
∏
r∈A
P (Xr, Yr|Cr, Zr, Tr ∈ Br; θ) ,
(2.4.4)
ACL2(ψ) =
∏
i∈F
mi∏
j=1
P (W¯ij |R¯ij , C¯ij , Z¯ij , Ti0 < Ci0;ψ)
∏
r∈A
P (Xr, Yr|Cr, Zr, Tr ∈ Br; θ) , (2.4.5)
respectively, where Br denotes the truncation interval for individual r in the auxiliary
sample. If, for example, we consider unselected individuals from the original registry, then
individuals in the auxiliary sample have right-truncated onset times like the probands; e.g.
Br = (0, Cr) for r ∈ A . For current status data from a cross-sectional survey there is no
truncation, so Br = (0,∞). The estimator of ψ can be found by maximizing the augmented
composite likelihoods, and the asymptotic properties of this estimator are similar as we
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developed in Section 2.3.
When the unknown parameters are high dimensional, two-stage estimation can be used.
To show how, we express (2.4.4) as
ACL1(ψ) = ACL11(θ)× ACL12(ψ) (2.4.6)
where
ACL11(θ) =
∏
i∈F
P (Ti0|Ci0, Zi0, Ti0 < Ci0; θ)
∏
r∈A
P (Xr, Yr|Cr, Zr, Tr ∈ Br; θ) (2.4.7)
and
ACL12(ψ) =
∏
i∈F
∏
1≤j<k≤mi
P (Wijk|R¯ijk, C¯ijk, Z¯ijk, ti0;ψ) . (2.4.8)
The first term in (2.4.6) is only a function of θ while the second term is a function of ψ. Un-
der a two-stage estimation procedure we maximize (2.4.7) to obtain θ˘. At the second stage
we plug θ˘ into (2.4.8) and maximize it with respect to the remaining parameters to obtain
γ˘. The two-stage estimation procedure can also be used for the second composite likeli-
hood ACL2(ψ) in the similar way. The proof that the two-stage estimator ψ˘ = (θ˘
′, γ˘ ′)′ has
an asymptotic normal distribution is given in the Appendix A along with the asymptotic
variance.
We carry out a simulation study to illustrate the performance of the two-stage estima-
tion procedure. We consider the same parameter setting of Section 2.4.1 with two types of
auxiliary data: right-truncated individual data (to mimic the PsA clinical data) and cur-
rent status data (to mimic the national PsA survey data). The same marginal distribution
is assumed for event times of all individuals from auxiliary sample and recruited family
sample. For the right-truncated auxiliary data, we let the clinic entry times Cr satisfy the
same distribution of that for the proband in the family study, which is normal distribution
with mean µ = 50 and variance σ2 = 20. Then we can generate the right-truncated event
time by Tr ∼ T |T < Cr, and the auxiliary data consist of {Tr, Cr, Yr = 1; r = 1, . . . , nA},
where nA is size of the auxiliary sample. Likewise, for the auxiliary current status sample,
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the examination time Cr is normally distributed with mean µ = 50 and variance σ
2 = 20,
and Tr satisfy the Weibull distribution indexed by the vector of parameters θ and we
observe {Cr, Yr; r = 1, . . . , nA}. We generate 1000 replicates in each scenario with the
sample size for the family sample set to nF = 1000 and the size of the auxiliary sample
set to nA = 1000 or 20000. Both simultaneous and two-stage estimation procedures are
carried out and the variance of estimates under the two-stage estimation procedure can
be estimated by formula (2.A.15) in which probands are selected by simple random sam-
pling. The empirical properties of estimators are summarized in Table 2.3 for the Gaussian
copula.
We can find that when size of the auxiliary sample increases, both simultaneous and two-
stage estimation can lead to more precise estimates and that simultaneous maximization
leads to more efficient estimates than the two-stage procedure in all cases. When it is
possible to write out and is not too complex to simultaneously estimate parameters, this
method is therefore recommended. Furthermore, when there is large set of auxiliary data,
the two-stage procedure utilizing the auxiliary information is almost as efficient as that
using simultaneous estimation.
2.5 Application to the Psoriatic Arthritis Family Study
Here we consider an application to data from a family study conducted in the Centre for
Prognosis Studies in the Rheumatic Diseases at the University of Toronto. Hereditary
factors are thought to be important in psoriatic arthritis, as some studies have suggested
that close blood relatives of psoriatic arthritis patients have higher risk of developing this
disease compared to the general population. Characterizing the within-family association is
an important step towards understanding the genetic basis for disease. Particular interest
lies in assessing whether the father-child association in disease is greater or smaller than
the mother-child association - studies of this sort address the question of the so-called
“parent of origin” effect (Burden et al., 1998).
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Table 2.3: Empirical properties of estimators based on augmented composite likelihoods
ACL1 and ACL2 for mixed-type family data in the presence of right-truncated or current
status auxiliary data; Gaussian copula with Kendall’s τpp = 0.1, τss = 0.4, τps = 0.2;
nF = 1000, nsim = 1000.
Augmented Composite Likelihood ACL1 Augmented Composite Likelihood ACL2
Simultaneous Two-Stage Simultaneous Two-Stage
PARAMETER† EBIAS ESE ASE ECP EBIAS ESE ASE ECP EBIAS ESE ASE ECP EBIAS ESE ASE ECP
Right-truncated Auxiliary Data; nA = 1000
log λ -0.002 0.041 0.042 0.956 -0.005 0.157 0.152 0.946 -0.001 0.047 0.048 0.956 -0.005 0.157 0.152 0.946
log κ 0.001 0.019 0.019 0.943 0.003 0.035 0.035 0.948 0.001 0.020 0.020 0.943 0.003 0.035 0.035 0.948
γ0 -0.001 0.062 0.062 0.952 0.005 0.132 0.131 0.917 -0.003 0.083 0.083 0.954 -0.000 0.151 0.151 0.919
γ1 0.004 0.074 0.073 0.953 -0.002 0.082 0.082 0.953 0.006 0.098 0.096 0.949 0.001 0.105 0.104 0.940
γ2 -0.000 0.051 0.052 0.952 -0.003 0.052 0.053 0.948 0.001 0.072 0.072 0.950 -0.002 0.073 0.074 0.945
τpp -0.000 0.031 0.031 0.953 0.002 0.064 0.064 0.913 -0.002 0.041 0.041 0.953 -0.001 0.074 0.074 0.917
τss 0.001 0.024 0.024 0.955 0.001 0.042 0.042 0.948 0.001 0.030 0.030 0.954 -0.001 0.048 0.049 0.955
τps -0.000 0.021 0.021 0.935 0.000 0.053 0.053 0.925 -0.001 0.027 0.026 0.948 -0.002 0.059 0.060 0.932
Right-truncated Auxiliary Data; nA = 20, 000
log λ -0.001 0.035 0.033 0.943 0.000 0.046 0.046 0.953 -0.001 0.0360 0.035 0.947 0.000 0.046 0.046 0.953
log κ -0.000 0.009 0.009 0.938 0.000 0.011 0.011 0.958 -0.000 0.009 0.009 0.938 0.000 0.011 0.011 0.958
γ0 -0.001 0.062 0.059 0.929 -0.000 0.066 0.065 0.944 -0.000 0.079 0.076 0.944 -0.001 0.082 0.081 0.941
γ1 -0.000 0.076 0.073 0.940 -0.001 0.077 0.073 0.939 0.001 0.099 0.096 0.941 0.000 0.099 0.096 0.942
γ2 0.000 0.053 0.052 0.946 0.000 0.053 0.052 0.942 0.001 0.074 0.072 0.951 0.001 0.073 0.072 0.952
τpp -0.000 0.030 0.029 0.930 -0.000 0.033 0.032 0.943 -0.000 0.039 0.038 0.944 -0.001 0.040 0.040 0.942
τss -0.001 0.024 0.023 0.949 -0.001 0.025 0.025 0.951 -0.000 0.029 0.029 0.950 -0.001 0.030 0.030 0.953
τps -0.000 0.020 0.019 0.942 -0.000 0.022 0.022 0.951 0.000 0.023 0.030 0.946 -0.000 0.026 0.026 0.954
Current Status Auxiliary Data; nA = 1000
log λ -0.001 0.030 0.030 0.949 0.000 0.038 0.038 0.944 -0.000 0.030 0.031 0.953 0.000 0.038 0.038 0.944
log κ 0.000 0.022 0.022 0.951 0.001 0.030 0.029 0.942 0.001 0.024 0.023 0.947 0.001 0.030 0.029 0.942
γ0 -0.001 0.058 0.058 0.952 -0.001 0.062 0.061 0.947 -0.003 0.076 0.074 0.948 -0.003 0.078 0.077 0.946
γ1 0.004 0.074 0.073 0.950 0.004 0.075 0.073 0.949 0.006 0.097 0.096 0.947 0.005 0.097 0.096 0.944
γ2 0.000 0.051 0.052 0.950 -0.000 0.051 0.052 0.951 0.001 0.072 0.072 0.946 0.001 0.072 0.072 0.947
τpp -0.001 0.029 0.028 0.951 -0.001 0.031 0.030 0.947 -0.002 0.037 0.037 0.949 -0.002 0.038 0.038 0.944
τss 0.001 0.023 0.023 0.954 0.001 0.024 0.024 0.943 0.001 0.028 0.029 0.950 0.001 0.029 0.030 0.949
τps -0.001 0.019 0.019 0.942 -0.001 0.021 0.021 0.947 -0.001 0.022 0.022 0.949 -0.001 0.024 0.024 0.951
Current Status Auxiliary Data; nA = 20, 000
log λ 0.000 0.009 0.009 0.947 0.001 0.010 0.010 0.951 0.000 0.009 0.009 0.946 0.001 0.010 0.010 0.951
log κ 0.000 0.022 0.021 0.936 0.001 0.028 0.027 0.946 0.001 0.024 0.023 0.938 0.001 0.028 0.027 0.946
γ0 -0.001 0.056 0.053 0.939 -0.001 0.056 0.053 0.939 -0.001 0.072 0.069 0.948 -0.001 0.072 0.069 0.948
γ1 -0.000 0.076 0.072 0.938 -0.001 0.076 0.073 0.938 0.000 0.098 0.095 0.938 0.000 0.098 0.095 0.939
γ2 0.000 0.053 0.051 0.945 0.000 0.053 0.051 0.944 0.001 0.073 0.072 0.952 0.001 0.073 0.072 0.951
τpp -0.001 0.028 0.026 0.939 -0.001 0.028 0.026 0.940 -0.001 0.035 0.034 0.947 -0.001 0.035 0.034 0.949
τss -0.001 0.023 0.022 0.952 -0.001 0.023 0.022 0.946 -0.001 0.028 0.028 0.947 -0.001 0.028 0.028 0.951
τps -0.000 0.016 0.016 0.956 -0.000 0.016 0.016 0.956 0.000 0.018 0.019 0.958 0.000 0.018 0.019 0.953
† True values for parameters: log λ = −4.112, log κ = 0.182, γ = (0.201, 0.647, 0.205)′.
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A total of 150 families were recruited for the study, which range in size from 2 to 7
individuals including the proband. The information on the onset time is of a mixed-type
as the event time is available for the proband, but for other family members it may only be
known whether they are diseased at the time of the assessment; the formulation of Section
2.4 can therefore be used in this setting. To explore the parent of origin question we adopt
a Weibull model and a piecewise-constant model for the marginal onset time distribution.
A Gaussian copula is used with a second-order regression model given by
log((1 + τijk)/(1− τijk)) = γ0 + γ1Vijk1 + γ2Vijk2 + γ3Vijk3 , (2.5.1)
where Vijk1 = I((j, k) pair are siblings), Vijk2 = I((j, k) pair is Father− Child), and Vijk3 =
I((j, k) pair is Mother− Child). The test of the null hypothesis that the association be-
tween father and child is the same as the association between mother and child is expressed
as H0 : γ2−γ3 = 0 vs. HA : γ2−γ3 6= 0. Due to the challenge of computing and maximizing
the full likelihood we focus on the composite likelihoods ACL1 and ACL2. As mentioned
earlier there is limited information on the marginal onset time distribution in the family
data alone since the onset times of the probands are all right-truncated. We therefore
make use of auxiliary data from n = 734 unselected individuals in the Psoriatic Arthritis
Toronto Cohort; these individuals all provide right-truncated onset times. The top panel
of Figure 2.2 displays contours of the negative log-likelihood for the Weibull parameters
(log λ, log κ) based on the full Toronto registry, which highlights the difficulty in estimating
the rate (λ) when all data are right-truncated.
In a second series of analyses we also integrate auxiliary data from a U.S. national
survey of the National Psoriasis Foundation conducted in 2001 and reported in Gelfand
et al. (2005). This study provides current status information on psoriatic arthritis from
n = 15, 307 respondents, 328 of which indicated they had been diagnosed with psoriatic
arthritis. The lower panel of Figure 2.2 shows the contour of the negative log-likelihood
based on the current status data from the survey of the National Psoriasis Foundation,
which also contains the point reflecting the maximum likelihood estimate of (log λ, log κ).
The absence of right-truncation in the survey data facilitates estimation and so this aux-
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iliary data plays an important role in the inferences that follow.
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Figure 2.2: Contour plots of the negative log-likelihood for the Weibull parameters
(log λ, log κ) based on unselected Toronto registry (top) and current status data from the
survey of the National Psoriasis Foundation (bottom).
As there are only 8 pairs of parents in the family data that contribute to the second
composite likelihood, it is not possible to estimate the intercept in model (2.5.1). We
therefore fix γ0 = 0 to reflect the scenario that there is no environmental familial effect on
the occurrence of psoriatic arthritis, and focus on the parent of origin hypothesis.
39
We first assume parametric, weakly, and non-parametric margins for the onset time of
psoriatic arthritis; the estimated cumulative hazard functions based on the current status
data from the National Psoriasis Foundation or combinations of this current status data
with Toronto psoriatic arthritis clinical registry data are shown in Figure 2.3. We also
estimate the cumulative hazards of PsA based on the simultaneous and two-stage estima-
tion of augmented composite likelihoods. We find that the estimated cumulative hazard
functions under the Weibull margin agrees generally with the estimates based on both the
piecewise constant model and non-parametric estimation approach, which indicates that
Weibull margin is reasonable in this case. For the piecewise constant model four cut points
were chosen to be 25, 32, 40 and 48 corresponding to the 20%, 40%, 60% and 80% quantiles
of the right-truncated onset time of PsA in the clinical cohort samples giving five pieces
(PWC-5). Also the estimated cumulative hazard function for the PsA onset time based
on the augmented composite likelihood (simultaneous and two-stage) agrees well with the
non-parametric estimation. Table 2.4 summarizes the estimates for the association param-
eters based on the augmented composite likelihoods with Weibull marginal distribution or
piecewise constant model for the PsA onset time under simultaneous and two-stage estima-
tion, where the maximization is done by the function ‘nlm’ in R (R Core Team, 2014). The
variance of the two-stage estimates can be estimated by the formula (2.A.15) in Appendix
A, in which simple random sampling of the selected probands is assumed and we don’t
need to model the sampling probability.
The results are in close agreement for the augmented composite likelihood approaches
and the Weibull model leads to similar results to the piecewise constant model for the
PsA onset time. There is moderate association between siblings with Kendall’s τss around
0.21, suggesting genetic factors on the onset time of PsA. Furthermore, the estimated
Kendall’s τ for father-child association is quite different with that for mother-child, which
suggests that there might be different effect of parents on children. For the ACL1 under
a piecewise constant model with simultaneous estimation, we find τ̂fc = 0.0790 (95% CI:
-0.0165, 0.1745) whereas τ̂mc = −0.0568 (95% CI: -0.1538, 0.0402). When ACL2 was
adopted with the same model and estimation procedure, we find τ̂fc = 0.0943 (95% CI:
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Figure 2.3: Estimated cumulative hazard functions for onset of psoriatic arthritis.
0.0032, 0.1854) and τ̂mc = −0.0121 (95% CI: -0.1191, 0.0949). A Wald test of the null
hypothesis H0 : γ2 = γ3 was carried out for each model based on augmented composite
likelihoods with parametric and piecewise constant model for onset time margin and the
results are reported in Table 2.5. We can find that under the Weibull model for the onset
time, the p-values are both 0.046 under the first augmented composite likelihood when
simultaneous and two-stage estimation approaches are adopted. Similarly, the p-values are
0.049 and 0.048 when piecewise constant model is adopted for the marginal distribution of
onset time. These values are all less than the 0.05 significant level, so we reject the null
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hypothesis and conclude that father-child association in the onset time of PsA is different
than the mother-child association, and the father has greater effect on the children with
regard to the onset time to psoriatic arthritis. The corresponding p-values are all larger
than 0.05 based on the second augmented composite likelihood. This may be due to the
loss of efficiency from the second augmented composite likelihood compared to the first
augmented composite likelihood.
2.6 Discussion
Family studies are ubiquitous in research on the genetic basis for disease. Response-
biased sampling of families is used routinely to enrich samples in the hope of increasing
information about the nature and extent of within family dependence and it is widely known
that adjustments to likelihood functions or estimating equations are necessary to ensure
valid inferences. Most analyses, however, are based on a binary designation of individuals’
disease status. One purpose of this Chapter is to highlight the utility of copula models as a
way of focusing on the disease onset time and for obtaining interpretable measures of within
family dependence. Gaussian copula models, in particular, allow one to accommodate a
dependence structure which is more elaborate than a simple exchangeable association.
Composite likelihood offers a computationally convenient approach to the analysis of
clustered and censored event times which is particularly appealing when some cluster sizes
are large. Efficiency losses can be modest when the within-family associations are modest,
and these can be offset by exploitation of auxiliary data. Such data may be closely aligned
with the probands, and may correspond, for example, to individuals in the same registry
as the proband who were not sampled for inclusion in the family study, or individuals
from similar but different registries. Alternatively, if cohort studies are available furnish-
ing information on the incidence of the disease of interest, these too can be exploited. The
cross-sectional survey of Gelfand et al. (2005) yields current status data of surveyed indi-
viduals which conveys useful information on disease incidence. Of course when combining
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Table 2.4: Estimates of all parameters based on the augmented composite likelihoods
ACL1 and ACL2, using reduced second-order regression model with γ0 = 0; augmentation
samples include unselected individuals from the University of Toronto Psoriatic Arthritis
Clinic and the data from Gelfand et al. (2005).
ACL1 ACL2
Simultaneous Two-Stage Simultaneous Two-Stage
Est. S.E Est. S.E Est. S.E Est. S.E
Weibull model for onset time
γ1 0.4685 0.1046 0.4673 0.1047 0.4387 0.0936 0.4381 0.0935
γ2 0.1440 0.0929 0.1441 0.0933 0.1764 0.0895 0.1752 0.0892
γ3 -0.1270 0.0999 -0.1275 0.0998 -0.0330 0.1081 -0.0340 0.1078
τss 0.2301 0.0495 0.2295 0.0496 0.2159 0.0446 0.2156 0.0446
τfc 0.0719 0.0462 0.0719 0.0464 0.0880 0.0444 0.0874 0.0443
τmc -0.0634 0.0498 -0.0637 0.0497 -0.0165 0.0540 -0.0170 0.0538
Piecewise constant (PWC-5) model for onset time
γ1 0.4457 0.1094 0.4406 0.1097 0.4137 0.0967 0.4102 0.0965
γ2 0.1583 0.0980 0.1622 0.0977 0.1891 0.0938 0.1891 0.0933
γ3 -0.1138 0.0994 -0.1122 0.0997 -0.0242 0.1092 -0.0242 0.1088
τss 0.2192 0.0521 0.2168 0.0523 0.2039 0.0464 0.2023 0.0463
τfc 0.0790 0.0487 0.0809 0.0485 0.0943 0.0465 0.0943 0.0462
τmc -0.0568 0.0495 -0.0561 0.0497 -0.0121 0.0546 -0.0121 0.0544
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Table 2.5: Wald tests of the parent-of-origin hypothesis based on the augmented composite
likelihoods with ascertained family data, unselected individuals from the University of
Toronto Psoriatic Arthritis Clinic and NPF current satus data, using simultaneous or two-
stage estimation procedures.
ACL1 ACL2
Simultaneous Two-Stage Simultaneous Two-Stage
WEIBULL MODEL Wald Statistic 1.995 1.995 1.490 1.489
P-value 0.046 0.046 0.136 0.136
PIECEWISE CONSTANT Wald Statistic 1.967 1.976 1.478 1.481
P-value 0.049 0.048 0.140 0.139
data from disparate sources questions naturally arise about the validity of homogeneity
assumptions, but these can be tested.
The construction of the complete data likelihood involving the unknown number of
“potential probands” offers an alternative way of conceptualizing the optimization prob-
lem which obviates the need for conditioning. This can be computationally advantageous
as the number of parameters in the marginal disease onset time distributions increases,
particularly if software is available for semiparametric maximization of the likelihoods in
untruncated samples (Lawless and Yilmaz, 2011). Variance estimation via missing informa-
tion principle and the method of Louis (1982) has also proven useful with semiparametric
methods involving current status data (Mongoue´-Tchokote´ and Kim, 2008; McMahan et al.,
2013) and otherwise incomplete responses.
Finally we remark that we have described how to conduct tests for particular hypothe-
ses regarding within-family dependence structures which may be motivated by questions
regarding heredity. An important topic for future work is the examination of the rela-
tive power properties of these tests based on likelihood and composite likelihood using
simultaneous and two-stage estimation procedures.
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Appendix A: Asymptotic Properties following Two-
Stage Estimation with Augmented Composite Likeli-
hood
Here we prove the asymptotic properties of the two-stage estimator for the augmented
composite likelihoods proposed in Section 2.4.2. The augmented composite likelihoods
can both be expressed as the product of two functions, the first is a function only of the
marginal parameter θ as in (2.4.7), and the second is a function of (θ′, γ′)′ as in (2.4.8).
We consider a set of independent individuals P for whom there is complete data and
from which subjects are sampled for inclusion in the family study; let the number of
individual in the set P be n. In Section 2.4.2, we assume that individuals are selected
by simple random sampling and the second part of the augmented composite likelihood
is constructed based on the sampled families only. We generalized this here to deal with
sampling schemes other than simple random sampling and derive here the asymptotic
properties of the two-stage estimator using inverse probability weights to account for the
selection mechanism. We let ∆i indicate that individual i is sampled for the family study
which occurs with probability pii(α) = P (∆i = 1|Di) where Di is a vector of covariates
containing attributes which potentially influence the probability of selection. One could,
with suitable assumptions, develop optimal sampling schemes for a particular inferential
objective by specifying the elements of Di and finding the value of α that minimizes the
asymptotic variance of key parameter estimates. Alternatively one can model the selection
process of families post hoc to provide protection against dependent sampling. We let
F = {i : ∆i = 1} and F c = {i : ∆i = 0}, so P = F ∪ F c.
The estimating functions for θ and γ are
U1(θ) =
∑
i∈F
Ui1(θ) +
∑
r∈F c
Ur1(θ) =
n∑
i=1
Ui1(θ) , (2.A.1)
U2(ψ, α) =
n∑
i=1
Ui2(ψ, α) =
n∑
i=1
∆i · U∗i2(ψ)
pii(α)
, . (2.A.2)
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respectively, where
Ui1(θ) =
∂
∂θ
logP (Xi, Yi|Ci, Zi, Ti ∈ Bi; θ) ,
and for the first augmented composite likelihood (2.4.4),
Ui2(ψ) =
∆i
pii(α)
·
∑
1≤j<k≤mi
∂
∂γ
logP (Wijk|R¯ijk, C¯ijk, Z¯ijk, ti0;ψ) ,
and for the second augmented composite likelihood (2.4.5),
Ui2(ψ) =
∆i
pii(α)
·
mi∑
j=1
∂
∂γ
logP (Wij|R¯ij, C¯ij, Z¯ij, ti0;ψ) .
It is easy to show that
E[Ui2(ψ, α)] = E{E[∆i · U∗i2(ψ)/pii(α)|Di]} = E{U∗i2(ψ)} = 0 .
When α is unknown, a logistic regression model can be used to model the selection
mechanism, leading to the additional estimating equation for α given as
U0(α) =
n∑
i=1
Ui0(α) =
n∑
i
∆i − pii
pii(1− pii)
∂pii
∂α
. (2.A.3)
Let η = (α′, θ′)′ and U¯1(η) = (U ′0(α), U
′
1(θ))
′. We then let U(ψ) = (U¯ ′1(η), U
′
2(ψ)), where
ψ = (η′, γ′)′, and let ψ˘ = (η˘′, γ˘′)′ denote the solution to (2.A.4) given by
U(ψ) =
(
U¯1(η)
U2(ψ)
)
=
n∑
i=1
Ui(ψ) =
n∑
i=1
 U¯i1(η)
∆i · U∗i2(ψ)/pii(α)
 = 0 . (2.A.4)
Since
U(ψ˘) = U(ψ) +
∂U(ψ)
∂ψ′
(ψ˘ − ψ) + op
(
1√
n
)
, (2.A.5)
then
√
n(ψ˘ − ψ) =
[
− 1
n
∂U(ψ)
∂ψ′
]−1 [
1√
n
U(ψ)
]
+ op(1) , (2.A.6)
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where
− 1
n
∂U(ψ)
∂ψ′
= − 1
n
n∑
i=1
 ∂U¯i1(η)∂η′ 0
∂
∂η′ (∆i · U∗i2(ψ)/pii(α)) ∂∂γ′ (∆i · U∗i2(ψ)/pii(α))
 . (2.A.7)
As n→∞, (2.A.7) converges in probability to
E (−∂Ui(ψ)/∂ψ′) =
 E
(
−∂U¯i1(η)
∂η′
)
0
E
(
− ∂
∂η′ (∆i · U∗i2(ψ)/pii(α))
)
E
(
− ∂
∂γ′ (∆i · U∗i2(ψ)/pii(α))
)

=
[
I11(ψ) 0
I21(ψ) I22(ψ)
]
= I(ψ) ,
From (2.A.6),
√
n(ψ˘ − ψ) is then asymptotically equivalent to[
E
(
− ∂Ui(ψ)
∂ψ′
)]−1 [
1√
n
U(ψ)
]
=
 I−111 (ψ) 0
− I−122 (ψ)I21(ψ)I−111 (ψ) I−122 (ψ)
[ 1√
n
U(ψ)
]
.
Furthermore, since
1√
n
U(ψ)→ N(0,B(ψ)) , (2.A.8)
where
B(ψ) =
(
B11(ψ) B12(ψ)
B21(ψ) B22(ψ)
)
=
 E [U¯i1(η)U¯ ′i1(η)] E [∆iU¯i1(η)U∗′i2 (ψ)/pii(α)]
E
[
∆iU
∗
i2(ψ)U¯
′
i1(η)/pii(α)
]
E
[
∆iU
∗
i2(ψ)U
∗′
i2 (ψ)/pi
2
i (α)
]

It follows that as n→∞,
√
n(ψ˘ − ψ)→ N(0, I−1(ψ)B(ψ) [I−1(ψ)]′) , (2.A.9)
and equivalently we obtain that
√
n(η˘ − η) D−→ N(0,Σ) , (2.A.10)
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√
n(γ˘ − γ) D−→ N(0,Γ) , (2.A.11)
where
Σ = I−111 (ψ)B11(ψ)
(I−1(ψ))′ , (2.A.12)
Γ = I−122 (ψ)
{
I21(ψ)I−111 (ψ)B11(ψ)
(I−111 (ψ))′ I ′21(ψ) + B22(ψ) (2.A.13)
− B21(ψ)
(I−111 (ψ))′ I ′21(ψ)− I21(ψ)I−111 (ψ)B12(ψ)}(I−122 (ψ))′ .
Furthermore, the asymptotic variance of the two-stage estimator can be consistently
estimated by Σ̂ and Γ̂, where
Σ̂ = Î −111 (ψ˘)B̂11(ψ˘)
(
Î −111 (ψ˘)
)′
, (2.A.14)
Γ̂ = Î−122 (ψ˘)
{
Î21(ψ˘)Î
−1
11 (ψ˘)B̂11(ψ˘)
(
Î −111 (ψ˘)
)′
Î ′21(ψ˘) + B̂22(ψ˘)
− B̂21(ψ˘)
(
Î −111 (ψ˘)
)′
Î ′21(ψ˘)− Î21(ψ˘)Î −111 (ψ˘)B̂12(ψ˘)
}(
Î −122 (ψ˘)
)′
. (2.A.15)
with these expressions easily calculated based on the sample. For example,
Î22(ψ˘) = − 1
n
n∑
i=1
∆i
pii(αˆ)
∂U∗i2(ψ)
∂γ′
∣∣
ψ=ψ˘
,
B̂22(ψ˘) =
1
n
n∑
i=1
∆i
pi2i (αˆ)
U∗i2(ψ)U
∗′
i2 (ψ)
∣∣
ψ=ψ˘
,
Î11(ψ˘) = − 1
n
n∑
i=1
∂U¯i1(η)
∂η′
∣∣
η=η˘
.
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Chapter 3
Sample Size and Robust Marginal
Methods for Cluster-Randomized
Trials with Censored Event Times
3.1 Introduction
Cluster-randomization is employed in clinical trials when it is appropriate on ethical (Ed-
wards et al., 1999), practical (Torgerson, 2001), or contextual (Silverman et al., 1999)
grounds to assign groups of individuals (e.g. families, schools, hospitals, or communities)
to receive one of two or more interventions to be compared. In studies aiming to reduce the
spread of infectious disease, for example, prevention strategies are most naturally admin-
istered to large groups of individuals (e.g. municipalities), and the resulting evidence of
impact thereby reflects direct effects (susceptibility), indirect effects (infectiousness of oth-
ers), as well as the effect of herd immunity (Hayes et al., 2000). Cluster-randomization also
offers a way of minimizing contamination across treatment groups, and can often enhance
compliance (Donner and Klar, 1994; Moerbeek, 2005). In some fields of research, the units
providing the response are paired or otherwise grouped, as is the case in ophthalmology or
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audiology. In such settings interventions that are administered and act through the blood
stream (e.g. medications) necessitate randomizing individuals and the units providing the
response are clustered within individuals. The many advantages of cluster-randomization
have led to its increased use in recent years in diverse areas of research including health
promotion (Cameron et al., 1999), education for disease management (Shah et al., 2001),
clinical research (Martin et al., 2004), and health policy and program evaluation (Camp-
bell et al., 2000). Donner and Klar (2000) give a thorough account of the practical and
methodological issues in the conduct of cluster-randomized trials.
While much of the methodological work on cluster-randomized trials to date has been
for continuous or binary responses, in many settings interest lies in evaluating the effect
of an intervention in delaying or preventing the occurrence of an event. In patients with
insulin-dependent diabetes mellitus, for example, interest may lie in the effect of medical
therapies on the time to severe vision loss in each eye (Lee et al., 1992); such times are
correlated within individuals due to shared exposure to blood sugar levels, blood pressures,
and other systemic features. Chronic otitis media is a condition arising in children char-
acterized by poor drainage of fluid from the inner ear. A common intervention involves
the surgical insertion of a ventilating tube and interest then may lie in assessing an exper-
imental post-surgery medical therapy designed to prolong the function of the ventilating
tubes. The child is then the unit of randomization (Le and Lindgren, 1996; Manatunga
and Chen, 2000), and the times to failure of the tubes in the left and right ears would
naturally be correlated. Settings involving time to event responses with larger cluster sizes
include studies of fall prevention in retirement homes (Lord et al., 2003), studies of primary
care practices and survival in patients with depression (Bogner et al., 2007), and studies
of pediatric clinics and time to discontinuation of breast-feeding (Kramer et al., 2001).
Cox regression models involving random effects, or frailty terms, are widely used for
analysing correlated time to event data (Bellamy et al., 2004; Glidden and Vittinghoff,
2004). In this framework failure times are typically considered to be independent condi-
tional on a latent variable representing unexplained differences between clusters and the
association among responses within clusters arises by marginalizing over the random ef-
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fects. There are several important limitations of this approach for the analysis of event
times in cluster-randomized trials. First, specification of a proportional hazard model
given cluster-level random effects is unappealing when the treatment indicator is fixed at
the cluster level (Neuhaus et al., 1991; Neuhaus and Kalbfleisch, 1998). Second, regression
coefficients reflect the multiplicative effects of the intervention, conditional on the latent
variable; the proportional hazards assumption does not hold in the marginal model ob-
tained by integrating out the random effects, making the interpretation of the intervention
effect challenging. Third, while the dependence within clusters is accommodated in the
marginal joint distribution, the association is not modeled in an appealing way. Simple
measures of within-cluster dependence do not in general arise from the random effects
formulation with censored failure time data, so it is difficult to extract useful informa-
tion for the design of future similar trials. Methods involving intervention effects specified
based on marginal Cox models feature none of these limitations and are therefore much
more appealing. For large numbers of small groups of correlated failure time, Lee et al.
(1992) developed very useful methods for robust inference about regression coefficients in
marginal Cox models fitted under a “working independence” assumption, similar in spirit
to the working independence assumption adopted when clustered categorical data are anal-
ysed via generalized estimating equations (Zeger and Liang, 1986) or when multivariate
failure time data are analysed by the marginal approach of Wei et al. (1989). Robust
“sandwich” variance estimates provided by Lee et al. (1992) ensure valid inference when
there is within-cluster dependence in event times. The simple marginal interpretation of
intervention effects and use of robust variance estimation make this a useful and simple
framework for the analysis of event times in cluster-randomized trials.
A considerable amount of attention has been directed at the development of sample size
formulae for the cluster-randomized trials with continuous and discrete outcomes (Corn-
field, 1978; Donner et al., 1981; Donner and Klar, 1994; Lee and Dubin, 1994; Hayes and
Bennett, 1999), but relatively little work has been done for trials involving censored event
times; in what follows the term sample size is used to mean the number of clusters. Jahn-
Eimermacher et al. (2013) developed sample size criteria based on a frailty model for the
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within-cluster dependence, but as mentioned earlier the frailty approach is unappealing for
use in cluster-randomized trials. Manatunga and Chen (2000) derived sample size formula
for bivariate event times under a parametric proportional hazards model with exponen-
tial margins. Jung (2007) proposed a simulation-based sample size calculation procedure
involving a weighted rank test for clustered survival data, which allows variable cluster
size. Moerbeek (2012) studied the effect of sample size on precision of parameter estimates
and statistical power for clustered randomized trials with discrete event times based on a
generalized linear mixed model. Xie and Waksman (2003) adapted the usual sample size
criteria for log-rank tests by the introduction of a design effect involving the average cluster
size and the intraclass correlation coefficient of the censoring (i.e. status) indicator of the
response times. While the formula is relatively simple, the sample size criterion is based
on an approximation of the asymptotic distribution of regression coefficients. More impor-
tantly, since the intraclass correlation coefficient in their design effect is for the censoring
indicators rather than the underlying failure times, its magnitude is driven by both the
dependence in the failure times within clusters as well as the within-cluster dependence in
the censoring times. As a result, the event times may be independent within clusters, for
example, but the censoring indicators may be highly correlated within clusters if the cen-
soring times are dependent. Moreover, the correlation in the censoring indicators depends
on both the administrative censoring time and the distribution of the random censoring
time, so any plans to modify a study by extending follow-up or attempting to reduce loss
to follow-up will render the measure of within-cluster dependence invalid.
We derive sample size criteria for cluster-randomized trials with censored time to event
responses when the intervention effect is specified through a marginal semiparametric pro-
portional hazards model fitted under a working independence assumption and robust vari-
ance estimates are used as in Lee et al. (1992). Of course at the design stage a fully
parametric model is required so a Weibull proportional hazard model is adopted to accom-
modate trend in the marginal hazard. Within-cluster dependence is conveniently modeled
using copula functions (Joe, 1997; Nelsen, 2006) since intervention effects may be speci-
fied in terms of the marginal distributions and within-cluster dependence is modeled by a
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separate association parameter. The resulting joint model is used to evaluate the compo-
nents of the robust variance formula (Lee et al., 1992) for a variety of practical settings,
and our approach does not involve any approximations apart from the usual ones used in
large sample theory. We also study the effect of copula misspecification and the impact
of within-cluster dependence in the random right censoring times. Sample size criteria are
also developed for cluster-randomized trials with interval-censored event times which arise
when the events are only detectable upon periodic inspection (e.g. radiographic examina-
tion, based on blood tests, urinalysis, etc.).
The remainder of this chapter is organized as follows. In Section 3.2 we define notation
and review the robust marginal method of Lee et al. (1992). The asymptotic distribution
of the test statistic is then derived to facilitate the development of sample size criteria, and
simulation studies are carried out to validate the derivations. In Section 3.3 we explore
the impact of misspecification of the copula function and the impact of within-cluster
dependence in the censoring times. Design criteria for cluster-randomized trials with type
II interval-censored failure times are developed in Section 3.4. Section 3.5 contains an
illustrative example, and concluding remarks and topics for future research are given in
Section 3.6.
3.2 Sample Size for Trials With Clustered Event Times
Subject to Right-Censoring
3.2.1 Notation and Robust Marginal Methods
We consider the setting in which n clusters, each comprised of J individuals, are randomly
assigned to receive either an experimental or standard intervention. We let Tij denote
an event time of interest for individual j in cluster i, j = 1, . . . , J , i = 1, . . . , n, and
assume interest lies in examining the effect of the experimental intervention by fitting a
Cox regression model. Let Zi be a binary covariate where Zi = 1 indicates that cluster i
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is assigned to the experimental intervention and Zi = 0 otherwise; we let P (Zi = 1) = p.
It is possible to generalize the methods that follow to accommodate a p × 1 cluster-level
covariate vector as we discuss in Section 3.6.
Suppose the plan is to observe individuals over the interval (0, C†] where C† is an
administrative censoring time, and let C∗ij denote a random (possibly latent) time of with-
drawal from the study for individual j in cluster i with survivor function G∗(s) = P (C∗ij ≥
s). Then Cij = min(C
∗
ij, C
†) denotes the resultant right-censoring time. We then let
Xij = min(Tij, Cij), Y
†
ij(t) = I(t ≤ Tij), Yij(t) = I(t ≤ Cij), and Y¯ij(t) = Yij(t)Y †ij(t) be
an indicator for individual j in cluster i is under observation and at risk of the event at
time t; thus here, and in what follows, quantities with a vinculum (overbar) are observable
in the presence of right censoring. Let Nij(t) = I(Tij ≤ t) indicate that individual j in
cluster i experienced the event at or before time t, and dNij(t) = I(Tij = t). When viewed
as a random function of time, {Nij(s), 0 < s} is a right-continuous stochastic process.
If dN¯ij(t) = Y¯ij(t)dNij(t) and N¯ij(t) =
∫ t
0
dN¯ij(s), then {N¯ij(s), 0 < s} is the observed
counting process for individual j in cluster i. Finally we let N¯i(t) = (N¯i1(t), . . . , N¯iJ(t))
′,
Y¯i(t) = (Y¯i1(t), . . . , Y¯iJ(t))
′ and let {Y¯i(·), N¯i(·), Zi} denote the data from cluster i.
Marginal proportional hazard models are based on the assumption that given Zi, Tij
has a hazard function of the form
λij(t|Zi) = λ0(t;α) exp(Ziβ) (3.2.1)
where λ0(t;α) is a baseline hazard function indexed by a vector of parameters α, and β
is a scalar regression coefficient; let θ = (α′, β)′. The marginal Cox regression model is
obtained by leaving λ0(t;α) of an unspecified form, making it a semiparametric model.
Lee et al. (1992) considered the semiparametric Cox model and proposed estimation
of β under a working independence assumption by which observations in each cluster are
treated as independent of one another. This gives a partial score function for β, written
as U(β) =
∑n
i=1 Ui(β), where
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Ui(β) =
J∑
j=1
∫ ∞
0
{
Zi − S1(t; β)
S0(t; β)
}
dN¯ij(t) , (3.2.2)
with Sr(t; β) =
∑J
j=1 Srj(t; β), Srj(t; β) = n
−1∑n
i=1 Y¯ij(t)Z
r
i exp(Ziβ), r = 0, 1, Z
0
i = 1
and Z1i = Zi; the root of U(β) = 0 is β̂, the estimate.
If the marginal Cox regression model is correctly specified, n−1/2U(β) is asymptotically
normally distributed with mean zero and variance (Lee et al., 1992)
B = E[U2i (β)] , (3.2.3)
estimated by
B̂ =
1
n
n∑
i=1
U2i (β)
∣∣∣∣
β=β̂
.
Lee et al. (1992) showed that β̂ is consistent with n1/2(β̂−β) D−→ N(0,Γ) asymptotically,
where Γ = B/A2 and
A = −E[∂Ui(β)/∂β] . (3.2.4)
Note that (3.2.4) can be consistently estimated by
Â = − 1
n
n∑
i=1
∂Ui(β)/∂β
∣∣∣∣
β=β̂
,
and so robust inferences are based on Γ̂ = B̂/Â2 for a given sample.
3.2.2 Sample Size Calculations via Copula Models for Clustered
Failure Times
While the robust analyses based on marginal Cox models in the previous section can be
carried out once data are collected, model assumptions are required to derive the sample
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size (number of clusters) based on large sample theory. In the context of clustered event
time data, copula functions offer a convenient way of constructing joint distributions with
proportional marginal hazards (Joe, 1997; Nelsen, 2006). In what follows we use J to
denote the dimension of the multivariate vector to coincide with the size of the clusters in
the previous section.
A copula function in J dimensions is a multivariate distribution on [0, 1]J whose margins
are uniform over [0, 1] (Nelsen, 2006). Thus for a J−dimensional uniform random vector
U = (U1, . . . , UJ)
′, the joint probability function
C(u1, . . . , uJ ;φ) = P (U1 ≤ u1, . . . , UJ ≤ uJ ;φ) ,
defines a copula indexed by the parameter φ. The family of Archimedean copulas (Genest
and Mackay, 1986) can be written as
C(u1, . . . , uJ ;φ) = H−1 (H(u1;φ) + · · ·+H(uJ ;φ);φ) ,
whereH : [0, 1]→ [0,∞) is a continuous, strictly decreasing and convex generator function
satisfying H(1;φ) = 0. Kendall’s τ , a widely used measure of association with event time
data can be written as
τ = 1 + 4
∫ 1
0
H(u;φ)
H′(u;φ)du
for Archimedean copulas.
If Ti = (Ti1, . . . , TiJ)
′ is a J×1 vector of failure times, a joint model for Ti|Zi is obtained
via the probability integral transforms Uij = F(Tij|Zi; θ), j = 1, . . . , J , and linking all
marginal survivor functions via the copula as
F(ti|Zi;ψ) = P (Ti1 > ti1, . . . , TiJ > tiJ |Zi;ψ) = C(F(ti1|Zi; θ), . . . ,F(tiJ |Zi; θ);φ) ,
(3.2.5)
where F(·|Zi; θ) is the survivor function for Tij given the covariate Zi and ψ = (θ′, φ)′.
Since Kendall’s τ is invariant to monotonic transformations, it also measures the associ-
ation between the event times defined by the conditional (given Zi) probability integral
transform(Genest and Mackay, 1986).
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The Clayton copula is widely used in survival analysis and has generator function
H(u;φ) = φ−1(u−φ − 1), and then yields a joint survivor function for Ti|Zi of the form
F(ti|Zi;ψ) =
(F(ti1|Zi; θ)−φ + · · ·+ F(tiJ |Zi; θ)−φ − (J − 1))−1/φ . (3.2.6)
The Frank copula with generator H(u;φ) = − log((exp(−φu) − 1)/(exp(−φ) − 1)) and
the Gumbel copula with generator H(u;φ) = (− log u)φ, are two other members of the
Archimedean family that we consider shortly.
Returning to the issue of sample size determination, we consider the null and alternative
hypotheses H0 : β = β0 = 0 and HA : β 6= β0 respectively, where βA denotes the clinically
important effect of interest. Under a two-sided test at the γ1 level of significance, the
number of clusters required to ensure 1 − γ2 power to reject H0 at βA can be determined
based on a Wald test. The asymptotic robust variance of this Wald statistic involves the
variance of the score statistic B and the information A. To derive the expressions for
these two quantities (3.2.3) and (3.2.4), we evaluate their asymptotic expressions under a
fully specified parametric model at the design stage. The variance of the score statistic
also depends on the within-cluster association of failure times and the form of the joint
distribution is implied by the copula function (3.2.5). Explicit expressions for (3.2.3) and
(3.2.4) are given in (3.A.9) and (3.A.10) of Appendix A. Note that (3.A.9) is derived for
a more general case, in which censoring times are also correlated within clusters, but if
we further assume independent within-cluster censoring times, then (3.A.13) can be used
instead. Let Γ = B/A2 denote the asymptotic variance of the estimator β̂, then the
required sample size (number of clusters) is
n ≥
{
zγ1/2
√
Γ0 + zγ2
√
ΓA
βA
}2
(3.2.7)
where zu is the 100(1− u)% percentile of the standard normal distribution and Γ0 and ΓA
are the asymptotic variances of βˆ evaluated under the null and alternative hypotheses.
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3.2.3 Empirical Validation of Sample Size Formula under Cor-
rect Model Specification
We consider a two-arm cluster-randomized trial with equal allocation probabilities where
the binary treatment indicator takes the value Zi = 1 if cluster i is randomized to the
experimental intervention and Zi = 0 otherwise; and P (Zi = 1) = P (Zi = 0) = 0.5.
We assume Tij|Zi has a proportional hazards structure as in (3.2.1), where the cumulative
baseline hazard is of a Weibull form with Λ0(t;α) =
∫ t
0
λ0(s;α)ds = (λ0t)
κ and α = (λ0, κ)
′.
The parameter κ accommodates a decreasing (κ < 1), constant (κ = 1) or increasing
(κ > 1) hazard; here we focus on the cases with κ = 0.75 and 1.0 to reflect modest
decreasing trend in risk and constant risk. If the plan is to observe individuals over(0, C†],
without loss of generality we let C† = 1 denote the administrative censoring time. The
parameter λ0 is then chosen as the solution to P (Tij > C
†|Zi = 0) = pa to give the desired
administrative censoring rate for the control group, where pa = 0.2, A random censoring
time for the jth individual in cluster i is denoted by C∗ij and assumed to be exponentially
distributed with rate ρ; we assume here that Cij ⊥ Cik|Zi so censoring is independent
within clusters. The effective right censoring time is then Cij = min(C
∗
ij, C
†) and the value
ρ which solves P (Tij > Cij|Zi = 0) = p0 gives p0, the net censoring rate in the control
arm; we consider p0 = 0.2 to correspond to the case of strictly administrative censoring
and p0 = 0.5 to correspond to the case of 30% random and 20% administrative censoring.
Suppose the within-cluster association in the failure time is induced by the Clayton
copula with parameter φ, so the joint survivor function for Ti = (Ti1, . . . , TiJ)
′
is given by
(3.2.6), where J is the cluster size. The copula parameter is chosen to give Kendall’s τ of
0.05, 0.1, and 0.25 for small, mild and moderate within-cluster associations, respectively.
We consider cluster sizes of J = 2, 5, 20, and 100 which represent from small to large
cluster sizes. For each parameter combination, we compute the required number of clusters
(n) based on (3.2.7) to give power 1−γ2 = 0.8 using a two-sided test with a type I error rate
γ1 = 0.05. We then generate the corresponding clustered event times and (independent)
censoring times, fit the marginal Cox model and obtain the robust variance estimate derived
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by Lee et al. (1992) to test the null hypothesis of no treatment effect. We report empirical
standard error (ESE) and average robust standard error (ASE) for βˆ, empirical rejection
rate (REJ%) defined as the percentage of samples in which the null hypothesis H0 : β = 0
is rejected by a two-sided Wald test at the nominal 5% level, and the empirical coverage
probability (ECP%) of nominal 95% confidence intervals for β (the proportion of simulated
samples for which the nominal 95% confidence interval contained the true value of β). Since
the empirical coverage probability is the complement of the empirical rejection rate when
β = 0, we do not report it in this case; see Table 3.1.
For each parameter configuration we generate 2000 samples, so the half-width of a
95% confidence interval for the type I error rate would be approximately 1.96(0.05 ×
0.95/2000)1/2 = 0.01 and one could expect the empirical rejection rate to fall outside the
range [0.04, 0.06] in one out of twenty settings by chance; by similar arguments one would
expect the empirical coverage probability to fall within the range 94% and 96% nineteen
times out of twenty. If the nominal power 0.80 is correct then the empirical power would
be expected to fall outside the range [0.78, 0.82] for one out of every twenty configurations.
From Table 3.1, it is apparent that the empirical rejection rates under β = 0 are within the
acceptable range for most cases. Under the alternative hypothesis the empirical coverage
probabilities are within the acceptable range of 94-96%, and the empirical rejection rates
are broadly compatible with the nominal level. It is worth remarking that for different
values of the shape parameter κ, the required sample size does not change dramatically
(see Table 3.1); this makes sense as the expected number of events is the same for these
values of the shape parameter, so the required sample size to ensure pre-specified power
should be approximately the same. All of these findings support the validity of the derived
sample size formula.
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Table 3.1: Sample size estimation and empirical properties of estimators under cluster-
randomized designs when within-cluster association between event times is induced by the
Clayton copula; βA = log 0.8, pa = 0.2, nsim = 2000.
20% Censoring (p0 = 0.2) 50% Censoring (p0 = 0.5)
β = 0 β = βA β = 0 β = βA
J τ n ESE ASE REJ% ESE ASE ECP% REJ% n ESE ASE REJ% ESE ASE ECP% REJ%
κ = 0.75
2 0.05 433 0.078 0.079 4.8 0.080 0.081 95.2 80.3 677 0.078 0.079 5.1 0.083 0.081 94.8 78.0
0.10 464 0.080 0.079 5.4 0.081 0.081 95.0 79.0 708 0.078 0.079 4.5 0.080 0.081 95.9 79.0
0.25 556 0.077 0.079 5.1 0.081 0.081 94.2 79.8 803 0.079 0.079 4.8 0.081 0.081 94.5 78.8
5 0.05 211 0.081 0.079 5.2 0.083 0.080 94.1 78.0 309 0.079 0.079 5.3 0.081 0.081 95.0 78.4
0.10 262 0.080 0.079 5.4 0.083 0.080 94.0 79.0 359 0.079 0.079 4.4 0.082 0.081 95.0 79.7
0.25 409 0.080 0.079 5.0 0.079 0.080 94.8 79.2 511 0.081 0.079 5.5 0.081 0.081 94.8 79.1
20 0.05 100 0.080 0.078 5.4 0.080 0.079 95.0 78.3 125 0.080 0.078 5.8 0.082 0.080 94.4 80.2
0.10 160 0.079 0.079 4.9 0.078 0.079 95.2 81.0 185 0.077 0.079 4.7 0.082 0.080 94.5 78.5
0.25 335 0.081 0.079 5.7 0.081 0.080 95.0 81.5 365 0.078 0.079 4.8 0.079 0.080 95.0 81.8
100 0.05 71 0.079 0.078 5.8 0.080 0.078 94.1 81.2 76 0.080 0.078 6.0 0.080 0.078 94.1 80.7
0.10 133 0.079 0.079 4.9 0.081 0.079 94.1 79.0 139 0.079 0.079 4.6 0.080 0.079 94.3 81.6
0.25 316 0.081 0.079 6.0 0.080 0.080 94.9 80.0 326 0.081 0.079 5.8 0.080 0.080 95.3 79.8
κ = 1.0
2 0.05 433 0.077 0.079 4.5 0.080 0.081 95.3 79.5 676 0.079 0.079 4.5 0.082 0.081 94.6 77.6
0.10 464 0.080 0.079 5.3 0.081 0.081 95.0 77.1 708 0.079 0.079 5.7 0.081 0.081 95.0 78.6
0.25 556 0.081 0.079 5.6 0.082 0.081 94.2 78.0 801 0.078 0.079 5.0 0.083 0.081 94.7 77.1
5 0.05 211 0.079 0.079 4.7 0.080 0.080 95.5 79.2 309 0.079 0.079 4.8 0.081 0.081 94.8 78.5
0.10 262 0.081 0.079 5.8 0.082 0.080 94.2 80.0 359 0.078 0.079 5.2 0.081 0.081 95.2 78.5
0.25 409 0.081 0.079 5.8 0.083 0.080 94.3 79.2 509 0.080 0.079 5.2 0.082 0.081 94.4 78.7
20 0.05 100 0.078 0.079 4.9 0.079 0.079 94.8 79.8 125 0.081 0.078 5.6 0.078 0.080 95.8 79.8
0.10 160 0.079 0.079 4.4 0.080 0.080 95.1 79.0 185 0.079 0.079 5.0 0.080 0.080 94.8 78.2
0.25 335 0.081 0.079 5.5 0.081 0.080 94.3 79.1 363 0.080 0.079 5.1 0.082 0.080 94.5 79.5
100 0.05 71 0.080 0.078 5.4 0.080 0.078 94.3 80.5 76 0.078 0.078 5.2 0.077 0.078 95.3 80.3
0.10 133 0.079 0.079 4.8 0.079 0.079 95.0 80.2 138 0.080 0.079 5.2 0.081 0.079 94.2 79.5
0.25 316 0.080 0.079 5.1 0.080 0.080 94.7 79.8 324 0.079 0.079 4.7 0.082 0.080 94.1 78.5
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3.3 Asymptotic Calculations Investigating Design Ro-
bustness and Relative Efficiency
3.3.1 Robustness of Power to Misspecification of the Copula
Function
Choosing a suitable copula at the design stage is challenging, so here we explore the sen-
sitivity of study power to misspecified copula functions. We consider the same parameter
configurations as in Section 3.2.3, where κ = 0.75 and the administrative censoring rate is
pa = 0.2. The sample size is estimated under the Clayton copula with Kendall’s τ = 0.1
and 0.25 with βA = log 0.8. Under the derived number of clusters, we construct the corre-
sponding power curves under the Frank or Gumbel copula functions with the same value of
Kendall’s τ . Figure 3.1 shows these power curves for different copula functions for J = 20
under different net censoring rates (p0 = 0.2, 0.5 and 0.7) in the control arm. When the
censoring rate is mild and due strictly to administrative censoring (p0 = 0.2), misspecifi-
cation of the copula function impacts power but use of the Clayton copula ensures power
is maintained under the Frank or Gumbel copula functions. When the net censoring rate
increases to 50%, the impact of copula misspecification is negligible, however when the net
censoring rate increases to 70%, the impact on power is again appreciable; in this case, the
Clayton copula leads to samples sizes which are too small. These findings suggest that the
misspecification of copula functions can have significant impact on study power and the
impact depends on the censoring rate. The findings are broadly similar for cluster sizes of
J = 2, 5 and 100.
To examine the effect of copula misspecification more fully we next consider the asymp-
totic relative efficiencies of the estimators through the functions
AREF :C =
asvarF (βˆ)
asvarC(βˆ)
, AREG:C =
asvarG(βˆ)
asvarC(βˆ)
, and AREF :G =
asvarF (βˆ)
asvarG(βˆ)
, (3.3.1)
where asvar() denotes an asymptotic variance and ‘C’, ‘F’, and ‘G’ denote the Clayton,
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Figure 3.1: Power curves for different copula functions when sample size is estimated based
on the Clayton copula with τ = 0.10 (left column) and τ = 0.25 (right column) under 20%
(top row), 50% (middle row) and 70% (bottom row) net censoring for the control arm;
κ = 0.75, βA = log 0.8, pa = 0.2, J = 20.
62
Frank and Gumbel copulas, respectively. We set κ = 0.75 and β = log 0.8 and set the
control administrative censoring rate to pa = 0.2 at C
† = 1; again λ0 is found to satisfy
P (Tij > C
†|Zij = 0) = pa. The random censoring times are assumed to be independently
exponentially distributed with rate ρ, which is selected to ensure a net censoring rate for
the control arm through the constraint P (Tij > Cij|Zi = 0) = p0, where p0 ranges from 0.2
to 0.8. Figure 3.2 displays the contour plots of the asymptotic relative efficiencies in (3.3.1)
as a function of the degree of within-cluster association in the event times (Kendall’s τ)
and the net censoring rate (p0) for both J = 20 (left panels) and J = 100 (right panels); we
restrict attention to values of Kendall’s τ ranging from 0 to 0.4 to cover realistic scenarios.
For J = 20, if the net censoring rate is less than 40%, the Gumbel copula leads to a more
efficient estimator, followed by the Frank copula and then the Clayton copula; the Clayton
copula should therefore be used for the sample size calculations to ensure adequate power
among this set of copulas. If the net censoring rate in this setting is higher than 40-50%,
the Gumbel copula should be adopted at the design stage since it yields the estimator with
the greater variance. The trend is broadly similar for J = 100.
Both Figure 3.1 and Figure 3.2 show that the proposed formula for calculating required
sample size is sensitive to both the copula function and censoring rate. A simple pragmatic
approach to deal with this sensitivity is to consider a class of copula functions and a range
of administrative and random censoring rates. The required sample sizes can be computed
for each configuration by (3.2.7) and the largest sample size can then be chosen to ensure
the pre-specified power requirements are met for any copula model and censoring pattern
among those considered.
3.3.2 Impact of Uncertainty in the Strength of Within-Cluster
Dependence
As other sample size formulae for cluster-randomized trials, the derived sample size formula
requires specification of the within-cluster dependence, which is measured by Kendall’s τ for
clustered event times here. Of course there may be uncertainty in the value of Kendall’s τ ,
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Figure 3.2: Contour plots of the asymptotic relative efficiencies in (3.3.1) for estimators
defined as the solution to (3.2.2) when clustered failure times are generated based on
different copula functions; κ = 0.75, β = log 0.8, pa = 0.2.
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and we recognize that it is unlikely in the clinical literature to report the values of Kendall’
τ . Here we investigate the impact of misspecified values of Kendall’s τ on study power.
We consider a two-arm cluster-randomized trial design with equal allocation probabilities,
and the parameter settings for the marginal distribution of failure time and the censoring
time are same as in Section 3.2.3. We let κ = 0.75, the administrative censoring rate for
the control group be pa = P (Tij > C
†|Zij = 0) = 0.2 and the net censoring rate for the
control group be p0 = P (Tij > Cij|Zij = 0) = 0.5. The required number of clusters is
calculated to ensure 80% power to detect β = log 0.8 based on a two-side Wald test at the
5% significant level under Clayton, Frank and Gumbel copulas, respectively, and assuming
there is no misspecification of copula functions. Lacking of knowledge on the strength
of within-cluster dependence, we let Kendall’s τ = 0, 0.1, 0.25 or 0.4 when calculate the
sample size based on (3.2.7). Under the calculated number of clusters, we construct the
corresponding power curves when the true value of Kendall’s τ varies from 0 to 0.6 for
small cluster size (J = 2) and large cluster size (J = 100). Figure 3.3 shows these power
curves as a function of the true values of Kendall’s τ when the sample size is estimated
based on the assumed degree of within-cluster dependence under different copulas. From
this figure, we can find that the extent of the within-cluster dependence has big effect on
the sample size calculation or power no matter which copula functions are adopted. By
comparing the curves in the top panel with those in the bottom panel, we can find that
the impact of the uncertainty in the strength of the within-cluster dependence is more
serious when the cluster size is large. Furthermore, if the assumed value of Kendall’s τ is
less than the true value, the proposed sample formula leads to underestimated sample size
which leads to insufficient power to detect the clinically significant effect. However, if the
assumed value of Kendall’s τ is larger than the true value of the strength of within-cluster
dependence, overestimated sample size is obtained by the proposed formula which results
in larger power to detect the clinically effect of interest. Therefore, the largest plausible
value of Kendall’s τ will lead to the largest sample size within a given copula family and
at a given censoring rate. We recommend that if there is uncertainty about the strength
of within-cluster dependence, one can specify the possible and meaningful largest value of
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Kendall’s τ to estimate the sample size to ensure the pre-specified power requirements are
met.
3.3.3 Impact of Within-Cluster Dependence in the Random Cen-
soring Times
Although the assumption of independent censoring times within clusters is commonly, the
factors inducing the association in the failure times within clusters may also induce an
association in the censoring times. Here we examine the impact of within-cluster depen-
dence in the censoring times on study power. We consider a trial designed to have 80%
power to detect β = log 0.8 based on a two-sided Wald test at the 5% significance level
under the assumption that random censoring times are independent within clusters and a
Clayton copula model is used for the response. In this case, the minimal required sam-
ple size is estimated under the within-cluster independent censoring assumption (3.2.7) in
which (3.A.13) is used to compute B. We then calculate the theoretical power when the
within-cluster censoring times are correlated and (3.A.9) is used to compute B. We let
κ = 0.75, pa = 0.2, and consider J = 2 and J = 20 with net censoring rates ranging from
0.2 to 0.8. The Clayton, Frank and Gumbel copula functions are considered for jointly
modeling the distribution of the censoring times within clusters. While it is more general
to allow different degrees of within-cluster associations for the failure and censoring times,
for parsimony we restrict attention to the case that the value of Kendall’s τ is the same
for the failure times (τ) and censoring times (τc).
Figure 3.4 suggests that the naive assumption of within-cluster independence in the
censoring times can lead to sample sizes which are too small and hence studies with inade-
quate power. As the net censoring rate increases (and hence the proportion of event times
censored by the random censoring time increases) this effect becomes more pronounced.
For example, for J = 20 and τ = 0.25, the power is 0.8 for all the copula functions when
p0 = 0.2 since in this case there is no dependent random censoring time. However, when
the net censoring rate increases to 80%, the power decreases to 0.756, 0.765 and 0.766
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(b) Large Cluster Size, J = 100
Figure 3.3: Power curves as a function of true values of Kendall’s τ when the sample size
is estimated based on the assumed value of Kendall’s τ under different copula functions.
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Figure 3.4: Power implications of within-cluster association in the random censoring times
under joint censoring models induced by different copula functions where the within-cluster
association in the failure and censoring times are constrained to be the same (τ = τc); the
original sample size is computed based on a Clayton copula model for the failure times and
the assumption of independent censoring times; κ = 0.75, βA = log 0.8, p0 = 0.2.
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under the Clayton, Frank and Gumbel copula models for the censoring times. Further, if
we compare the left panel to the right panels of Figure 3.4, we find that when the associa-
tion in the censoring times increases, the power implications of ignoring the within-cluster
dependence become more serious for all copula functions. The power is also more seriously
impacted with larger cluster sizes; compare the top panels to the respective bottom panels
of Figure 3.4.
Although it is not the focus of our interest, we also examine the effect of misspecifying
the shape of the baseline hazard function in the marginal event time distribution in the
setting where the administrative and random censoring rates are correct; this ensures that
the expected number of events is comparable in the assumed and true parameter settings,
but would mean, naturally, that the times of the events would be misspecified. The details
on how this was investigated, along with the associated findings, are given in Appendix C.
We find that there is negligible impact on power of misspecifying the shape parameter in
this setting when there is only administrative censoring. When the event times are subject
to random censoring there can be an increase or decrease in the power compared to the
nominal level, and the extent of the effect depends on the copula function modeling the
within-cluster dependence; this is not surprising since it is well-known that the different
copula functions model the association between event times differently over the range of
possible values.
3.4 Sample Size for Clustered Interval-Censored Event
Times
3.4.1 Estimating Equations and Sample Size Criteria
Interval-censored event times arise when it is only possible to determine whether events
have occurred at periodic assessments (Sun, 2006). In rheumatology studies, for example,
interest lies in the time to the development of joint damage, but the extent of joint damage
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is only possible to determine when patients undergo radiographic examination (Gladman
et al., 1995). In this case the time of joint damage will only be known to fall between
the time of the first radiograph showing evidence of damage and the time of the preceding
radiographic examination. Other examples include trials aiming to evaluate osteoporosis
treatments for the prevention of asymptomatic fractures, studies of the development of
new metastatic lesions, and studies in nephrology on the development of kidney stones.
We assume again that Tij|Zi follows a proportional hazards model (3.2.1) with a q × 1
parameter α indexing the baseline hazard and β the regression parameter of interest. The
marginal survivor function F(t|Zi; θ) = P (Tij ≥ t|Zi; θ) is then indexed by a (q + 1) × 1
parameter θ = (α′, β)′. In the present setting, we consider a cluster-randomized trial in
which the plan is to observe each individual at R pre-specified assessment times a1, . . . , aR;
we let a0 = 0 and aR+1 = ∞. Under this observation scheme we observe Yijr = I(ar−1 <
Tij ≤ ar), r = 1, . . . , R + 1. The response data provided by individual j in cluster i is
Yij = (Yij1, . . . , YijR)
′, where Yij,R+1 = 1 −
∑R
r=1 Yijr, and Yi = (Y
′
i1, . . . , Y
′
iJ)
′ contains all
response data from cluster i, i = 1, . . . , n. Let µij = (µij1, . . . , µijR)
′ where
µijr = E[Yijr|Zi; θ] = P (ar−1 < Tij ≤ ar|Zi; θ) = F(ar−1|Zi; θ)−F(ar|Zi; θ) , r = 1, . . . , R.
Like Kor et al. (2013), we consider the following generalized estimating equations for
the parameters θ, under a working independence assumption, with the presumption that
a robust variance estimator will be used at the time of analysis to account for the within-
cluster dependence of the event times,
U(θ) =
n∑
i=1
Ui(θ) =
n∑
i=1
[
Ui(α)
Ui(β)
]
=
n∑
i=1
D′iV
−1
i (Yi − µi) , (3.4.1)
where µi = (µ
′
i1, . . . , µ
′
iJ)
′ is a JR × 1 vector, Di = [∂µi/∂α′, ∂µi/∂β] is a JR × (q + 1)
matrix of derivatives of the mean, and Vi is a JR× JR working covariance matrix. Under
the working independence assumption, Vi is block diagonal with R × R block diagonal
matrices Vij = Cov(Yij, Y
′
ij|Zi), j = 1, . . . , J , which account for the correlation of responses
at different assessment times within individuals, i.e.
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Vi =

Vi1
. . .
ViJ
 =

Cov(Yi1, Y
′
i1|Zi) 0
. . .
0 Cov(YiJ , Y ′iJ |Zi)
 , (3.4.2)
and the (r, s)th entry of Vij is
Cov(Yijr, Yijs|Zi) =
{
µijr(1− µijr), r = s ;
−µijrµijs, r 6= s .
(3.4.3)
Note that if the marginal regression models are correctly specified, n−1/2U(θ) is asymp-
totically multivariate normal with mean zero and covariance given analogously to (3.2.3)
by
B = E[Ui(θ)Ui(θ)′] , (3.4.4)
estimated as
B̂ =
1
n
n∑
i=1
Ui(θ)U
′
i(θ)
∣∣∣∣
θ=θ̂
.
The estimator θ̂ is the root of U(θ) = 0 and is consistent for θ with n1/2(θ̂−θ) D−→ N(0,Γ)
asymptotically, where Γ = A−1B[A−1]′, and A = −E[∂Ui(θ)/∂θ′]. Again the matrix A can
be consistently estimated by
Â = − 1
n
n∑
i=1
∂Ui(θ)/∂θ
′
∣∣∣∣
θ=θ̂
. (3.4.5)
Model assumptions are required to derive the sample size formula based on the above
asymptotic variance formula for clustered interval-censored data. Copula functions can be
used to construct the joint distribution with any specified marginal properties. Consider a
cluster-randomized trial in which the treatment is randomly allocated to clusters. Suppose
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we aim to test whether the treatment has an effect on the time to a certain event. The
null hypothesis is H0 : β = β0 = 0, and the alternative hypothesis is HA : β 6= β0, and let
βA denote the clinically important effect.
As in Section 3.2, the limiting distribution of a Wald statistic can be used to select
the required sample size (number of clusters) for a two-sided test with significance level γ1
and power 1 − γ2. The key point is to derive the formulae for A = E[−∂Ui(θ)/∂θ′] and
B = E[Ui(θ)U ′i(θ)], and hence the form of Γ = A−1B[A−1]′, so the required sample size can
be obtained based on Ψ = Γq+1,q+1, the element from the covariance matrix; the formulae
are outlined in Appendix B. The resulting sample size n necessary to detect the effect of
treatment with the specified power is
n ≥
{
zγ1/2
√
Ψ0 + zγ2
√
ΨA
βA
}2
, (3.4.6)
where Ψ0 and ΨA are the elements of Γ computed under the null and alternative settings. At
the design stage of clinical trials, to estimate the required number of clusters, specifications
of the effect of interest βA, cluster size J , inspection times a1, . . . , aR, parametric baseline
hazard function, and especially the joint distribution for clustered event times are required.
3.4.2 Empirical Validation of Sample Size Formula for Clustered
Interval-Censored Event Times
Here we examine the performance of the proposed sample size formula for clustered interval-
censored data. Consider an equal allocation cluster-randomized trial with binary treatment
covariate Zi, P (Zi = 1) = P (Zi = 0) = 0.5. Assume that Tij follows the proportional
hazards model given by (3.2.1) with Weibull baseline cumulative hazard Λ0(s) = (λ0s)
κ,
where α = (log λ0, log κ)
′, q = 2, and θ = (α′, β)′, j = 1, . . . , J, i = 1, . . . , n; we consider
cluster sizes of J = 2, 5, 20 and 100. Suppose κ = 0.75 and choose λ0 so that P (Tij > 1|Zi =
0) = pa to give a specified administrative censoring rate; we set pa = 0.2. Suppose the
plan is to assess each individual R times over the interval [0, 1] at pre-specified assessment
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times a1, . . . , aR evenly spaced over the observation interval, i.e. ar = r/R, r = 1, . . . , R,
with R = 2, 4 or 12. Let Yij = (Yij1, . . . , YijR)
′
denote the event information provided by
individual j in cluster i, where Yijr = I(ar−1 < Tij ≤ ar).
Suppose the within-cluster association in the underlying failure times is induced by
the Clayton copula with Kendall’s τ of 0.05, 0.10, and 0.25 for small, mild and moderate
within-cluster association respectively. For each parameter combination, we estimate the
sample size (number of clusters) by (3.4.6) given βA = log 0.8, the type I error rate γ1 = 0.05
and power 1 − γ2 = 0.8. After obtaining the required minimum sample size, we generate
the corresponding covariate Zi and clustered response Yi. Parameter estimate are then
obtained via the estimating equation (3.4.1). For each parameter combination, nsim = 2000
datasets are simulated and analysed to yield 2000 estimates of β and respective robust
variance estimates. The empirical standard error (ESE), average robust standard error
(ASE), empirical rejection rate (REJ%) and 95% empirical coverage probability (ECP%)
are summarized in Table 3.2.
The empirical rejection rate is close to the nominal type I error rate when β = 0 and
close to the nominal power when β = log 0.8, with the latter supporting the validity of
the sample size formula. The empirical biases (not shown) are all negligible, so it is not
surprising that the empirical coverage probabilities are all compatible with the nominal
95% level. As the number of assessments increases, the required sample size is found to
decrease, but the extent of this decrease from the case of R = 4 to R = 12 is quite small,
particularly when cluster sizes are large. To clearly understand the impact of the number of
assessments on the efficiency, we computed the asymptotic relative efficiency of estimators
for the marginal parameters, defined as
AREr,k =
asvar(θ˜k)
asvarr(θˆk)
,
where asvar(θ˜k) is the asymptotic variance of θk for R = 100; this value is large enough
to mimic the case that the event times are known precisely; i.e. the case of clustered
right-censored event times. The term asvarr(θˆk) represents the asymptotic variance of θ̂k
73
Table 3.2: Sample size estimation and empirical properties of estimator βˆ under cluster-
randomized design for interval-censored data when the Clayton copula is used to induce
the within-cluster association between event times; κ = 0.75, βA = log 0.8, pa = 0.2,
nsim = 2000.
β = 0 β = log 0.8 β = 0 β = log 0.8
J τ R n ESE ASE REJ% ESE ASE REJ% ECP% J τ R n ESE ASE REJ% ESE ASE REJ% ECP%
2 0.05 2 458 0.081 0.079 5.6 0.083 0.081 79.0 94.3 20 0.05 2 103 0.078 0.079 4.8 0.078 0.079 80.6 95.7
4 440 0.078 0.079 4.9 0.080 0.081 81.3 95.4 4 101 0.079 0.079 5.5 0.080 0.080 78.7 94.9
12 433 0.079 0.079 5.1 0.081 0.081 79.6 95.4 12 101 0.079 0.078 5.6 0.080 0.079 78.9 95.1
0.10 2 490 0.079 0.079 4.6 0.080 0.081 78.5 95.6 0.10 2 164 0.080 0.079 4.7 0.080 0.079 78.9 94.8
4 471 0.079 0.079 5.2 0.081 0.081 78.0 94.9 4 161 0.080 0.079 4.9 0.080 0.080 80.1 94.8
12 465 0.080 0.079 5.2 0.082 0.081 79.8 94.6 12 160 0.080 0.079 5.3 0.080 0.080 78.5 95.1
0.25 2 584 0.077 0.079 4.2 0.079 0.080 78.1 95.5 0.25 2 342 0.080 0.079 5.3 0.080 0.080 79.0 95.1
4 564 0.080 0.079 5.7 0.082 0.081 80.9 94.3 4 337 0.081 0.079 5.7 0.081 0.080 79.4 94.8
12 557 0.081 0.079 5.0 0.082 0.081 80.0 94.4 12 336 0.078 0.079 4.9 0.079 0.080 79.4 95.3
5 0.05 2 222 0.076 0.079 4.8 0.078 0.080 82.2 95.7 100 0.05 2 72 0.080 0.078 5.1 0.082 0.079 79.7 93.5
4 214 0.080 0.079 5.6 0.082 0.081 79.5 94.3 4 71 0.078 0.079 4.6 0.078 0.079 79.7 95.5
12 212 0.079 0.079 5.7 0.081 0.080 79.6 94.4 12 71 0.076 0.078 4.6 0.077 0.078 81.3 95.3
0.10 2 272 0.080 0.079 5.4 0.082 0.080 80.0 93.9 0.10 2 135 0.080 0.079 5.4 0.080 0.079 80.1 94.9
4 265 0.080 0.079 5.4 0.081 0.080 79.1 94.4 4 134 0.080 0.079 5.5 0.080 0.079 81.5 94.9
12 262 0.080 0.079 5.5 0.082 0.080 78.6 94.9 12 133 0.081 0.079 5.7 0.081 0.079 79.4 94.8
0.25 2 422 0.079 0.079 4.8 0.079 0.080 81.1 95.1 0.25 2 320 0.079 0.080 4.9 0.079 0.080 81.0 95.4
4 413 0.079 0.079 5.3 0.079 0.080 79.7 95.3 4 317 0.079 0.079 4.3 0.079 0.080 82.0 95.4
12 409 0.081 0.079 5.1 0.082 0.080 79.5 95.0 12 316 0.081 0.079 5.4 0.082 0.080 79.2 94.3
for the case R = r, corresponding to clustered interval-censored failure time data, where
k = 1, 2, 3.
Figure 3.5 shows the trend of asymptotic relative efficiency for estimators of the marginal
parameters with cluster sizes of J = 2, 5, and 20, respectively. From these figures, we note
that when the number of assessments increases to R = 8, the asymptotic relative efficien-
cies for both λ0 and β are close to 1 in all cases considered. This also supports the empirical
findings that the number of clusters required decreases very little when the number of as-
sessments increases from R = 4 to 12. Figure 3.5 also shows that the impact of the number
of assessments is more severe for small cluster sizes, which agrees with what we found from
Table 3.2. As one might expect, however, the number of assessments seriously affects the
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efficiency of the estimator for the trend parameter κ, so when the entire marginal distri-
bution is of interest, increasing the number of assessments certainly can improve efficiency
for some features of the distribution. There is of course a trade-off between the statisti-
cal goals of precision and power and the economic and other costs. The development of
optimal design criteria which enables one to weigh the merits of increasing the number of
clusters or the number of follow-up assessments to be scheduled, subject to prespecified
budgetary constraints represents an important area of future research.
3.5 Illustrative Example Involving Treatment for Oti-
tis Media
Otitis media is inflammation of the inner ear which puts patients at risk of permanent
damage and loss of hearing. We illustrate the steps in trial design by considering the
study discussed in Manatunga and Chen (2000) in which children from six months to
eight years of age with otitis media requiring surgical insertion of tubes in the auditory
canal are randomized to receive either two weeks of medical therapy with prednisone and
sulfamethoprim or no medical therapy (standard care). The trial is conceived based on the
data in Le and Lindgren (1996) in which all children except one had bilateral inflammation
and so we consider clusters of size two with J = 2. In the absence of information on the
trend we set κ = 1. The median time to failure of the inserted tube was estimated to
be seven months, assuming 30 days per month yields λ0 = − log 0.5/210 ≈ 0.0033. As in
Manatunga and Chen (2000) we set τ = 0.56 to reflect moderate to strong within-child
association in the failure times. Since follow-up is planned for 1.5 years we set C† = 540 and
anticipate an administrative censoring rate of 17% for the control arm. To accommodate
study withdrawal we adopt an exponential model for loss to follow-up to give a net rate
of censoring in the control arm of 40% or 60%. Note that this setting is slightly different
than the setting discussed in Section 3.3 where different individuals within each cluster had
different censoring times; here the clusters are defined by children and the times to failure
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Figure 3.5: Asymptotic relative efficiency of estimators for marginal parameters for clus-
tered interval-censored event times as a function of the number of assessments, degree of
dependence and copula function.
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of the left and right tubes would be censored at a common time. The formula in Appendix
A can be easily modified to address this by defining G˜(·) as the survival distribution for the
cluster-level censoring time and replacing G(s, t) by G˜(max(s, t)) in (3.A.9). Under Clayton,
Frank and Gumbel copulas, we compute the number of children required to randomize to
ensure 80% power to detect a 30, 40 or 50% reduction in the marginal hazard for failure
based on a two-sided test at the 5% level. The results displayed in Table 3.3 provide a
simple illustration of how the most conservative copula depends on the rate of censoring.
When the net censoring is expected to be 40% the Clayton copula yields the largest sample
size but when it is 60%, the Frank copula yields the largest sample sizes.
Table 3.3: Number of clusters (children) required for otitis media study under Clayton,
Frank and Gumbel copulas for different clinically important treatment effects and net
censoring rates.
exp(β) = 0.7 exp(β) = 0.6 exp(β) = 0.5
Cens % Clayton Frank Gumbel Clayton Frank Gumbel Clayton Frank Gumbel
40% 366 357 347 181 177 172 101 99 96
60% 521 530 519 258 263 259 144 147 145
3.6 Discussion
We derived sample size formulae for cluster-randomized trials involving right- and interval-
censored event times in which the analysis is based on a marginal proportional hazards
assumption. For right-censored data, we derived expressions for the asymptotic robust
variance of the Wald statistic based on the approach of Lee et al. (1992) and for clustered
interval-censored data we likewise adopted the structure of Kor et al. (2013). Both of
these frameworks invoke a working independence assumption, so robust variance estimation
is required to ensure valid inference in the presence of within-cluster association. The
simulation studies conducted confirm that the formulae are valid. Code for computing the
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required sample size is available in R from the authors upon request. Robustness of these
formulae to the misspecification of copula functions and to within-cluster dependence in
the censoring times is also investigated using large sample theory for clustered failure times
in the context of right-censored data.
As in other sample size formula for cluster-randomized trials, the derived formulae
require specification of the degree of within-cluster dependence, measured in the failure time
setting by Kendall’s τ . A good approximation to the degree of within-cluster dependence
is important (Korendijk et al., 2010), so it is therefore customary to rely on estimates
reported in the literature. We recognize that it is unlikely that values of Kendall’s τ would
be reported in the clinical literature and so we recommend the conduct of small pilot
studies. More recently there has been increased interest in planning trials with adaptive
sample size re-estimation. This is carried out in its simplest form by having an internal
pilot study, after which blinded data are used to estimate unknown parameters; these new
estimates are then used to revise sample size calculations. This is a generally important
area of research as these methods increase efficiency. We have developed such methods in
another context (Cook et al., 2009) and plan to study this in the present setting in future
work.
We have focussed on settings with a single binary treatment indicator, but the pro-
posed methods extend naturally to deal with trials where analyses control for cluster-level
covariates. A two-dimensional covariate vector would arise if one designed a three-armed
trial, in which case one might specify Zi = (Zi1, Zi2)
′ where Zi1 and Zi2 indicate assign-
ment to the first and second experimental treatments respectively and Zi1 = Zi2 = 0 if
cluster i is assigned to the control intervention. More generally, other multidimensional
descriptive cluster-level covariates can be incorporated into the analyses, but at the design
stage their joint distribution would have to be specified to facilitate computation of the
matrix expectations in the robust variance formula; see Appendix A and B. Individual level
covariates can also be controlled for in the analysis in principle, but assumptions would
again be required regarding their joint distribution, and in particular the extent to which
these covariates are dependent within clusters.
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In principle, the method we develop could be adapted for use in the setting where the
number of clusters is fixed, and the goal is to determine the number of individuals within
each cluster necessary to achieve the desired power. A practical setting where this may
be a more appealing framework would be a health promotion study in which clinics are
randomized to deliver one of two smoking cessation programs. If there are a fixed number
of clinics available to take part, but patients are continually being referred to these clinics,
it is natural to want to know how many patients should be recruited from these clinics to
ensure adequate power to detect a specified effect of an experimental cessation program.
As pointed out by Hemming et al. (2011), it is important to note that the limiting robust
standard deviation of estimators obtained under the working independence assumption
decreases as the cluster size increases, but it does not decrease to zero; i.e. there is a
positive limiting value. As a result, for a given number of clusters, minimal clinically
important effect, and type I error rate, there is a limit to the power that can be achieved
by increasing the cluster size. Conversely, for a given number of clusters, power and
type I error rate, there is a limit to how small the clinically important effect can be with
increasing cluster sizes. In situations where small clinically important effects are specified,
it may therefore be necessary to select the number of clusters and the cluster size in concert
to ensure practical and statistical constraints are met.
When the clustered event times are interval-censored data, our sample size formula is
derived based on the assumption that all the assessments on each individual are available.
Individuals may of course prematurely drop-out of studies leading to missed assessments.
In this case the response vectors are incompletely observed, but modifications to the es-
timating functions are straightforward if assumptions about the withdrawal process are
made.
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Appendix A: Limiting Distribution of the Wald Statis-
tic based on Clustered Event Time Data
In what follows we consider the setting in which Zi is a fixed binary treatment indicator
and assume that the marginal distribution of Tij, the event time for individual j in cluster
i, satisfies the proportional hazard assumption with
λij(t|Zi) = λ0(t;α) exp(Ziβ) ,
where λ0(t;α) is the baseline hazard function indexed by a vector α and β is the coefficient
of interest, j = 1, . . . , J , i = 1, . . . , n. If C† is an administrative censoring time, the plan
is to observe over (0, C†], but C∗ij is a random censoring time with survivor function G∗(c),
representing a possible early withdrawal time. The net censoring time for individual j
in cluster i is then Cij = min(C
∗
ij, C
†), with survivor function G(c). In counting process
notation we let {Nij(t), 0 < t} denote the right-continuous counting process for Tij, where
Nij(t) = I(Tij ≤ t) indicates that the event occurred at or before time t for individual j in
cluster i. Then dNij(t) = 1 if individual j in cluster i experiences the event at time t, and
dNij(t) = 0 otherwise. Let Y¯ij(t) = Yij(t)Y
†
ij(t) be the indicator that the jth individual in
cluster i is under observation and at risk of event at time t, where Y †ij(t) = I(Tij ≥ t) and
Yij(t) = I(Cij ≥ t).
Under working independence assumption, the partial score function for β is
U(β) =
n∑
i=1
J∑
j=1
∫ ∞
0
Y¯ij(t)
(
Zi −
∑J
j=1 S1j(t; β)∑J
j=1 S0j(t; β)
)
dNij(t) ,
where Srj(t; β) = n
−1∑n
i=1 Y¯ij(t)Z
r
i exp(Ziβ), r = 0, 1 and Z
0
i = 1 and Z
1
i = Zi.
Lee et al. (1992) show that the score function is asymptotically equivalent to a sum of
independent identically distributed terms
n−1/2U(β) = n−1/2
n∑
i=1
J∑
j=1
ζij
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where
ζij =
∫ ∞
0
Y¯ij(t)(Zi −W (t))dMij(t) ,
where we suppress the functional dependence on β in the terms
W (t) =
J∑
j=1
s1j(t; β)/
J∑
j=1
s0j(t; β) ,
with srj(t; β) the limit of Srj(t; β), and
Mij(t) = Nij(t)−
∫ t
0
Y¯ij(u) exp(Ziβ)λ0(u)du
where {Mij(t), 0 < t} is a martingale. By the Central Limit Theorem, n−1/2U(β) converges
to a normal random variable with mean 0 and variance B, where
B = n−1
n∑
i=1
Var(ζi·) =
J∑
j,k=1
Cov (ζij, ζik) =
J∑
j,k=1
E(ζijζik) , (3.A.1)
where ζi· =
∑J
j=1 ζij, i = 1, . . . , n.
The root of U(β) = 0 is a consistent estimator β̂ with n1/2(β̂ − β) D−→ N(0,Γ), where
Γ = B/A2 and A = −E[∂Ui(β)/∂β]. The sample size formula is derived based on this
limiting distribution with the B and A computed based on parametric models. We give the
results of these derivations in the following two sections under the assumption of dependent
within-cluster censoring times and independent censoring within clusters.
General Derivation of B
We first consider a general case in which the censoring times could be correlated within
clusters. Assume (Ci1, . . . , CiJ)
′ ⊥ Zi and let G(u) = P (Cij ≥ u) be the survivor function
for the censoring time Cij, and G(s, t) = P (Cij ≥ s, Cik ≥ t) denote the joint survivor
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function for the censoring times (Cij, Cik) within cluster i; both are assumed common
across the two groups. The joint survivor function G(s, t) describes the association between
within-cluster censoring times.
To derive an expression for (3.A.1) we first consider the case where j = k and note
E
[
ζ2ij
]
= E
[∫ C†
0
Y¯ij(s)(Zi −W (s))2λij(s)ds
]
= EZi
[
EY †ij(s)|Zi
{
EYij(s)|Y †ij(s),Zi
[∫ C†
0
Y¯ij(s)(Zi −W (s))2λij(s)ds
]}]
= EZi
[
EY †ij(s)|Zi
{∫ C†
0
G(s)Y †ij(s)(Zi −W (s))2λij(s)ds
}]
= EZi
[∫ C†
0
G(s)P (Tij ≥ s|Zi)(Zi −W (s))2λij(s)ds
]
= EZi
[∫ C†
0
G(s)(Zi −W (s))2fj(s|Zi)ds
]
(3.A.2)
where fj(s|Zi) is the conditional density of the event time for individual j in cluster i. And
EZi [·] depends on the trial allocation probability.
For j 6= k, since
E[ζijζik] = E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dMij(s)dMik(t)
]
,
and Prentice and Cai (1992) have shown that
dMij(s)dMik(t) = dNij(s)dNik(t)− dNij(s)Y¯ik(t)dΛik(t)
− Y¯ij(s)dΛij(s)dNik(t)− Y¯ij(s)Y¯ik(t)dΛij(s)dΛik(t) ,
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then
E[ζijζik] = E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dNij(s)dNik(t)
]
− E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dNij(s)dΛik(t)
]
− E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dΛij(s)dNik(t)
]
+ E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dΛij(s)dΛik(t)
]
. (3.A.3)
The first term in (3.A.3) is then computed as
E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dNij(s)dNik(t)
]
= EZi
[
EY †ij(s),Y
†
ik(t)|Zi
{
EdNij(s),dNik(t)|Y †ij(s),Y †ik(t),Zi
[
EYij(s),Yik(t)|Zi,Y †ij(s),Y †ik(t),dNij(s),dNik(t)
{
∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dNij(s)dNik(t)
}]}]
= EZi
[
EY †ij(s),Y
†
ik(t)|Zi
{
EdNij(s),dNik(t)|Y †ij(s),Y †ik(t),Zi
[
∫∫
(0,C†]2
G(s, t)Y †ij(s)Y †ik(t)(Zi −W (s))(Zi −W (t))dNij(s)dNik(t)
]}]
= EZi
[
EY †ij(s),Y
†
ik(t)|Zi
{∫∫
(0,C†]2
G(s, t)Y †ij(s)Y †ik(t)(Zi −W (s))(Zi −W (t))
× P (Tij = s, Tik = t|Y †ij(s), Y †ik(t), Zi)dsdt
}]
= EZi
[ ∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))fjk(s, t|Zi)dsdt
]
(3.A.4)
where fjk(s, t|Zi) is the pairwise conditional density for (Tij, Tik) obtained through the
specification of a copula function. Using the same strategy for the remaining terms of
(3.A.3) we obtain,
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E[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dNij(s)dΛik(t)
]
(3.A.5)
= EZi
[ ∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂s
)
λ0(t)e
Ziβdsdt
]
,
E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dΛij(s)dNik(t)
]
(3.A.6)
= EZi
[ ∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂t
)
λ0(s)e
Ziβdsdt
]
,
and
E
[∫∫
(0,C†]2
Y¯ij(s)Y¯ik(t)(Zi −W (s))(Zi −W (t))dΛij(s)dΛik(t)
]
(3.A.7)
= EZi
[ ∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))Fjk(s, t|Zi)λ0(s)eZiβλ0(t)eZiβdsdt
]
.
where Fjk(s, t|Zi) is the pairwise conditional survivor function for (Tij, Tik) obtained through
the specification of a copula function. Plugging (3.A.4 - 3.A.7) into (3.A.3), we obtain
E[ζijζik] = EZi
{∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))fjk(s, t|Zi)dsdt (3.A.8)
−
∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂s
)
λ0(t)e
Ziβdsdt
−
∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂t
)
λ0(s)e
Ziβdsdt
+
∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))Fjk(s, t|Zi)λ0(s)eZiβλ0(t)eZiβdsdt
}
.
Therefore, by plugging (3.A.2) and (3.A.8) into the general form of B (3.A.1), the
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asymptotic variance of n−1/2U(β) can then be calculated as
B =
J∑
j=1
EZi
[∫ C†
0
G(s)(Zi −W (s))2fj(s|Zi)ds
]
(3.A.9)
+
∑
j 6=k
[
EZi
{∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))fjk(s, t|Zi)dsdt
−
∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂s
)
λ0(t)e
Ziβdsdt
−
∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂t
)
λ0(s)e
Ziβdsdt
+
∫∫
(0,C†]2
G(s, t)(Zi −W (s))(Zi −W (t))Fjk(s, t|Zi)λ0(s)eZiβλ0(t)eZiβdsdt
}]
.
The expression for A is likewise computed as,
A = E
{
J∑
j=1
∫ ∞
0
Y¯ij(t)
[
(
∑
k s2k(t;β)) (
∑
k s0k(t;β))− (
∑
k s1k(t;β))
2
(
∑
k s0k(t;β))
2
]
dNij(t)
}
(3.A.10)
= EZi
{
J∑
j=1
∫ C†
0
[
(
∑
k s2k(t;β)) (
∑
k s0k(t;β))− (
∑
k s1k(t;β))
2
(
∑
k s0k(t;β))
2
]
G(t)fj(t|Zi)dt
}
,
where
s0k(t; β) = E
(
Y¯ik(t) exp(Ziβ)
)
= EZi
(G(t)Fk(t|Zi) exp(Ziβ)) (3.A.11)
and
s1k(t; β) = s2k(t; β) = E
(
Y¯ik(t) exp(Ziβ)Zi
)
= EZi (G(t)Fk(t|Zi) exp(Ziβ)Zi) . (3.A.12)
Having expressions for B and A the asymptotic variance of β̂ can then be obtained and
used for power and sample size calculations.
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Derivation of B When Censoring Times are Independent Within
Clusters
In the special case in which the censoring times are independent within clusters, the term
A is unaffected. The computation of E[ζijζik] for j 6= k and hence the derivation of B is
however affected. In this case we obtain
B =
J∑
j=1
EZi
[∫ C†
0
G(s)(Zi −W (s))2fj(s|Zi)ds
]
(3.A.13)
+
∑
j 6=k
[
EZi
{∫∫
(0,C†]2
G(s)G(t)(Zi −W (s))(Zi −W (t))fjk(s, t|Zi)dsdt
−
∫∫
(0,C†]2
G(s)G(t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂s
)
λ0(t)e
Ziβdsdt
−
∫∫
(0,C†]2
G(s)G(t)(Zi −W (s))(Zi −W (t))
(
−∂Fjk(s, t|Zi)
∂t
)
λ0(s)e
Ziβdsdt
+
∫∫
(0,C†]2
G(s)G(t)Fjk(s, t|Zi)(Zi −W (s))(Zi −W (t))λ0(s)eZiβλ0(t)eZiβdsdt
}]
,
where the pairwise survivor function of the censoring times G(s, t) in (3.A.9) is simply
replaced by G(s)G(t) under the independent within-cluster censoring assumption.
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Appendix B: Limiting Distribution of Wald Statistics
with Clustered Interval-Censored Data
We assume again that Tij|Zi satisfies the proportional hazards assumption in (3.2.1) with
marginal distribution indexed by θ = (α′, β)′ where α is a q×1 parameter vector. Consider
a trial in which individuals are event-free at a0 = 0, and are scheduled to be observed at
R assessment times a1, . . . , aR over (0, C
†] where aR = C† and aR+1 = ∞. Let Yij =
(Yij1, . . . , YijR)
′ denote the event time information provided by individual j in cluster i,
where Yijr = I(ar−1 < Tij ≤ ar) indicates that the event was determined to have occurred in
(ar−1, ar]; let Yi = (Y ′i1, . . . , Y
′
iJ)
′. Adopted the strategy in Kor et al. (2013), the estimating
function for parameter θ can be written as
U(θ) =
n∑
i=1
Ui(θ) =
n∑
i=1
D′iV
−1
i (Yi − µi) ,
where µi = E[Yi|Zi] is the conditional mean of Yi|Zi, Di = ∂µi/∂θ′, and Vi is the working
matrix. Under the working independence assumption, Vi is a block diagonal matrix with
the blocks Vij = Cov(Yij, Y
′
ij|Zi), j = 1, . . . , J , which accounts for the negative dependence
between responses at different assessment times for each individual; that is
Vi =

Cov(Yi1, Y
′
i1|Zi) 0
. . .
0 Cov(YiJ , Y ′iJ |Zi)
 . (3.B.1)
As stated in Section 4, the estimator θ̂ is the root of U(θ) = 0 and has asymptotically
normal distribution,
n1/2(θ̂ − θ)→ N(0,Γ) ,
where Γ = A−1B [A−1]′. Hence the asymptotic distribution for β is
n1/2(β̂ − β)→ N(0,Ψ) , (3.B.2)
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where Ψ = Γ[q + 1, q + 1].
The null and alternative hypotheses are H0 : β = β0 = 0 and HA : β 6= β0 respectively,
and let βA be the clinically important effect of interest. To derive the expression for A and
B we note that
A = E[−∂Ui(θ)/∂θ′] = EZi [D′iV −1i Di] ,
B = E[Ui(θ)U ′i(θ)] = E[D′iV −1i (Yi − µi)(Yi − µi)′V −1i Di] = EZi [D′iV −1i WiV −1i Di] ,
where Wi = Cov(Yi, Y
′
i |Zi) is the full covariance matrix of Yi which accounts for both
the within-cluster association between Yij and Yik, j, k = 1, . . . , J , and the association
within-individuals over time (i.e. between Yijr and Yijs, r, s = 1, . . . , R) such that
Wi =

Cov(Yi1, Y
′
i1|Zi) Cov(Yi1, Y ′i2|Zi) · · · Cov(Yi1, Y ′iJ |Zi))
Cov(Yi2, Y
′
i2|Zi) · · · Cov(Yi2, Y ′iJ |Zi)
. . .
...
Cov(YiJ , Y
′
iJ |Zi)
 . (3.B.3)
Note that
Cov(Yij , Y
′
ij |Zi) =

Cov(Yij1, Yij1|Zi) Cov(Yij1, Yij2|Zi) · · · Cov(Yij1, YijR|Zi)
Cov(Yij2, Yij2|Zi) · · · Cov(Yij2, YijR|Zi)
. . .
...
Cov(YijR, YijR|Zi)

,
(3.B.4)
where
Cov(Yijr, Yijr|Zi) = µijr(1− µijr) , and Cov(Yijr, Yijs|Zi) = −µijrµijs , (3.B.5)
j = 1, . . . , J . The covariance between Yij and Y
′
ik, j 6= k, is more involved and makes use
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of the copula assumptions. Specifically,
Cov(Yij, Y
′
ik|Zi) = E[YijY ′ik|Zi]− µijµ′ik (3.B.6)
=

E[Yij1Yik1|Zi] E[Yij1Yik2|Zi] · · · E[Yij1YikR|Zi]
E[Yij2Yik2|Zi] · · · E[Yij2YjkR|Zi]
. . .
...
E[YijRYikR|Zi]

− µijµ′ik ,
where
E[YijrYiks|Zi] = F(ar−1, as−1|Zi)−F(ar−1, as|Zi)−F(ar, as−1|Zi) + F(ar, as|Zi) ,
(3.B.7)
can be calculated based on the copula model. By plugging (3.B.4) and (3.B.6) into (3.B.1)
and (3.B.3), we obtain the expression for Vi and Wi, and hence we can obtain A and B.
Based on the asymptotic property of the Wald statistic (3.B.2), we derive the sample size
criteria (3.4.6).
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Appendix C: Impact of Misspecification of Marginal
Distribution
We further explore the effect of misspecification here by considering whether there is any
impact of misspecifying the extent of trend in the baseline hazard function on sample size,
when the expected number of events is correctly specified. We assume that the marginal
distribution of Tij|Zi is of the proportional hazards form (3.2.1), where the baseline hazard
is λ0(s;α)ds = dΛ0(s;α) with Weibull cumulative hazard Λ0(s;α) = (λ0s)
κ, α = (λ0, κ)
′.
As in Section 3.2, we focus on the test of H0 : β = 0 vs. HA : β 6= 0 and let βA denote
the minimal clinically important effect of interest. The sample size is determined to ensure
100(1− γ2)% = 80% power to reject H0 at βA, given the type I error rate 100γ1% = 5%.
If the administrative censoring rate pa and net censoring rate p0 are correctly specified
but there is no useful pilot data on what κ values are appropriate, one might use κ = 1.0 to
compute the required number of clusters by (3.2.7) at βA = log 0.8. To explore sensitivity
of the power to the parameter κ, with the derived number of clusters we next examine the
theoretical power at different values of κ under an administrative censoring rate of pa = 0.2
and net censoring rate of p0 = 0.2 or 0.5 for the control group, we consider values of κ
ranging from 0.5 to 1.5 and examine the impact of misspecification under the Clayton,
Frank, and Gumbel copula functions. Figure 3.6 and Figure 3.7 show the power of such
test when the sample size is calculated based on formula (3.2.7) by using κ = 1.0 for 20%
and 50% net censoring rates, respectively. Settings with cluster sizes of 2 and 100 and weak
(τ = 0.1) and moderate (τ = 0.25) degrees of within cluster association are considered. As
can be seen from Figure 3.6, when there is only administrative censoring there is no impact
on power from misspecification of κ; all power functions are horizontal lines with value 0.8
for all copula models. When there is random censoring, Figure 3.7 indicates the effect of
misspecifying the shape parameter. The effect of κ misspecification is smaller when J = 2
than when J = 100. Moreover the power is more robust to misspecification of the shape
parameter under the Clayton copula than it is under the Frank and Gumbel copulas.
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Figure 3.6: Theoretical power as a function of κ for trials designed with the correct values
of pa = p0 = 0.2 but sample size is determined under the assumption κ = 1.
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Figure 3.7: Theoretical power as a function of κ for trials designed with the correct values
of pa = 0.2 and random censoring yielding a 50% net censoring rate (p0 = 0.50), but sample
size is determined under the assumption κ = 1.
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Chapter 4
Assessment of Treatment Effects on
Post-Progression Survival under an
Additive Hazards Model
4.1 Introduction
4.1.1 Background
While the ultimate goal in therapeutic cancer studies is the reduction in mortality, phase III
trials are routinely designed based on the primary response of progression-free survival time.
The rationale for this composite endpoint is two-fold. First, improvements in standard of
care have led to longer survival times making it infeasible to detect clinically meaningful
treatment effects in an cost-effective and timely manner. If treatment effects are similar for
overall and progression-free survival times, there is a potential for increased power, reduced
sample size requirements, or shorter trial duration based on since progression is often
observed prior to death (Freemantle et al., 2003). Second, the occurrence of progression
and other intermediate events often prompts treatment crossover or use of subsequent line
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therapies (Dancey, 2014); this can happen in as many as 50-60% of patients in trials in renal
cell carcinoma (Rini et al., 2008). The dynamic response-dependent changes in therapy
post-randomization appropriately made to optimize the care of individual patients, make
it challenging to interpret the effect of randomized interventions on overall survival (Hotte
et al., 2011).
Progression-free survival time is often implicitly viewed as a surrogate for overall sur-
vival and there is increasing understanding of the pitfalls of such assumptions (D’Agostino,
2000; Freemantle and Calvert, 2007); see also Fleming et al. (2009). In light of this, many
researchers have examined the literature to assess the plausibility of this assumption. Buyse
et al. (2007) reported that progression-free survival time is a reasonable surrogate for over-
all survival in colorectal cancer, a position reaffirmed by Sidhu et al. (2013) in the context
of modern standard of care. For other tumour types, however, progression-free survival has
not proven to be a valid surrogate endpoint for overall survival (Buyse et al., 2010). Amir
et al. (2012) note that the association between findings based on progression-free survival
and overall survival may be weaker in settings where individuals live a relatively long time
following progression. Viewed more generally, progression-free survival is a composite end-
point, and as with any such response a clear and complete interpretation of the associated
treatment effects is challenging. Booth and Eisenhauer (2012) give a critical discussion of
the utility of progression-free survival as an endpoint in phase III trials.
Despite the ultimate goal of improving survival, accelerated approval is often considered
based on progression-free survival which in turn raises questions about what can be said
about effects on overall survival in this setting. Broglio and Berry (2009) consider a
decomposition of the therapeutic effect on overall survival into an effect on progression and
an effect on post-progression survival. Matulonis et al. (2014) raise the idea of examining
treatment effects on post-progression survival with a view to understanding differences
between progression-free survival and overall survival; see also Finkelstein and Schoenfeld
(2014).
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4.1.2 Framework and Notation
0 1
2
Alive and
Progression−Free Progression
Dead
Figure 4.1: An illness-death model for joint consideration of progression and death.
The three state illness-death model depicted in Figure 4.1 provides a useful framework
for considering the possible experiences of individuals following recruitment to a study
in the setting of semi-competing risks (Xu et al., 2010). If we let Tk denote the time of
entry to state k, T1 is the time to progression (TTP), overall survival time (OS) is T2, the
progression-free survival (PFS) time is T = min(T1, T2), and the post-progression survival
time (PPS) is defined as W1 = T2− T1 among those individuals for whom T1 < T2. We let
{Z(s), 0 < s} represent a three-state stochastic process in which state 0 is occupied at time
s by an individual who is alive and progression-free (i.e. s < min(t1, t2)), state 1 is occupied
by an individual who has progressed but is alive (i.e. t1 ≤ s < t2), and the absorbing state
2 is entered upon death and occupied thereafter (t2 ≤ s). We also let Nk(s) = I(Tk ≤ s)
indicate that state k has been entered by time s, k = 1, 2, let N(s) = (N1(s), N2(s))
′, and
define {N(s), 0 < s} as a bivariate counting process. Progression through the states in
Figure 4.1 can therefore be equivalently represented by the times T1 and T2, the multistate
process {Z(s), 0 < s}, or the bivariate counting process {N(s), 0 < s}.
We let X1 denote a binary indicator taking the value 1 for individuals given an exper-
imental therapy and 0 if they receive standard care. We consider the setting of a clinical
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trial where X1 is determined by balanced randomization. Fixed covariates measured at the
time of randomization are represented by X2, and time-varying internal covariates poten-
tially responsive to X1 and dependent on X2 and {N1(s), 0 < s} are represented by X3(s);
we let X(−1)(s) = (X ′2, X
′
3(s))
′ and X(s) = (X1, X ′2, X
′
3(s))
′. In the absence of censoring
the process history is denoted by H(t) = {(N(s), X(s)), 0 < s < t}.
Transitions between the states are governed by intensity functions defined as
lim
∆t↓0
P (∆Nk(t) = 1|H(t))
∆t
= I(Z(t−) = 0) · λ0k(t|H(t)) , k = 1, 2, (4.1.1)
for transitions out of state 0, and
lim
∆t↓0
P (∆N2(t) = 1|H(t))
∆t
= I(Z(t−) = 1) · λ12(t|H(t)) , (4.1.2)
for transitions from state 1 to 2 (Andersen et al., 1993). The intensity is defined condition-
ally on the history so it accommodates stochastic dependencies and hence plays a key role
in the formation of models aiming to advance scientific understanding of complex process
dynamics. In particular the intensities can be used to understand mechanisms by which
treatments have their effect; if {X3(u), 0 < u} is responsive to treatment one can examine
treatment effects on this marker process and model the effect of the marker process and
treatment on the transition intensities, thereby estimating indirect and direct effects. In a
similar spirit, for 1→ 2 transitions the intensity can incorporate information on the time
to progression or other aspects of the process history.
In clinical trials, however, the aim is generally to make causal statements about the
effect of an experimental treatment on a marginal feature of a disease process. Therefore
while recognizing these complexities are present, simple hazard-based models are typically
adopted. The cause-specific hazards for the first event are denoted by h0k(t|X1) where
lim
∆t↓0
P (∆Nk(t) = 1|Z(t−) = 0, X1)
∆t
= I(Z(t−) = 0) · E{λ0k(t|H(t))|Z(t−) = 0, X1}
= I(Z(t−) = 0) · h0k(t|X1) , k = 1, 2. (4.1.3)
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In (4.1.3) the conditional expectations are taken with respect to {X(−1)(s), 0 < s < t}.
It is important to note that these models do not presume the absence of any fixed or time-
varying covariates, nor do they presume that these factors have no effect; rather these are
typically specified as partially conditional “working models” for the purpose of assessing a
treatment effect.
Models for (4.1.3) are easily and commonly fitted by cause-specific competing risk
analyses. When components of X2 or {X3(s), 0 < s} are shared across the 0→ 1 and 0→ 2
intensities (or even if the distinct covariates are correlated), the usual strategy of censoring
individuals for T1 upon this earlier occurrence of T2 induces a form of dependent censoring
for T1 which explains the general reluctance of trialists to adopt standard competing risks
analyses in the evaluation of randomized therapies.
The risk of death following progression may be compared between treatment arms based
on the sojourn time distribution in state 1 of Figure 4.1. For the purpose of the following
calculations we presume there is only a baseline variable X2 in addition to X1. The
history of the process is then greatly simplified and we can define the survivor function for
W1|X,T1 < T2, where W1 = T2−T1 and X = (X1, X2)′, and denoted by P (W1 ≥ s|X,T1 <
T2) as∫ ∞
0
exp
(
−
∫ t1+s
t1
λ12(u|t1, X)du
)
λ01(t1|X) exp (−(Λ01(t1|X) + Λ02(t1|X)) dt1 .
The survivor function for W1|X1, T1 < T2 can then be obtained as
P (W1 ≥ s|X1, T1 < T2) = EX2|X1,T1<T2 {P (W1 ≥ s|X,T1 < T2)} . (4.1.4)
Then hazard function for the post-progression survival time given only the treatment in-
dicator X1 can then be obtained by
h12(s|X1, T1 < T2) = d
ds
[− logP (W1 ≥ s|X1, T1 < T2)] . (4.1.5)
Our interest here is primarily on inference regarding the effect of treatment on the
post-progression survival time W1 through study of (4.1.5).
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The remainder of this chapter is organized as follows. In Section 2 we specify a simple
additive intensity model for the illness-death process and derive the limiting values of
estimators under naive analyses of the sojourn time distribution in state 1. We define
the parameters reflecting the causal effect by re-deriving the limiting values in the case
where confounding and dependent censoring have been addressed and show how to obtain
consistent estimates of these through use of inverse probability weights. Simulation studies
are carried out in Section 3 to investigate the finite sample properties of estimators. An
extension is given in Section 4 to deal with the introduction of rescue interventions at the
time of progression. Concluding remarks are made in Section 5.
4.2 Causal Issues on Post-Progression Survival
4.2.1 Notation and Setting
To illustrate the issues we first consider a simple model involving a treatment indicator
and a single binary covariate X2 and let X = (X1, X2)
′. Also assume that there are no
unmeasured confounders. Due to balanced randomization, X1 ⊥ X2 and P (X1 = 1) =
P (X1 = 0) = 0.5. We suppose the trial is planned so that individuals are to be observed
over (0, A] where A is an administrative censoring time. We let R denote a random non-
informative censoring time withR ⊥ (T1, T2) giving a net censoring time C = min(R,A). In
the framework of additive intensity functions (Aalen, 1989), we assume that the parametric
function in (4.1.1) is of the form
λ0k(t|H(t)) = X ′α0k(t) = α0k0(t) + α0k1(t)X1 + α0k2(t)X2 , (4.2.1)
where α0k(t) = (α0k0(t), α0k1(t), α0k2(t))
′, k = 1, 2, and
λ12(t|H(t)) = X ′α12(s) , (4.2.2)
where α12(s) = (α120(s), α121(s), α122(s))
′ and s = B1(t) = t − t1 is the time since entry
to state 1. The corresponding cumulative intensity functions are Λ0k(t|X) = X ′A0k(t)
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and Λ12(s|X) = X ′A12(s), where Ajk(u) = (Ajk0(u), Ajk1(u), Ajk2(u))′ and Ajkl(u) =∫ u
0
αjkl(v)dv, l = 0, 1, 2, 0 ≤ j < k ≤ 2.
Suppose we now have a sample of m independent individuals. If Yi(t) = I(t ≤ Ci) then
Y¯i(t) = Yi(t) · I(t ≤ min(Ti1, Ti2)) indicates that individual i is under observation and at
risk of transition out of state 0 at time t. Let S0k denote the set of all observed unique
0→ k transition times, k = 1, 2, and S12 be the set of all observed unique 1→ 2 transition
times. We define
X(t) =

Y¯1(t) Y¯1(t)X11 Y¯1(t)X12
Y¯2(t) Y¯2(t)X21 Y¯2(t)X22
...
...
...
Y¯m(t) Y¯m(t)Xm1 Y¯m(t)Xm2
 , Ik(t) =

Y¯1(t)dN1k(t)
Y¯2(t)dN2k(t)
...
Y¯m(t)dNmk(t)
 , (4.2.3)
The cumulative coefficients A0k for 0 → k transitions given (X1, X2) are estimated
nonparametrically by
Â0k(t) =
∑
u∈S0k: u<t
dÂ0k(u) , k = 1, 2 , (4.2.4)
where
dÂ0k(u) = (X′(u)X(u))−1X′(u)Ik(u) , (4.2.5)
The asymptotic properties of this nonparametric estimate have been established under
regularity conditions discussed by Aalen et al. (2008); Martinussen and Scheike (2007).
Under these conditions as m→∞,
m1/2(Â0k(t)− A0k(t)) D−→ Uk ,
where Uk is a Gaussian martingale with covariance function
Φk(t) =
∫ t
0
φk(u)du , (4.2.6)
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with
φk(t) =
{
E[Y¯i(t)X
⊗2
i ]
}−1
E[Y¯i(t)X
⊗2
i X
′
iα0k(t)]
{
E[Y¯i(t)X
⊗2
i ]
}−1
,
where Xi = (1, Xi1, Xi2)
′, X⊗2i = XiX
′
i. A uniformly consistent estimator of the variance
function is (Aalen, 1989; Aalen et al., 2008)
Φ̂k(t) = m
∫ t
0
(X′(u)X(u))−1X′(u)diag(dNk(u))X(u)(X′(u)X(u))−1 (4.2.7)
Nonparametric estimates of the cumulative coefficients for 1 → 2 transitions given
(X1, X2) and their uniformly consistent variance estimator can be similarly defined with
Y¯i1(t) = Yi(t) · I(Zi(t−) = 1) replacing Y¯i(t); see Aalen et al. (2001) for a discussion about
the use of additive intensity models for multistate processes. The cumulative coefficients
can be consistently estimated by the “aalen” function in the R package timereg (R Core
Team, 2014).
4.2.2 Randomization and Collapsibility of Aalen’s Model
Randomization plays an important role in the evaluation of intervention effects in clinical
trials. Randomization eliminates biases that may arise in how treatment decisions are
made by allocating individuals to treatment groups by random manipulation of treatment.
This renders the treatment indicator independent with known, unknown, and unmeasured
confounders making many comparisons between treatment groups objective and valid.
The Cox regression model (Cox, 1972) is commonly used in clinical trials where treat-
ment effects are summarized and interpreted in terms of hazard ratios. The Cox model
has some particularly restrictive properties however. As pointed out by Ford et al. (1995)
two Cox models with different sets of covariates cannot both be valid; see also Lawless
(2003). Moreover Greenland et al. (1999) and Herna´n (2010) point out that hazard ratios
from Cox models do not lend themselves to a causal interpretation even if treatment is
randomly assigned at the beginning of the study. This problem arises because the in-
dependence property between treatment and fixed potential confounders, guaranteed at
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the beginning of the study by randomization, is lost because risk sets are changing over
time and are only comprised, at time t say, of the improper subgroup (Yusuf et al., 1991)
of individuals who have not yet failed. Aalen’s model (Aalen, 1989), in which covariates
act additively on the linear scale is collapsible (Martinussen and Vansteelandt, 2013) and
independence is retained between treatment and baseline variables as time passes since
X1 ⊥ X2|T ≥ t if X1 ⊥ X2|T = 0 (Aalen et al., 2015). It is for this reason we adopt the
framework of additive models in this study.
It is important to distinguish between parametric functions that are being estimated in
different settings so we use α for the parameters in the true intensities and β for the para-
metric functions we wish to estimate; parameters corresponding to limiting values under
naive analyses are denoted by γ. We focus primarily on the coefficient of the treatment
indicator. Because the Aalen model is collapsible we let
hβ0k(t|X1) = EX2{λ0k(t|H(t))|X1, Z(t−) = 0} = β0k0(t) + β0k1(t)X1 ,
denote the cause-specific hazards for transitions out of state 0, where β0k0(t) = α0k0(t) +
α0k2(t)E{X2|Z(t−) = 0} and β0k1(t) = α0k1(t).
When considering treatment effects on post-progression survival the issues are slightly
more challenging. Figure 4.2 is a Lexis diagram illustrating the induced dependent cen-
soring of the post-progression survival time W1 arising from the omission of X2 from the
transition models. In addition there is an association induced between X1 and X2 upon
restricting attention to individuals who progressed so the benefit of randomization is lost in
this subgroup of individuals. To see this, note that for a naive analyses of post-progression
survival,
hγ12(s|X1) = E{h12(s|X1, X2)|X1, T1 < min(C − s, T2),W1 ≥ s}
= γ120(s) + γ121(s)X1 , (4.2.8)
where
γ120(s) = α120(s) + α122(s)E{X2|X1 = 0, T1 < min(C − s, T2),W1 ≥ s} , (4.2.9)
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and
γ121(s) = α121(s) + α122(s)
{
E{X2|X1 = 1, T1 < min(T2, C − s),W1 ≥ s}
− E{X2|X1 = 0, T1 < min(T2, C − s),W1 ≥ s}
}
, (4.2.10)
where E{X2|X1, T1 < min(T2, C − s),W1 ≥ s} is computed by
P (W1 ≥ s|X1, X2 = 1)P (T1 < min(T2, C − s)|X1, X2 = 1)P (X1, X2 = 1)∑
x2
P (W1 ≥ s|X1, X2 = x2)P (T1 < min(T2, C − s)|X1, X2 = x2)P (X1, X2 = x2) .
The fact that γ121(s) 6= α121(s) reflects the confounding arising by conditioning on the
collider event of “progression” (Aalen et al., 2015).
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Figure 4.2: Lexis diagram illustrating the time scale time since randomization and time
since progression; omission of X2 from the 0 → 1 and 1 → 2 transiton models renders T1
and W1 dependent and hence C − T1 is a dependent censoring time for W1 even if C is
completely independent of {Z(s), 0 < s}.
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To conceive of the causal effect of X1 on W1 we conceptualize a “trial” in which X1
is rendered independent of X2 among individuals who have progressed within the planned
study period (0, A], perhaps through re-randomization. When X1 ⊥ X2|T1 < min(T2, A)
we may re-derive the limiting values of the coefficients under this setting as
hβ12(s|X1) = EX2|T1<min(T2,A),W1≥s {α120(s) + α121(s)X1 + α122(s)X2}
= β120(s) + β121(s)X1 , (4.2.11)
where
β120(s) = α120(s) + α122(s)P(X2 = 1|T1 < min(T2, A),W1 ≥ s) , (4.2.12)
β121(s) = α121(s) , (4.2.13)
and the symbols E and P denote expectations and probabilities relevant for the setting
where X1 ⊥ X2|T1 < min(T2, A). Note that
P(X2 = 1|T1 < min(T2, A),W1 ≥ s) =
∑
x1
P(X1 = x1, X2 = 1|T1 < min(T2, A),W1 ≥ s)
(4.2.14)
where P(X1 = x1, X2 = 1|T1 < min(T2, A),W1 ≥ s) is given by
P (W1 ≥ s|X1 = x1, X2 = 1)P †(X1 = x1)P †(X2 = 1)∑
x1
∑
x2
P (W1 ≥ s|X1 = x1, X2 = x2)P †(X1 = x1)P †(X2 = x2)
=
P (W1 ≥ s|X1 = x1, X2 = 1)P (X2 = 1|T1 < min(T2, A))∑
x1
∑
x2
P (W1 ≥ s|X1 = x1, X2 = x2)P (X2 = x2|T1 < min(T2, A)) ,
where P †(X1) and P †(X2) indicates the new marginal distribution of X1 and X2 after the
randomization upon entry to the progression state. Also note that
P (X2 = x2|T1 < min(T2, A)) =
∑
x1
P (X1 = x1, X2 = x2|T1 < min(T2, A)) (4.2.15)
where P (X1 = x1, X2 = x2|T1 < min(T2, A)) is obtained as
P (T1 < min(T2, A)|X1 = x1, X2 = x2)P (X1 = x1, X2 = x2)∑
x1
∑
x2
P (T1 < min(T2, A)|X1 = x1, X2 = x2)P (X1 = x1, X2 = x2)
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and P (T1 < min(T2, A)|X1, X2) is the cumulative incidence function for T1 evaluated at
time A. By plugging (4.2.14) and (4.2.15) into (4.2.12) and (4.2.13), we can calculate the
limiting values of β12(s).
4.2.3 Inverse Weighting Methods
Note that naive analysis in which we fit W1|X1 without weights leads to estimates which
are consistent for γ12(s). Inverse weighting can be used to account for both the confound-
ing arising from the conditioning on the collider (progression) as well as the dependent
censoring arising by the omission of X2 in the model for W1|X1. Let Yi1(s) = I(Ti1 <
min(Ti2, Ci − s)) indicate that individual i made the transition to state 1 and did so early
enough that the sojourn in state 1 was not censored prior to s, let Yi2(s) = I(Wi1 ≥ s) indi-
cate they remained in state 1 for a duration of at least s units, and let Y˜i(s) = Yi1(s)Yi2(s),
i = 1, . . . ,m. Letting dNi2(s) = I(Wi1 = s), we define
X(s) =

Y˜1(s) Y˜1(s)X11
Y˜2(s) Y˜2(s)X21
...
...
Y˜m(s) Y˜m(s)Xm1
 , I(s) =

Y˜1(s)dN12(s)
Y˜2(s)dN22(s)
...
Y˜m(s)dNm2(s)
 .
The cumulative coefficients for the model ofW1|X1, denoted here byB12(s) = (B120(s), B121(s))′,
can be nonparametrically and consistently estimated by
B̂12(s) =
∑
u∈S12: u<s
dB̂12(u) , (4.2.16)
where S12 is the set of unique observed times for W1, and
dB̂12(s) = (X′(s)W(s)X(s))−1X′(s)W(s)I(s) ,
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and W(s) is a diagonal weight matrix of the form
W(s) =

Y˜1(s)
pi1(s)
0 0 · · · 0 0
0 Y˜2(s)
pi2(s)
0 · · · 0 0
...
. . .
...
0
0 0 Y˜m(s)
pim(s)

.
The terms 1/pii(s) are individual specific weights which account for both the dependent
censoring and confounding issues and are given by
pii(s) = P (Xi1|Xi2, Ti1 < min(Ti2, A)) · P (Ti1 ≤ Ci − s|Xi1, Xi2, Ti1 < min(Ti2, A)) .
(4.2.17)
The first term in (4.2.17) accounts for the confounding induced by the association between
X1 and X2 arising from restricting attention to individuals who progressed. The second
term in (4.2.17) accounts for the dependent censoring of W1 arising because of the associa-
tion between T1 and W1 arising from the omission of X2. Thus while unweighted analysis of
W1|X1 gives estimates consistent for γ12(s), use of inverse weighting gives estimates which
are consistent for β12(s).
Therefore, under the regularity conditions (Aalen, 1989; Aalen et al., 2008), this in-
verse weighted estimator of the cumulative coefficient for W1|X1 under the additive model
satisfies following asymptotic properties,
m1/2(B̂12(s)−B12(s)) D−→ U ,
where U is a Gaussian martingale with covariance function
Φ(s) =
∫ s
0
φ(u)du ,
φ(u) =
{
E
[
Y˜i(u)Wi(u)X
⊗2
i
]}−1
E
[
Y˜i(u)W
2
i (u)X
⊗2
i X
′
iα12(u)
]{
E
[
Y˜i(u)Wi(u)X
⊗2
i
]}−1
,
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and Xi = (1, Xi1)
′ and Wi(s) = Y˜i(s)/pii(s) is the (i, i) component of W(s). A uniformly
consistent estimator of the variance function is
Φ̂(s) = m
∫ s
0
(X′(u)W(u)X(u))−1X′(u)W(u)diag(dNi2(u))W′(u)X(u)(X′(u)W(u)X(u))−1 .
(4.2.18)
Furthermore, note that
pi(s) = P (X1|X2, T1 < min(T2, A))P (T1 ≤ C − s|X1, X2, T1 < min(T2, A))
=
H(s|X1, X2)P (X1|X2)∑
x1
P (T1 < min(T2, A)|X1 = x1, X2)P (X1 = x1|X2) ,
where
H(s|X1, X2) = P (C − T1 ≥ s, T1 < min(T2, A)|X1, X2)
= P (A− T1 ≥ s, A ≤ R, T1 < min(T2, A)|X1, X2)
+ P (R− T1 ≥ s, A > R, T1 < min(T2, A)|X1, X2)
= P (T1 < min(T2, A− s)|X1, X2)G(A)
+ P (T1 + s ≤ R < A, T1 < min(T2, A)|X1, X2)
=
∫ A−s
0
G(t1 + s)λ01(t1|X1, X2) exp (−(Λ01(t1|X1, X2) + Λ02(t1|X1, X2))) dt1 ,
and G(r) is the survivor function for random censoring time R.
By fitting separate cause-specific additive hazards models for 0→ 1 and 0→ 2 transi-
tions given (X1, X2) we can obtain consistent estimates of dΛ̂0k(u|X1, X2), k = 1, 2. This
enables us to estimate the cumulative incidence function for T1 at A by
ĈIF 1(A|X1, X2) =
∑
u∈S01: u<A
d̂Λ01(u|X1, X2) exp
(
−[Λ̂01(u|X1, X2) + Λ̂02(u|X1, X2)]
)
.
The survivor function of the random censoring time R is likewise easily estimated non-
parametrically by the Kaplan-Meier method (Kaplan and Meier, 1958) using ‘survfit’ in
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R to give Ĝ(u). We can then estimate H(s|X1, X2) for each distinct event time s ∈ S12 by
Ĥ(s|X1, X2), where
Ĥ(s|X1, X2) =
∑
u∈S01: u<A−s
Ĝ(u+ s)d̂Λ01(u|X1, X2) exp
(
−(Λ̂01(u|X1, X2) + Λ̂02(u|X1, X2))
)
.
(4.2.19)
In addition, the conditional probability of P (X1|X2) can be consistently estimated by
P̂ (X1 = x1|X2 = x2) =
∑
i I(Xi1 = x1, Xi2 = x2)∑
i I(Xi2 = x2)
(4.2.20)
as required, but if we are in the setting of a randomized trials simpler marginal estimate
are apparent. The inverse weights are then consistently estimated by
pii(s) =
Ĥ(s|X1 = xi1, X2 = xi2) · P̂ (X1 = xi1|X2 = xi2)∑
x1
ĈIF 1(A|X1 = x1, X2 = xi2)P̂ (X1 = x1|X2 = xi2)
. (4.2.21)
4.3 Simulation Study of Treatment Effects on Post-
Progression Survival
Consider a randomized trial with study window (0, A], where without loss of generality we
set A = 1. We consider a binary treatment indicator X1 realized by randomization upon
accrual. The binary covariate X2 with probability P (X2 = 1) = 0.5 has an effect on all
transitions. Suppose the 0 → k transition intensities are of the form (4.2.1), k = 1, 2 and
the 1 → 2 transition intensity is of the form (4.2.2). We assume the baseline intensities
are of the Weibull form (i.e. Ajk0(u) = (λjku)
κjk ; 0 ≤ j < k ≤ 2) and we let κ01 =
κ12 = 1 and κ02 = 1.25. We set (α011, α012)
′ = (−1.2, 0.6)′, (α021, α022)′ = (−0.5, 0.3)′
and (α121, α122)
′ = (−1.0, 0.6)′ to reflect the scenario that the treatment has significant
effect on reducing the risk of both progression and death, while the risk of progression and
death is higher for individuals with X2 = 1; the coefficients of both the treatment and
auxiliary variable are constant. As before, we let Tk denote the time of 0 → k transition,
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k = 1, 2, and let W1 denote the sojourn time in state 1. We determined the value of λjk
to satisfy the constraints P (min(T1, T2) < A) = p0, P (T1 < T2|min(T1, T2) < A) = p1 and
P (T1 + W1 < A|T1 < min(T2, A)) = p2, where p0 is the probability of transition out of
state 0 before administrative censoring A, p0 × p1 is the cumulative incidence function of
T1 evaluated at A, and p0 × p1 × p2 is the probability of transition 1→ 2 occurring before
the administrative censoring time. We set p0 = 0.75 and p1 = p2 = 0.6. We let the random
censoring time R be gamma distributed with mean µ and variance φ, and set φ = 0.04 and
choose µ such that P (R < A) = pi = 0.2.
One thousand datasets of size m = 2000 were then generated and we fit the additive
model for W1|X1 under naive analysis (no weights) and using inverse weighting by (4.2.16).
The limiting values of cumulative intercept and cumulative treatment coefficient under
naive analyses and with inverse weighting have been calculated based on (4.2.9 - 4.2.10)
and (4.2.12 - 4.2.13), respectively and these are used to assess the agreement between the
calculations and the empirical results.
The empirical properties of estimates of the cumulative intercept and cumulative coef-
ficient of treatment for the sojourn time in state 1 are summarized in Table 4.1 at different
time points under naive analysis and analyses using inverse weighting. We find that the
biases under naive analysis are significant when compared to the limiting causal value∫ s
0
β12(u)du. We also note that the 95% empirical coverage probabilities are lower than the
acceptable range, with the performance getting worse as time increases. These support
our theoretical finding that naive analysis of the post-progression survival cannot provide
a consistent estimate of the causal effect of treatment. The biases of estimates obtained
by inverse weighting methods (with true or non-parametrically estimated weights) are all
negligible. This confirms that the weight proposed adjusts for confounding and dependent
censoring and the resulting inverse weighting method can provide consistent estimate of the
causal effect of treatment on the post-progression survival. When using inverse weighting,
the empirical standard error (ESE) and average computed standard error (ASE) are in
close agreement and the 95% empirical coverage probability are all within the acceptable
range.
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Table 4.1: Empirical estimates of cumulative intercept and cumulative treatment coefficient
for sojourn time in state 1 at different time points under naive analysis and with inverse
weighting in the presence of random censoring time; m = 2000, nsim = 1000.
INVERSE WEIGHTING METHOD
NAIVE METHOD TRUE WEIGHT ESTIMATED WEIGHT
TIME TRUE
(W1) VALUE BIAS
† ECP† BIAS ESE ASE ECP BIAS ESE ASE ECP BIAS ESE ASE ECP
Cumulative Intercept
0.1 0.1894 -0.0013 0.953 -0.0056 0.0182 0.0184 0.932 -0.0013 0.0188 0.0190 0.951 -0.0013 0.0188 0.0190 0.951
0.2 0.3778 -0.0003 0.947 -0.0087 0.0273 0.0275 0.935 -0.0001 0.0281 0.0284 0.953 -0.0001 0.0281 0.0284 0.951
0.3 0.5654 0.0003 0.958 -0.0120 0.0362 0.0358 0.931 0.0004 0.0371 0.0369 0.965 0.0005 0.0371 0.0369 0.959
0.4 0.7522 -0.0000 0.946 -0.0158 0.0442 0.0441 0.924 -0.0001 0.0451 0.0454 0.951 -0.0000 0.0452 0.0454 0.946
0.5 0.9380 0.0026 0.953 -0.0164 0.0533 0.0531 0.934 0.0024 0.0544 0.0545 0.957 0.0025 0.0545 0.0545 0.956
0.6 1.1229 0.0022 0.950 -0.0196 0.0636 0.0629 0.928 0.0021 0.0646 0.0645 0.953 0.0022 0.0647 0.0645 0.953
0.7 1.3069 0.0008 0.953 -0.0234 0.0739 0.0746 0.932 0.0007 0.0748 0.0763 0.954 0.0008 0.0748 0.0763 0.955
0.8 1.4900 0.0026 0.954 -0.0235 0.0898 0.0901 0.941 0.0025 0.0901 0.0918 0.961 0.0026 0.0903 0.0919 0.958
Cumulative Coefficient of Treatment
0.1 -0.1000 0.0020 0.957 0.0158 0.0263 0.0267 0.913 0.0021 0.0262 0.0264 0.948 0.0018 0.0264 0.0264 0.947
0.2 -0.2000 0.0009 0.961 0.0290 0.0378 0.0396 0.903 0.0010 0.0379 0.0392 0.959 0.0005 0.0381 0.0393 0.953
0.3 -0.3000 0.0004 0.954 0.0431 0.0504 0.0512 0.874 0.0007 0.0510 0.0507 0.951 -0.0001 0.0515 0.0507 0.950
0.4 -0.4000 0.0008 0.948 0.0583 0.0616 0.0625 0.873 0.0013 0.0621 0.0619 0.945 0.0003 0.0630 0.0620 0.945
0.5 -0.5000 -0.0044 0.952 0.0682 0.0734 0.0745 0.863 -0.0024 0.0742 0.0738 0.952 -0.0037 0.0756 0.0739 0.948
0.6 -0.6000 -0.0019 0.956 0.0861 0.0844 0.0879 0.841 -0.0001 0.0849 0.0870 0.951 -0.0017 0.0867 0.0872 0.949
0.7 -0.7000 -0.0000 0.963 0.1035 0.1011 0.1037 0.834 0.0011 0.1011 0.1024 0.961 -0.0008 0.1035 0.1026 0.953
0.8 -0.8000 -0.0029 0.954 0.1164 0.1235 0.1242 0.845 -0.0008 0.1244 0.1226 0.950 -0.0033 0.1275 0.1231 0.947
BIAS† and ECP† are evaluated based on the limiting values of naive analysis.
When we compute the sample variance estimates for a given dataset using estimated
weights, we did not account for the variability from the weights. Therefore the variance of
the estimates of cumulative coefficients for W1|X1 under inverse weighting method while
using the estimated weights is estimated by m−1Φ˜(s), where
Φ˜(s) =
∫ s
0
(X′(u)Ŵ(u)X(u))−1X′(u)Ŵ(u)diag(dNi2(u))Ŵ′(u)X(u)(X′(u)Ŵ(u)X(u))−1 ,
and Ŵ(s) is the estimated diagonal weight matrix with the (i, i) component Y˜i(s)/pii(s),
where pii(s) is the nonparametric estimate of pii(s) obtained by (4.2.21), i = 1, . . . ,m. While
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this may lead to an inappropriate estimate of the variance, empirical standard errors are
actually in close agreement with the average standard errors in most cases and the coverage
probability is in agreement with the nominal level. These results are consistent with Wu
and Cook (2014) who justify this through the application of Newey (1994).
Figure 4.3 contains plots of the naive and adjusted limiting values as well as the av-
erage estimated values under unweighted and weighted analyses (with true and estimated
weights). The results illustrate close agreement between the theoretical and empirical
performance.
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Figure 4.3: Limiting values and empirical estimates of cumulative intercept and cumulative
treatment coefficient under the naive analysis and with inverse weighting methods (True
weights and estimated weights) in presence of random censoring; m = 2000, nsim = 1000.
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Figure 4.4 provides a graphical summary of the bias and variability of naive analysis
and inverse weighting methods at three times post progression: s = 0.2, 0.4 and 0.6. The
estimates of the intercept (top panel) and coefficient (bottom panel) illustrate that naive
analyses lead to a biased estimates, while inverse weighting method results in consistent
estimates of the effects. The inverse weighting method with estimated weight performs
nearly as well as that with true weights. Also when the time increase, the variabilities of
estimates increase for all methods. This is to be expected as fewer individuals contribute
to the analyses when time increase due to the death or censoring.
To investigate the small sample property, we carry out a similar simulation study in
which the parameter settings are same as before, but with sample size m = 500 and the
simulation repeats nsim = 2000 times. Table 4.2 summarizes the empirical properties
of estimates of the cumulative intercept and cumulative coefficient of treatment for W1
at different time points under naive analysis and analyses using inverse weighting. We
still find that the naive analysis is biased when comparing to the limiting causal value∫ s
0
β12(u)du, but the biases are not as significant as they are when the sample size is large
(see Table 4.1). The 95% empirical coverage probabilities are a slightly lower than the lower
limit of the acceptable range [0.94, 0.96]. The biases of estimates obtained by the inverse
weighting methods (with true or estimated weights) are all negligible and the empirical
coverage probabilities of nominal 95% confidence intervals are all within the acceptable
range. Furthermore, although we did not account for the variability from the weights
by using the estimated weights, the empirical standard errors are in general close to the
average standard errors and the coverage probability is in agreement with the nominal
level. These results might reflect that the proposed inverse weighting method performs
well for small sample size.
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Figure 4.4: Boxplot for estimates of cumulative intercept (top panel) and treatment effect
(bottom panel) at times 0.2, 0.4 and 0.6 under naive analysis (NAIVE), inverse weighting
method with true weights (IPW-TRUE) and by inverse weighting with estimated weights
(IPW-EST) in the presence of random censoring; m = 2000, nsim = 1000.
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Table 4.2: Empirical estimates of cumulative intercept and cumulative treatment coefficient
for sojourn time in state 1 at different time points under naive analysis and with inverse
weighting in the presence of random censoring time; m = 500, nsim = 2000.
INVERSE WEIGHTING METHOD
NAIVE METHOD TRUE WEIGHT ESTIMATED WEIGHT
TIME TRUE
(W1) VALUE BIAS
† ECP† BIAS ESE ASE ECP BIAS ESE ASE ECP BIAS ESE ASE ECP
Cumulative Intercept
0.1 0.1894 0.0003 0.942 -0.0040 0.0368 0.0368 0.935 0.0003 0.0375 0.0380 0.944 0.0003 0.0376 0.0380 0.943
0.2 0.3778 -0.0013 0.946 -0.0097 0.0550 0.0549 0.938 -0.0012 0.0561 0.0567 0.952 -0.0011 0.0563 0.0567 0.952
0.3 0.5654 -0.0009 0.953 -0.0131 0.0700 0.0715 0.936 -0.0007 0.0714 0.0737 0.954 -0.0006 0.0716 0.0738 0.952
0.4 0.7522 -0.0004 0.951 -0.0162 0.0869 0.0882 0.937 -0.0004 0.0884 0.0907 0.951 -0.0002 0.0888 0.0908 0.950
0.5 0.9380 0.0025 0.949 -0.0166 0.1052 0.1062 0.935 0.0022 0.1069 0.1090 0.950 0.0024 0.1074 0.1092 0.951
0.6 1.1229 0.0025 0.943 -0.0193 0.1264 0.1261 0.933 0.0021 0.1282 0.1292 0.943 0.0023 0.1290 0.1293 0.943
0.7 1.3069 0.0018 0.943 -0.0224 0.1494 0.1497 0.936 0.0012 0.1510 0.1530 0.945 0.0014 0.1515 0.1532 0.949
0.8 1.4900 0.0040 0.946 -0.0221 0.1871 0.1812 0.931 0.0032 0.1889 0.1845 0.946 0.0033 0.1892 0.1847 0.949
Cumulative Coefficient of Treatment
0.1 -0.1000 -0.0009 0.956 0.0130 0.0527 0.0532 0.952 -0.0007 0.0523 0.0526 0.952 -0.0015 0.0529 0.0528 0.954
0.2 -0.2000 0.0005 0.953 0.0286 0.0791 0.0791 0.944 0.0018 0.0785 0.0785 0.954 0.0000 0.0802 0.0791 0.950
0.3 -0.3000 -0.0000 0.951 0.0426 0.1016 0.1023 0.944 0.0017 0.1010 0.1015 0.953 -0.0007 0.1039 0.1025 0.947
0.4 -0.4000 -0.0012 0.961 0.0563 0.1227 0.1253 0.935 0.0019 0.1222 0.1242 0.959 -0.0018 0.1266 0.1257 0.950
0.5 -0.5000 -0.0058 0.956 0.0668 0.1468 0.1494 0.935 -0.0020 0.1468 0.1480 0.953 -0.0075 0.1529 0.1500 0.946
0.6 -0.6000 -0.0045 0.952 0.0835 0.1766 0.1767 0.932 -0.0008 0.1762 0.1744 0.950 -0.0087 0.1847 0.1776 0.942
0.7 -0.7000 -0.0048 0.956 0.0987 0.2067 0.2086 0.930 0.0003 0.2062 0.2058 0.954 -0.0095 0.2405 0.2153 0.947
0.8 -0.8000 -0.0082 0.954 0.1110 0.2521 0.2507 0.935 -0.0014 0.2537 0.2470 0.947 -0.0156 0.2847 0.2599 0.943
BIAS† and ECP† are evaluated based on the limiting values of naive analysis.
4.4 Causal Inference on Post-Progression Survival when
a New Treatment is Assigned at Progression
4.4.1 Notation and Setting
Here we consider a more complex clinical trial, where a new treatment may be assigned
upon progression. Physicians contemplating the introduction of such a new treatment will
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typically make the decision based on the course of the disease for a patient. Marker values
reflected in X3(s) could influence this decision; patients with poor prognosis based on
their marker value at the time of progression could be more likely to receive a potentially
helpful rescue medication. We consider a simpler setting in which the introduction of
rescue medication is influenced by whether the patient rapidly progressed from state 0
to state 1. To this end we let D = I(T1 < min(T2, A/2)) be an indicator for early
progression, so D = 1 if individual progressed in the first half of planned observation
window and D = 0 otherwise. Here we redefine X3 as an indicator of whether a rescue
treatment is introduced at progression and let the probability of assigning new treatment
depend on D; specifically we let P ∗1 (X3 = x3) = P (X3 = x3|D = 1, T1 < min(T2, A))
and P ∗0 (X3 = x3) = P (X3 = x3|D = 0, T1 < min(T2, A)), x3 = 0 or 1. In general
P ∗1 (X3 = 1) > P
∗
0 (X3 = 1), because individuals progress sooner might be at higher risk of
death and physicians tend to be more likely to assign rescue treatment X3 to those people.
The intensity function for 1→ 2 transitions in this setting becomes
λ12(t|H(t)) = α120(s) + α121(s)X1 + α122(s)X2 + α123(s)X3 , (4.4.1)
where X1 is a binary treatment indicator, X2 is a single binary covariate and X =
(X1, X2, X3)
′. Also we assume here that there are no unmeasured confounders. As dis-
cussed in Section 4.2.2, omission of X2 from the transition models could lead to dependent
censoring of the post-progression survival time W1. Moreover in the setting with a new
treatment assigned at the progression time, X3 and X1 are dependent and so X3 is another
confounder. For a naive analyses of post-progression survival in this setting we obtain
hγ12(s|X1) = E{h12(s|X1, X2, X3)|X1, T1 < min(C − s, T2),W1 ≥ s}
= γ120(s) + γ121(s)X1 , (4.4.2)
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where
γ120(s) = α120(s) + α122(s)E[X2|T1 < min(T2, C − s),W1 ≥ s,X1 = 0]
+ α123(s)E[X3|T1 < min(T2, C − s),W1 ≥ s,X1 = 0] , (4.4.3)
γ121(s) = α121(s) + α122(s)
{
E[X2|T1 < min(T2, C − s),W1 ≥ s,X1 = 1]
− E[X2|T1 < min(T2, C − s),W1 ≥ s,X1 = 0]
}
+ α123(s)
{
E[X3|T1 < min(T2, C − s),W1 ≥ s,X1 = 1]
− E[X3|T1 < min(T2, C − s),W1 ≥ s,X1 = 0]
}
, (4.4.4)
E[X2|T1 < min(T2, C − s),W1 ≥ s,X1] and E[X3|T1 < min(T2, C − s),W1 ≥ s,X1] are
computed by∑
x3
F(s|X1, X2 = 1, X3 = x3)P (T1 < min(T2, C − s), X3 = x3|X1, X2 = 1)P (X1, X2 = 1)∑
x3
∑
x2
F(s|X1, X2 = x2, X3 = x3)P (T1 < min(T2, C − s), X3 = x3|X1, X2 = x2)P (X1, X2 = x2) ,
and∑
x2
F(s|X1, X2 = x2, X3 = 1)P (T1 < min(T2, C − s), X3 = 1|X1, X2 = x2)P (X1, X2 = x2)∑
x2
∑
x3
F(s|X1, X2 = x2, X3 = x3)P (T1 < min(T2, C − s), X3 = x3|X1, X2 = x2)P (X1, X2 = x2) ,
respectively, where F(s|X1, X2, X3) = P (W1 ≥ s|X1, X2, X3) is the survival function of
W1|X which can be obtained from (4.4.1). Note that
P (T1 < min(T2, C − s), X3|X1, X2)
=
1∑
r=0
P (T1 < min(T2, C − s), X3, D = r|X1, X2)
=
1∑
r=0
P (X3|D = r, T1 < min(T2, A))P (T1 < min(T2, C − s), D = r|X1, X2)
= P ∗1 (X3)P (T1 < min(T2, C − s, A/2) |X1, X2)
+ P ∗0 (X3)P (T1 < min(T2, C − s), T1 ≥ A/2 |X1, X2) .
115
We can therefore show that γ121(s) 6= α121(s) reflecting the confounding arising by both
conditioning on the collider event of “progression” and omission of new treatment X3.
To conceive of the causal effect of X1 on W1 in this setting we conceptualize a “trial”
in which the treatment is rendered independent of both X2 and X3 among individuals who
have progressed within the planned study period (0, A] perhaps through re-randomization.
When X1 ⊥ (X2, X3)|T1 < min(T2, A), we could derive the limiting values of the coefficients
under this setting as
hβ12(s|X1) = E(X2,X3)|T1<min(T2,A),W1≥s {α120(s) + α121(s)X1 + α122(s)X2 + α123(s)X3}
= β120(s) + β121(s)X1 , (4.4.5)
where
β120(s) = α120(s) + α122(s)P(X2 = 1|T1 < min(T2, A),W1 ≥ s)
+ α123(s)P(X3 = 1|T1 < min(T2, A),W1 ≥ s) , (4.4.6)
β121(s) = α121(s) . (4.4.7)
and the symbols E and P denote expectations and probabilities relevant for the setting
where X1 ⊥ (X2, X3)|T1 < min(T2, A). Note that
P(X2 = 1|T1 < min(T2, A),W1 ≥ s)
=
∑
x1
∑
x3
P(X1 = x1, X2 = 1, X3 = x3|T1 < min(T2, A),W1 ≥ s) (4.4.8)
where P(X1 = x1, X2 = 1, X3 = x3|T1 < min(T2, A),W1 ≥ s) is given by
F(s|X1 = x1, X2 = 1, X3 = x3)P †(X1 = x1)P †(X2 = 1, X3 = x3)∑
x1
∑
x2
∑
x3
F(s|X1 = x1, X2 = x2, X3 = x3)P †(X1 = x1)P †(X2 = x2, X3 = x3)
=
F(s|X1 = x1, X2 = 1, X3 = x3)P (X2 = 1, X3 = x3|T1 < min(T2, A))∑
x1
∑
x2
∑
x3
F(s|X1 = x1, X2 = x2, X3 = x3)P (X2 = x2, X3 = x3|T1 < min(T2, A))
(4.4.9)
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where P †(X1) and P †(X2, X3) represent the new marginal distribution of X1 and (X2, X3)
following the randomization upon entry to the progression state. Moreover note that
P (X2 = x2, X3 = x3|T1 < min(T2, A))
=
∑
x1
P (X1 = x1, X2 = x2, X3 = x3|T1 < min(T2, A))
=
∑
x1
P (T1 < min(T2, A), X3 = x3|X1 = x1, X2 = x2)P (X1 = x1, X2 = x2)∑
x1
∑
x2
∑
x3
P (T1 < min(T2, A), X3 = x3|X1 = x1, X2 = x2)P (X1 = x1, X2 = x2) (4.4.10)
where P (T1 < min(T2, A), X3 = x3|X1 = x1, X2 = x2) is obtained as
1∑
r=0
P (T1 < min(T2, A), X3 = x3, D = r|X1 = x1, X2 = x2)
= P ∗1 (X3 = x3)P (T1 < min(T2, A/2) |X1 = x1, X2 = x2)
+ P ∗0 (X3 = x3)P (A/2 ≤ T1 < min(T2, A) |X1 = x1, X2 = x2)
Therefore by plugging (4.4.9) and (4.4.10) into (4.4.8), we can calculate P(X2 = 1|T1 <
min(T2, A),W1 ≥ s). Similarly, we can calculate P(X3 = 1|T1 < min(T2, A),W1 ≥ s) and
then the limiting values of β12(s).
4.4.2 Use of Inverse Weights with Rescue Therapy
Since the naive analyses in which fittingW1|X1 without weights leads to estimates which are
consistent to γ12(s). Inverse weighting can be used to account for the both the dependent
censoring by the omission of X2 and the confounding arising from the conditioning on
the collider (progression) and omitting X3 in the model for W1|X1. The nonparametric
weighted estimates for the cumulative intercept and coefficient are of the same form as
(4.2.16), but with different weight function as we need to further adjust for the confounding
arising from omission of X3 in this setting. Let the new weight be 1/ηi(s), where
ηi(s) = P (Ti1 ≤ Ci − s|Ti1 < min(Ti2, A), Xi1, Xi2, Xi3)P (Xi1|Xi2, Xi3, Ti1 < min(Ti2, A)) ,
(4.4.11)
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where the first term in (4.4.11) accounts for the dependent censoring of W1 arising because
of the association between T1 and W1 when omitting X2. The second term in (4.4.11)
accounts for the confounding induced by the association between X1 and X2 arising from
restricting attention to individuals who progressed and by the association between X1 and
X3. Therefore use of inverse weighting gives estimates consistent for β12(s), while the un-
weighted analysis of W1|X1 gives biased estimates, but consistent for γ12(s). Furthermore,
note that
η(s) =
P (T1 < C − s, T1 < min(T2, A), X3|X1, X2)P (X1|X2)∑
x1
P (T1 < min(T2, A), X3|X2, X1 = x1)P (X1 = x1|X2) , (4.4.12)
where
P (T1 < C − s, T1 < min(T2, A), X3|X1, X2)
= P (T1 < A− s, A ≤ R, T1 < min(T2, A), X3|X1, X2)
+ P (T1 < R− s, R < A, T1 < min(T2, A), X3|X1, X2)
=
∑
r
P (T1 < min(T2, A− s, A), X3, D = r|X1, X2) · G(A)
+
∑
r
P (T1 < R− s, R < A, T1 < min(T2, A), X3, D = r|X1, X2)
=
{
P ∗1 (X3)P (T1 < min(T2, A− s, A/2)|X1, X2)
+ P ∗0 (X3)P (A/2 ≤ T1 < min(T2, A− s, A)|X1, X2)
} · G(A)
+ P ∗1 (X3)P (T1 < min(T2, R− s, A/2), R < A|X1, X2)
+ P ∗0 (X3)P (A/2 ≤ T1 < min(T2, A,R− s), R < A|X1, X2)
= P ∗1 (X3)Q1(s|X1, X2) + P ∗0 (X3)Q2(s|X1, X2) ,
and
Q1(s|X1, X2) =
∫ min(A−s,A
2
)
0
G(t1 + s)λ01(t1|X1, X2) exp
(− (Λ01(t1|X1, X2) + Λ02(t1|X1, X2)))dt1 ,
(4.4.13)
Q2(s|X1, X2) =
∫ A−s
min(A−s,A
2
)
G(t1 + s)λ01(t1|X1, X2) exp
(− (Λ01(t1|X1, X2) + Λ02(t1|X1, X2)))dt1 .
(4.4.14)
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Similarly we obtain that
P (T1 < min(T2, A), X3|X2, X1) = P ∗1 (X3)L1(X1, X2) + P ∗0 (X3)L2(X1, X2) ,
where
L1(X1, X2) = CIF1(A/2 |X1, X2) , (4.4.15)
L2(X1, X2) = CIF1(A|X1, X2)− CIF1(A/2 |X1, X2) . (4.4.16)
Then η(s) can be written as
η(s) =
{
P ∗1 (X3)Q1(s|X1, X2) + P ∗0 (X3)Q2(s|X1, X2)
}
P (X1|X2)∑
x1
{
P ∗1 (X3)L1(X1 = x1, X2) + P
∗
0 (X3)L2(X1 = x1, X2)
}
P (X1 = x1|X2)
Note that in Section 4.2.3 we showed that P (X1 = x1|X2 = x2) can be consistently
estimated by (4.2.20), and the cumulative incidence function for T1 can be estimated by
ĈIF 1(u|X1, X2) =
∑
t∈S01: t<u
d̂Λ01(t|X1, X2) exp
(
−[Λ̂01(t|X1, X2) + Λ̂02(t|X1, X2)]
)
.
(4.4.17)
By (4.4.17), we can consistently estimate L1(X1, X2) and L2(X1, X2) using
L̂1(X1, X2) = ĈIF 1(A/2 |X1, X2) , (4.4.18)
L̂2(X1, X2) = ĈIF 1(A|X1, X2)− ĈIF 1(A/2 |X1, X2) , (4.4.19)
respectively. Furthermore, a function of the form
V (u|X1, X2) =
∫ u
0
G(t1 + s)λ01(t1|X1, X2) exp (−(Λ01(t1|X1, X2) + Λ02(t1|X1, X2))) dt1
can be estimated by
V̂ (u|X1, X2) =
∑
t∈S01:t<u
Ĝ(t+ s)d̂Λ01(t|X1, X2) exp
(
−(Λ̂01(t|X1, X2) + Λ̂02(t|X1, X2))
)
,
(4.4.20)
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as we discussed in Section 4.2.3. Therefore, Q1(s|X1, X2) and Q2(s|X1, X2) can be esti-
mated by
Q̂1(s|X1, X2) = V̂
(
min(A− s, A/2)|X1, X2
)
(4.4.21)
Q̂2(s|X1, X2) = V̂ (A− s|X1, X2)− V̂
(
min(A− s, A/2)|X1, X2
)
(4.4.22)
In order to estimate P ∗1 (X3 = x3) and P
∗
0 (X3 = x3), consider the estimating function
Ur(µr) =
m∑
i=1
I(Ti1 < min(Ti2, A))I(Di = r)I(Ti1 < Ci)
G(Ti1) (Xi3 − µr) , (4.4.23)
where µr = E[Xi3|Ti1 < min(Ti2, A), Di = r]; r = 0, 1. This estimating function can be
shown to be unbiased, so solving Ur(µr) = 0 provides a consistent estimate of µr. Doing
so gives
P̂ ∗1 (X3 = 1) = µ̂1 =
∑m
i=1 I(Ti1 < min(Ti2, A))I(Di = 1)I(Ti1 < Ci)Xi3/Ĝ(ti1)∑m
i=1 I(Ti1 < min(Ti2, A))I(Di = 1)I(Ti1 < Ci)/Ĝ(ti1)
, (4.4.24)
and
P̂ ∗0 (X3 = 1) = µ̂0 =
∑m
i=1 I(Ti1 < min(Ti2, A))I(Di = 0)I(Ti1 < Ci)Xi3/Ĝ(ti1)∑m
i=1 I(Ti1 < min(Ti2, A))I(Di = 0)I(Ti1 < Ci)/Ĝ(ti1)
. (4.4.25)
By plugging (4.2.20), (4.4.18 - 4.4.19), (4.4.21 - 4.4.22) and (4.4.24 - 4.4.25) into (4.4.12),
we obtain a consistent estimate for ηi(s).
4.4.3 Simulations with Response-Dependent Introduction of Res-
cue Therapy
A simulation study is carried out to assess the validity of the inverse weighting approach
developed here. The parameter settings are the same as Section 4.3. In addition we let
P ∗1 (X3 = 1) = P (X3 = 1|D = 1, T1 < min(T2, A)) = 0.75 and P ∗0 (X3 = 1) = P (X3 =
1|D = 0, T1 < min(T2, A)) = 0.25. We set α123 = −0.8, reflecting the scenario that the
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new treatment also has a strong effect on reducing the risk of death following progression.
We generate one thousand datasets of size m = 1000 individuals and fit the additive model
for W1|X1 under a naive analysis (4.2.4) and using inverse weighting by (4.2.16) but with
weights 1/ηi(s), (4.4.12). The limiting values of cumulative intercept and cumulative treat-
ment coefficient under the naive analyses and with inverse weighting have been calculated
based on (4.4.3 - 4.4.4) and (4.4.6 - 4.4.7), respectively and these are used to assess the
agreement between the calculations and the empirical results.
Table 4.3: Empirical estimates of cumulative intercept and cumulative treatment coefficient
for sojourn time in state 1 at different time points under naive analysis and with inverse
weighting in the presence of random censoring; a new treatment X3 is assigned at the
progression time; m = 1000, nsim = 1000.
INVERSE WEIGHTING METHOD
NAIVE METHOD TRUE WEIGHT ESTIMATED WEIGHT
TIME TRUE BIAS† ECP† BIAS ESE ASE ECP BIAS ESE ASE ECP BIAS ESE ASE ECP
Cumulative Intercept
0.1 0.1949 0.0001 0.949 -0.0065 0.0259 0.0263 0.936 0.0000 0.0273 0.0275 0.948 -0.0000 0.0273 0.0275 0.949
0.2 0.3875 0.0015 0.948 -0.0124 0.0377 0.0393 0.936 0.0016 0.0395 0.0413 0.948 0.0014 0.0394 0.0413 0.946
0.3 0.5778 0.0018 0.956 -0.0204 0.0493 0.0508 0.925 0.0018 0.0513 0.0536 0.956 0.0016 0.0512 0.0536 0.960
0.4 0.7658 0.0022 0.958 -0.0294 0.0593 0.0622 0.913 0.0024 0.0618 0.0660 0.963 0.0022 0.0614 0.0661 0.964
0.5 0.9517 0.0035 0.953 -0.0390 0.0718 0.0741 0.893 0.0040 0.0748 0.0795 0.961 0.0037 0.0743 0.0796 0.961
0.6 1.1354 0.0051 0.952 -0.0489 0.0870 0.0872 0.888 0.0057 0.0920 0.0946 0.957 0.0054 0.0916 0.0947 0.959
0.7 1.3169 0.0071 0.951 -0.0577 0.1050 0.1027 0.884 0.0078 0.1115 0.1121 0.950 0.0075 0.1108 0.1122 0.955
0.8 1.4964 0.0055 0.949 -0.0692 0.1222 0.1224 0.895 0.0055 0.1296 0.1337 0.960 0.0051 0.1285 0.1339 0.962
Cumultive Coefficient of Treatment
0.1 -0.1000 -0.0008 0.948 0.0184 0.0386 0.0386 0.933 -0.0003 0.0384 0.0381 0.951 -0.0006 0.0386 0.0382 0.951
0.2 -0.2000 -0.0028 0.944 0.0349 0.0585 0.0572 0.903 -0.0022 0.0581 0.0567 0.945 -0.0028 0.0578 0.0569 0.954
0.3 -0.3000 -0.0032 0.945 0.0523 0.0747 0.0733 0.889 -0.0028 0.0757 0.0733 0.941 -0.0038 0.0756 0.0736 0.947
0.4 -0.4000 -0.0048 0.954 0.0676 0.0867 0.0887 0.894 -0.0036 0.0885 0.0899 0.960 -0.0050 0.0889 0.0904 0.960
0.5 -0.5000 -0.0059 0.954 0.0823 0.1053 0.1045 0.880 -0.0042 0.1088 0.1082 0.955 -0.0058 0.1102 0.1089 0.955
0.6 -0.6000 -0.0058 0.943 0.0977 0.1258 0.1219 0.876 -0.0039 0.1327 0.1286 0.948 -0.0064 0.1350 0.1296 0.948
0.7 -0.7000 -0.0081 0.949 0.1111 0.1468 0.1421 0.863 -0.0059 0.1569 0.1516 0.950 -0.0100 0.1596 0.1527 0.949
0.8 -0.8000 -0.0058 0.950 0.1290 0.1688 0.1679 0.884 -0.0002 0.1820 0.1809 0.958 -0.0068 0.1861 0.1822 0.947
BIAS† and ECP† are evaluated based on the limiting values of naive analysis.
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Table 4.3 summarized the empirical properties of estimators of the cumulative inter-
cept and cumulative coefficient of treatment for the sojourn time in state 1 at differ-
ent time points under naive analysis and with inverse weighting (true weights and non-
parametrically estimated weights). We find that naive analysis leads to biased estimates
of causal value
∫ t
0
β12(s)ds and hence result in poor coverage probabilities with the em-
pirical coverage worsening as time increase. These support our theoretical finding that
naive analysis of the post-progression survival cannot provide a consistent estimate of the
causal effect of treatment. The biases of estimates obtained by inverse weighting (with
true or non-parametrically estimated weights) are all negligible. This confirms that the
weight proposed adjusts for the confounding and dependent censoring and the method for
estimating the weights yields consistent estimation of the causal effect of treatment on the
post-progression survival. The ESE and ASE under the inverse weighting methods are in
close agreement and the 95% empirical coverage probabilities are all within the acceptable
range. As in Section 4.3, we did not account for the variability from the weights when we
compute the sample variance estimates for the inverse weighting method with estimated
weights.
Figure 4.5 provides a graphical summary of the bias and variability of estimates of
cumulative intercept (top panel) and cumulative treatment coefficient (bottom panel), re-
spectively, under naive analysis and with inverse weighting at three times post progression:
s = 0.2, 0.4 and 0.6. These figures further illustrate that naive analysis is not appropriate
and results in biased estimates while suitable inverse weighting leads to consistent estima-
tion of the causal effects; the variability of estimates increases with increasing time for all
methods.
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Figure 4.5: Boxplot for estimates of cumulative intercept (top panel) and treatment effect
(bottom panel) at times 0.2, 0.4 and 0.6 under naive analysis (NAIVE), inverse weighting
method with true weights (IPW-TRUE) and by inverse weighting with estimated weights
(IPW-EST) in the presence of random censoring; new treatment X3 is assigned at the
progression time; m = 1000, nsim = 1000.
123
4.5 Discussion
We have considered the issues in the assessment of treatment effects on survival following
progression in cancer clinical trials. The goal of this work was to consider the influence of
two major factors leading to problems in the analyses of post-progression survival. One is
the effect of baseline prognostic values and their associated confounding effects on post-
progression survival, and the dependent censoring process that results from their omission.
The second is the complication arising from the response-dependent introduction of rescue
therapy upon progression. In this Chapter, only single binary covariate is considered and
we also assume there are no unmeasured confounders. Further work will then involve the
explanation of the role of time-varying markers which may be associated with progression
and death following progression, as well as the decision to introduce rescue therapy. The
additive model was used because it is collapsible and because the time-varying coefficients
can reflect complex causal effects which are not possible to represent in a parsimonious
way. Location-scale models or models based on time-transforms (Geraci and Jones, 2015)
could also be explored.
The Granger school of causal inference (Granger, 1988) offers a framework for studying
causal effects which is congruent with the general intensity-based approaches for the anal-
ysis of life history data (Aalen et al., 2012), but these tools and approaches are not aligned
with the approach typically adopted for causal analysis of data from randomized trials.
Thus there is an apparent tension between the need to provide an adequate representa-
tion of a complex dynamic process and the need to express simple marginal causal effects.
This is well known, but we have considered the issue from the specific setting of an illness
death model to simplify the discussion and make observations pertinent to phase III cancer
clinical trials where the aim is to better understand the relation between treatment effects
on progression-free survival and overall survival. In particular we have directed efforts at
understanding the effect of the randomized treatment on post-progression survival.
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Chapter 5
Remarks and Future Research
5.1 Overview
In this thesis new statistical methods have been developed for analysing dependent failure
time data in both the observational and clinical trial settings. In Chapter 2, we focus on
characterizing the nature and extend of the within-family dependence structure to investi-
gate the hereditary nature of disease process. Copula functions and second-order regression
models are used to model the within-family association and composite likelihood methods
have been considered for estimation and inference for event time data subject to a mixture
of right-censoring and current status observation schemes. The biased sampling scheme
and low incidence rate mean that the family data does not provide much information about
the marginal onset time distribution, so we develop methods which exploit auxiliary infor-
mation. A two-stage estimation procedure has also been developed along with a derivation
of the asymptotic properties of the resulting estimators. We have found that use of aux-
iliary data can improve the estimation efficiency and in settings where there is a lot of
auxiliary data the two-stage estimation procedure can yield relatively efficient estimators
compared to those obtained from simultaneous estimation.
The design of cluster-randomized clinical trials with censored responses was addressed
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in Chapter 3, contributing a useful advance given the relatively little amount of work
that has been carried out in this setting (Zhong and Cook, 2015). We propose a novel
way to derive the sample size formulae for cluster-randomized trials involving right- and
interval-censored event times, in which analysis is based on a marginal proportional hazards
assumption. Copula functions are used to facilitate the derivation of asymptotic variance
of estimators from the Cox regression model, and based on this we developed sample size
criteria. Validity of the proposed sample size formulae was assessed by comprehensive sim-
ulation studies. We also examine the robustness of these formulae to the misspecification
of copula functions and within-cluster dependence in the censoring process.
In Chapter 4 attention was directed at causal inference regarding randomized treatment
effects on post-progression survival in the context of a three-state illness-death model. We
carry out this study based on an additive model, determine limiting values of the integrated
regression coefficients under naive analyses, define the causal quantities of interest, and
develop weighted estimating equations which render consistent estimates for the causal
functions we derive. Much additional work can be done in this setting and so in addition
to offering a useful contribution in itself it lays the ground-work for much further research
relevant to helping scientists understand the relation between treatment effects based on
different endpoints in cancer trials.
In the following sections the contributions of the various chapters are reviewed and
topics of further research are outlined. The final section deals with research ideas in
settings with another form of response-dependent sampling, arising in prevalent cohort
studies.
5.2 Ongoing Work in Family-Based Designs
There are a number of areas of future research planned based on the family study design.
An immediate goal is the development of statistical methods incorporating nonparametric
and semiparametric methods for estimating the marginal disease onset time distribution.
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The approach to nonparametric estimation depends on the nature of the data to be used
for the estimation of the marginal parameters as well as whether the intention is to use two-
stage or simultaneous estimation. Use of the pooled-adjacent-violators algorithm (PAVA)
is natural if only current status data are to be used in a two-stage procedure, but other-
wise more general methods for nonparametric estimation are required such as Turnbull’s
algorithm (Turnbull, 1976). The two-stage method of analysis requires adaptation of the
variance formulae but the large sample properties of estimators from isotonic regression
(Barlow et al., 1972) can be exploited to achieve this.
Another important extension is to integrate the assessment of genetic variables to study
how these might alter the marginal onset time distribution or the structure of the within-
family dependence. If this is to be carried out by regression analyses it will necessarily
be restricted to individuals from the Toronto cohort as there are no genetic data available
from individuals participating in the survey of the National Psoriasis Foundation; other
PsA cohorts for which genetic data are available could be used however, along with any
family members that are genotyped. A variety of marginal regression models can be consid-
ered including parametric proportional hazards or location-scale models, semiparametric
proportional hazards models, or additive models. Simultaneous and two-stage estimation
procedures can be adopted in this regression setting as well.
A particularly exciting avenue for further exploration is the use of auxiliary data for
which there is no genotype information when interest lies in testing genetic effects. This
data can be used in the computation of score tests in which parameter estimates are only
required under the null hypothesis; in this case data from individuals in the National Pso-
riasis Foundation survey may be used to improve efficiency in estimation of the parameters
under the null hypothesis. It is anticipated that the gain in precision in the estimates of
the marginal parameters under the null hypothesis should translate to increased power of
tests for genetic associations; following initial estimation of the marginal parameters under
the null hypothesis the score test will be applied only to patients having genetic data.
The robustness and computational appeal of pairwise likelihood is similar in spirit to
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the appeal of the robustness from estimating function methodology. We intend to explore
the use of second-order estimating functions for modeling the within family association
structure and have carried out some preliminary work examining conditional GEE2 meth-
ods. Use of auxiliary data from the National Psoriasis Foundation survey can also be used
to introduce weights based on the cumulative incidence of disease and to obviate the need
for conditioning, and score tests will also be developed in this framework.
5.3 Ongoing work in Cluster-Randomized Trials
In Chapter 3, we focus on sample size calculations for cluster-randomized trials with cen-
sored event times, but restricted attention to the setting in which cluster sizes are fixed
at a common value, denoted by J . While this is often reasonable, cluster sizes routinely
vary in cluster-randomized trials. When planning studies in this case it is perhaps most
common to use formula derived for fixed cluster sizes, but to use the anticipated average
cluster size J¯ =
∑n
i=1 Ji/n in the formula in place of J (Donner, 1984; Xie and Waksman,
2003; Jahn-Eimermacher et al., 2013). When cluster sizes vary and the response is con-
tinuous, use of the average size in the formula derived for common cluster sizes can lead
to inadequate power; the loss in power can be small, however, if the cluster size tends to
be large and the intraclass correlation coefficient is small (Manatunga et al., 2001; Van
Breukelen et al., 2007). Manatunga et al. (2001) developed a refinement to the usual sam-
ple size formula for continuous outcomes to deal with variable cluster sizes, which involves
adding a correction term (a function of the coefficient of variation of the cluster size) to
the formula based on a common cluster size. Van Breukelen et al. (2007) investigated the
consequences of unequal versus equal cluster sizes in terms of the precision of treatment
effects estimators in cluster-randomized trials with continuous outcomes. They provide
a formula for the approximate relative efficiency of the estimators, which can be used to
adjust an initial estimate of the number of clusters required based on a common cluster
size. Candel and Van Breukelen (2010) extended this approach to varying cluster size with
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binary outcomes when the analysis is based on the mixed logistic regression. We are not
aware of any methods for dealing with variable cluster sizes for event time responses, and
so extensions to deal with this represent an important area of future research.
Another important area to be developed is the development of adaptive sample size
estimation in cluster-randomized trials. The nature and extent of within-cluster depen-
dence is often unknown at the design stage. Methods that involve exploitation of interim
data for blinded estimation of dependence parameters may enable researchers to commence
studies when there is uncertainty about the extent of within-cluster dependence but refine
the design as data are collected. There is currently much interest in adaptive clinical trial
design and this represents an important area of future work related to the contributions of
Chapter 3.
5.4 Ongoing Work for Cancer Clinical Trials
The issue of causal inference on transition intensities arises in many other settings involving
multistate models. A setting of particular interest is in health promotion studies where
interest lies in examining intervention effects on behaviour change in health promotion
studies. In this setting individuals are randomized to one or two or more interventions and
interest lies in how transition rates may differ between randomized groups. The effects of
interventions on the rate of change from the initial state are protected by randomization,
but any comparisons between groups in transition rates beyond the first state at the first
time point are susceptible to the kind of confounding we consider here. Inverse probability
weighted estimating equations can be used in this context as well. Another setting is in
the analysis of second and subsequent gap times in recurrent event analysis (Cook and
Lawless, 2007). In this case it is generally appreciated that it is important to model the
dependence in successive gap times through use of random effect or copula-based models,
but inverse weighting can of course be used. Lin and Ying (2001) discuss non-parametric
estimation of the joint distribution of gap times for the development of inverse weighted
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estimating equations for estimation of marginal second gap time distributions.
Further work in this area is warranted and much related work on causal inference has
bearing on analysis from randomized trials in settings with complications due to missing
data, censoring, selection effect or conditioning. Our attention has focussed in fixed con-
founders or confounders introduced at the single time of progression. Marker data are
routinely available at least intermittently, and the observed values are often highly influen-
tial in treatment decision making. Further work which deals with this type of time varying
marker data is under way.
Finally we note that while we have developed a specific framework for thinking about
the causal analysis of treatment effects on post-progression survival we have not fully
exploited it to obtain an estimate of the effect of the randomized treatment on overall
survival. Another avenue for exploration is the use of the multistate models for the purpose
of estimating the transition intensities in each treatment arm separately, removing the
confounding effects from conditioning on the collider of progression and the introduction
of rescue medication. These can then be used to construct an estimate of the survival
probability for each arm and treatment comparisons can be made based on these. Careful
thought is required to decide how precisely to remove the confounding effects however as it
is important that the resulting estimates and treatment contrasts have clear meaning and
contextual relevance. This too is ongoing work.
5.5 Measurement Error for Age of Onset in Prevalent
Cohort Studies
Prevalent cohort studies of chronic diseases involving screening populations and sampling
individuals with the condition of interest for prospective follow-up (Zelen and Feinleib,
1969). Examples of such studies include cancer screening trials (Zelen, 2004), studies of HIV
prevalence (Lagakos et al., 2006) and studies of dementia (Wolfson et al., 2001; Asgharian
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et al., 2002). The prevalent cohort design features a form of response-dependent sampling,
however, in the sense that diseased individuals with long survival times are preferentially
selected for inclusion into the cohort (Cox and Miller, 1965; Zelen and Feinleib, 1969; Zelen,
2004); some authors refer to the resulting data as “length-biased”.
Two broad frameworks are commonly used to address the sampling in the likelihood
construction: conditional framework and unconditional framework. The conditional frame-
work is based on the fact that individuals who died before the time of screening cannot be
sampled, and so the survival times among sampled individuals are left-truncated by the
time from disease onset to enrollment. Parametric, nonparametric (Wang, 1991) and semi-
parametric (Kalbfleisch and Lawless, 1991; Keiding and Moeschberger, 1992; Wang et al.,
1993) methods based on this framework has been well established. The unconditional
framework is based on the density of the survival times derived under the prevalent cohort
sampling scheme. That is, if the disease incidence is stationary, the onset times follow a
time homogeneous Poisson process, and the resulting left truncation times have a constant
density. If the probability an individual is sampled is proportional to their survival time,
the density of times subject to this sampling scheme can be derived and used for likelihood
construction. Nonparametric (Vardi, 1982, 1989; Asgharian et al., 2002; Huang and Qin,
2011) and semiparametric estimation methods (Wang, 1996; Luo and Tsai, 2009; Tsai,
2009) have been established for length-biased data. Both conditional and unconditional
analyses make use of the retrospectively reported times of disease onset, with the latter
further based on the assumption of a stationary (Poisson) incidence process.
However, there is often considerable error and uncertainty in the retrospectively re-
ported onset times. This is particularly true for onset times related to disease featuring
cognitive impairment or mental health disorders. In some settings the reported times may
better represent times of symptom onset, rather than the actual start of the disease pro-
cess which may lead to underestimation of disease duration. In other settings the errors
may lead to earlier or later reported onset times. Therefore we are interested in examin-
ing the impact of measurement error in the retrospectively reported onset time for both
the conditional and unconditional frameworks, and proposing methods to correct for this
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measurement error.
Consider a population and a chronic disease such that at any time an individual in the
population is in one of three states: alive and disease-free (D0), alive with disease (D1),
and dead (D2). For individuals who develop the disease, the path is D0 → D1 → D2 and
interest often lies in the distribution of the survival time with the disease, or equivalently
the sojourn time distribution for state D1. For individual i, let Vi0 be the calendar time
of disease onset and Vi1 be the calendar time of death (time of entry to state D2); then
Ti = Vi1 − Vi0 denotes the time of interest. Consider a study starting at calendar time
R (recruitment time), when individuals in the population are screened for the disease of
interest and those who are diseased are to be recruited into the study. Figure 5.1 shows a
hypothetical situation in the prevalent cohort study, where calendar time is represented on
the horizontal axis. Individuals who are sampled must have developed the disease of interest
at some point over the calendar time interval [A,R], and be still alive at the recruitment
time R. Those who develop the disease over [A,R] but die before the recruitment time
cannot, of course, be selected for inclusion in the sample. Those who develop the disease
after the recruitment time are also not eligible for recruitment. The times Wi = R − Vi0
and S = Vi1 − R are called the backward and forward recurrence times for individual i
respectively, and Ti = Wi+Si is the survival time of interest. To accommodate incomplete
follow-up, let Ci denote the right censoring time for individual i from disease onset, and
Xi = min(Ti, Ci) denote the survival time from disease onset; δi = I(Ti1 < Ci) is a indicator
of whether death is observed.
Let fT (t; θ) and FT (t; θ) be the so-called population (unbiased) probability density and
survivor functions for Ti, where a p × 1 parameter vector θ indexes the distribution. The
relevant density function for the observed left-truncated survival data for individual i is
f(ti|vi0, Ti > R− vi0; θ) = fT (ti; θ)FT (R− vi0; θ) . (5.5.1)
We now consider the distribution of the onset times over the interval [A,R] in the target
population. Let f0(v0)dv0 = P (v0 ≤ V0 ≤ v0 + dv0|A ≤ V0 ≤ R) be the probability an
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Figure 5.1: Diagram of calendar times and study times of disease onset, left-truncation
and survival.
onset time occurs in an interval [v0, v0 + dv0] given it happens over [A,R]. We assume
T ⊥ V0, so that the distribution of the survival time since disease onset does not depend
on onset time.
Then the conditional and unconditional likelihoods for right-censored left-truncated
survival data are
LC(θ) ∝
n∏
i=1
f(xi|vi0, Ti > R− vi0; θ) = f
δi
T (xi; θ)F1−δiT (xi; θ)
FT (R− vi0; θ) , (5.5.2)
and
LF (θ) ∝
n∏
i=1
f(vi0, xi|A ≤ V0 ≤ R, V1 ≥ R; θ) =
n∏
i=1
f ∗0 (vi0; θ)
f δiT (xi; θ)FT (xi; θ)1−δi
FT (R− vi0; θ) ,
(5.5.3)
respectively, and we can write
LF (θ) = LM(θ)× LC(θ) ,
where LM(θ) =
∏n
i=1 f
∗
0 (vi0; θ), and
f ∗0 (vi0; θ) =
f0(vi0)FT (R− vi0; θ)∫ R
A
f0(u)FT (R− u; θ)du
,
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which is the sample onset time density for individuals who satisfy the inclusion criterion.
The details can be found in Zhong and Cook (2014).
The estimators θ̂C and θ̂F can be found by maximizing the conditional (5.5.2) and
unconditional (5.5.3) likelihoods respectively when parametric models are applied. Further,
the resulting estimators have asymptotic normal distributions, so
√
n(θ̂C − θ) D−→ N(0, I−1C ) ,
√
n(θ̂F − θ) D−→ N(0, I−1F ) ,
where IC and IF are the Fisher information matrices for conditional and unconditional
likelihoods.
Both the conditional and unconditional analyses make use of the reported onset time,
and the latter requires the additional assumption of a stationary disease incidence process.
For individuals determined to have the disease at the time of assessment, the disease may
have begun several years earlier, making accurate recall of the onset time difficult. There
may therefore be considerable uncertainty about the reported onset time and the difference
between the true onset time and the reported onset time represents recall, reporting, or
measurement error; we will henceforth use the term measurement error. Both the condi-
tional and unconditional approaches to the analysis of prevalent cohort data will in general
lead to biased estimators in the presence of measurement error. Let V0 be the exact disease
onset time which is not observed and U0 be the retrospectively reported disease onset time.
A classical error model (Carroll et al., 2006) leads to
U0 = V0 +  (5.5.4)
where  ∼ N(0, σ2) is random measurement error, and A ≤ V0 ≤ R. Notice that diseased
individuals who are still alive at the recruitment time and selected into the study need to
report their onset time retrospectively, and their reported onset time should also satisfy
the condition A ≤ U0 ≤ R. In this case the sample distribution of U0 given V0 becomes
a truncated normal distribution, with density function written as g(u0|v0;φ), suppressing
the condition A ≤ U0 ≤ R,
g(u0|v0;φ) = f(u0 − v0;φ)
F(R− v0;φ)− F(A− v0;φ) (5.5.5)
134
where f(·;φ) and F(·;φ) are the density and cumulative distribution functions of  with
parameter φ = log σ, where σ is the standard deviation; we let ψ = (θ′, φ)′ denote the
vector of all parameters. The impact of this measurement error in both frameworks for
parametric and nonparametric settings is investigated in Zhong and Cook (2014).
A ‘correct’ likelihood approach (Zhong and Cook, 2014) can be used to account for the
measurement error in the onset time and will yield unbiased estimators of the parameters
of interest if the component model assumptions are correctly specified. Such a likelihood
should be based on the reported onset time and the (possibly censored) survival time,
which will require explicit modeling of the measurement error process. Let h(v1|u0) be the
density function of the calendar time of death given the reported onset time, i.e
h(v1|u0;ψ) = P (v1|u0, A ≤ U0, V0 ≤ R, V1 ≥ R;ψ)
=
∫ R
A
fT (v1 − v0; θ)g(u0|v0;φ)f0(v0)dv0∫ R
A
FT (R− v0; θ)g(u0|v0;φ)f0(v0)dv0
(5.5.6)
The ‘correct’ conditional likelihood for right-censored left-truncated data is of the form
L∗C(ψ) =
n∏
i=1
{(∫ R
A fT (vi1 − vi0; θ)g(ui0|vi0;φ)f0(vi0)dvi0∫ R
A FT (R− vi0; θ)g(ui0|vi0;φ)f0(vi0)dvi0
)δi
×
(∫ R
A FT (vi1 − vi0; θ)g(ui0|vi0;φ)f0(vi0)dvi0∫ R
A FT (R− vi0; θ)g(ui0|vi0;φ)f0(vi0)dvi0
)1−δi }
. (5.5.7)
Similarly, the joint density of the observed onset time and calendar time of death is
h(v1, u0;ψ) = P (v1, u0|A ≤ U0, V0 ≤ R, V1 ≥ R; ) = P (u0, A ≤ V0 ≤ R, V1 ≥ R) h(v1|u0;ψ)
P (A ≤ U0 ≤ R,A ≤ V0 ≤ R, V1 ≥ R)
=
∫ R
A
FT (R− v0; θ)g(u0|v0;φ)f0(v0)dv0∫ R
A
FT (R− v0; θ)f0(v0)dv0
h(v1|u0;ψ) . (5.5.8)
where the last equality is derived by (5.5.5).
The ‘correct’ unconditional likelihood can then be constructed as follows,
L∗F (ψ) = L
∗
M(ψ)× L∗C(ψ) , (5.5.9)
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where
L∗M(ψ) =
(
n∏
i=1
∫ R
A
FT (R− vi0; θ)g(ui0|vi0;φ)f0(vi0)dvi0∫ R
A
FT (R− vi0; θ)f0(vi0)dvi0
)
. (5.5.10)
Since L∗M(ψ) might contain the information about parameters we are interested in,
the ‘correct’ unconditional likelihood might be more efficient than the ‘correct’ conditional
likelihood. Further, when the underlying onset time is a stationary process, then we can let
f0(v0) = (R−A)−1 and let A→ −∞ to obtain both ‘correct’ likelihoods for length-biased
data.
The maximum likelihood estimators θ̂∗C and θ̂
∗
F under (un)conditional likelihoods can
be easily found by maximizing (5.5.7) and (5.5.9) respectively and have asymptotic normal
distribution as n→∞ such that
√
n(ψ̂∗C − ψ) D−→ N(0, I∗−1C ) ,
√
n(ψ̂∗F − ψ) D−→ N(0, I∗−1F ) ,
where I∗C and I∗F are information matrices based on conditional (L∗C) and unconditional
(L∗F ) likelihoods function.
A simulation study has been carried out to examine the performance of ‘correct’ like-
lihoods in the presence of measurement error in disease onset time; see Zhong and Cook
(2014) for details. Based on the simulation study, we can find that the proposed ‘correct’
likelihood approach adjusts the measurement error well and yields consistent estimators.
The methods we proposed to correct for measurement error are based on the parametric
model. It is of interest to investigate what the limiting value of standard nonparametric
estimators is for both the conditional and unconditional frameworks. The modest increase
in the standard error of the Weibull shape and scale parameters that arises when φ is
estimated suggests it is promising to consider nonparametric estimation in the corrected
conditional and unconditional settings. Extending the corrected likelihoods to accommo-
date misspecification of the onset times is also of interest for both frameworks. We focused
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on the classical error model in this study, but other measurement error models are also of
interest; often individuals will report later onset times since their views on disease onset
may be more closely tied to the onset of symptoms than the actual disease. Methods to
correct for this kind of measurement error are also important and are under development.
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